Using Protein Interactome Networks To Understand Human Disease And Evolution by Das, Jishnu
	  	   	  
USING PROTEIN INTERACTOME NETWORKS TO UNDERSTAND HUMAN 
DISEASE AND EVOLUTION 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
  By 
  Jishnu Das
August 2016 
 
 
 
 
	  	   	  
 
 
 
 
 
 
 
 
 
© 2016 Jishnu Das 
ALL RIGHTS RESERVED 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   	  
USING PROTEIN INTERACTOME NETWORKS TO UNDERSTAND HUMAN 
DISEASE AND EVOLUTION 
 
Jishnu Das 
Cornell University 2016 
 
 Proteins are macromolecules that perform many key biological functions in living 
organisms. However, despite their functional complexity, they do not act in isolation but are part 
of a large underlying cellular network – the protein interactome. In my thesis, I focus on ways in 
which the structure, topology and properties of this interactome network can be leveraged to 
better understand mechanisms of human disease and evolution at a molecular level. This work 
can be broken down into 3 broad categories – (1) in chapters 2-4, I focus on combining protein 
structure with interactome networks to better understand disease mechanisms via loss or gain of 
specific functions; (2) in chapters 5 and 6, I use gene expression data in conjunction with 
networks to study interaction dynamics and how this is useful in predicting cancer outcome; (3) 
in chapters 7 and 8, I examine global principles of protein network evolution from yeasts to 
human. At the beginning of each chapter, I have outlined both my role and the role of my 
colleagues in conducting the research described in the chapter. 
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CHAPTER 1 
A NETWORK PERSPECTIVE 
 
John Donne wrote – “No man is an island”, golden words in today’s interconnected and 
interdependent world. But it is not just humans who are part of intrinsic networks; the 
molecules that make us human are also part of complex biological networks. In the 
following chapter, I outline the relevance of the network perspective in biology. 
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1.1 INTRODUCTION 
 
The building blocks of life, nucleic acids and proteins, are complex bio-molecules that 
can carry out numerous biological functions. However, despite their functional 
complexity, the vast majority of these molecules do not act in isolation. Rather, they are 
part of well-coordinated biological networks that are robust, fault-tolerant and highly 
efficient. In my thesis, I focus on one such biological network – the protein-protein 
interaction network. In this network, the nodes are proteins and edges between these 
nodes represent biophysical interactions between proteins. My dissertation focuses on 
ways in which we can use the protein network to elucidate molecular mechanisms of 
human disease and evolution.  
 
In the first part of my thesis – chapters 2, 3 and 4, I discuss how interaction networks can 
be combined with protein structures to generate three-dimensional structurally resolved 
networks. I then study disease mutations in the concept of these 3D networks to obtain 
novel insights into mechanisms of disease progression. 
In the second part of my thesis – chapters 5 and 6, I focus on combining gene expression 
data with protein networks to understand the dynamics of interactions, as well as improve 
cancer outcome prediction. 
In the third and final part of my thesis – chapters 7 and 8, I study the evolution of protein 
networks from yeasts to human. I develop statistical frameworks that can be used to 
2
compare protein networks from different organisms and enunciate the molecular basis of 
network evolution. 
 
The overall theme of this thesis is to show how network structure, organization and 
dynamics can be leveraged to gain key insights into mechanisms of complex biological 
processes. In future, similar methods may be applied to other biological networks such as 
transcriptional or metabolic networks, to uncover hitherto unknown mechanisms. 
3
  
 
 
CHAPTER 2 
HINT: High-quality protein interactomes and their applications in 
understanding human disease 
In the following chapter, we describe the development of HINT, a high-quality repository of 
protein-protein interactions in different organisms. I am the sole first author of the paper 
resulting from this chapter (Das and Yu, BMC Systems Biology 2012). There is another paper on 
which I am a co-first author (Meyer*, Das* et al Bioinformatics 2013 *=Equal contribution) that 
builds on HINT and describes the generation of structurally-resolved interactomes. I do not 
devote a separate chapter to it as a lot of the relevant conceptual details are covered in Chapter 3. 
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2.1 ABSTRACT 
A global map of protein-protein interactions in cellular systems provides key insights into the 
workings of an organism. A repository of well-validated high-quality protein-protein interactions 
can be used in both large- and small-scale studies to generate and validate a wide range of 
functional hypotheses. We develop HINT (http://hint.yulab.org) - a database of high-quality 
protein-protein interactomes for human, Saccharomyces cerevisiae and Schizosaccharomyces 
pombe. These were collected from several databases and filtered both systematically and 
manually to remove low-quality/erroneous interactions. The resulting datasets are classified by 
type (binary physical interactions vs. co-complex associations) and data source (high-throughput 
systematic setups vs. literature-curated small-scale experiments). We find strong sociological 
sampling biases in literature-curated datasets of small-scale interactions. An interactome without 
such sampling biases was used to understand network properties of human disease-genes - hubs 
are unlikely to cause disease, but if they do, they usually cause multiple disorders. HINT is of 
significant interest to researchers in all fields of biology as it addresses the ubiquitous need of 
having a repository of high-quality protein-protein interactions. These datasets can be utilized to 
generate specific hypotheses about specific proteins and/or pathways, as well as analyzing global 
properties of cellular networks. HINT will be regularly updated and all versions will be tracked. 
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2.2 INTRODUCTION 
Numerous recent efforts in systems biology have tried to characterize the set of all possible 
pairwise physical interactions or the binary protein “interactome” of an organism (Bader et al., 
2008; Cusick et al., 2005; Vidal, 2005). Most proteins perform their functions through 
interactions (Pawson and Nash, 2000). Thus, these large-scale maps are critical in elucidating the 
biological roles of functional products of genes that are identified by large-scale genome and 
cDNA sequencing projects. Because most of these efforts are discovery-oriented and try to 
explore previously unknown functionalities, it is of utmost importance to ensure that the resultant 
maps are of high quality. Erroneous results at this stage could propagate into both ill-conceived 
hypotheses and futile downstream experiments. Moreover, it has been shown that high-quality 
interaction networks can provide key insights into fundamental topological and biological 
properties of cellular systems (Batada et al., 2006, 2007; Bertin et al., 2007; Han et al., 2004). 
Although there are numerous databases (Hu et al., 2009; Kerrien et al., 2012; Keshava Prasad et 
al., 2009; Licata et al., 2012; Mewes et al., 2011; Salwinski et al., 2004; Stark et al., 2011; 
Turner et al., 2010) that try to systematically curate the entire repository of interactions for 
different organisms, there has been very little effort in filtering out unreliable ones. This has led 
to low overlaps between independent publications and resultant confusion as to which 
interactions are correct (Cusick et al., 2009; Venkatesan et al., 2009; Yu et al., 2008).  
There are two major types of protein-protein interaction data – binary physical interactions and 
co-complex associations. While some databases distinguish between these two orthogonal 
datasets, others fail to do so. Binary interactions represent a direct biophysical interaction 
between two proteins. On the other hand, co-complex associations provide information about co-
membership in a complex. A lot of these associations may actually represent indirect interactions 
6
(Cusick et al., 2009; Yu et al., 2008). The biological information conveyed by these two kinds of 
interactions is different and for many applications it is necessary to have a clear distinction 
between these two.  
There are two major methods to obtain a global map of binary interactions – literature-curation 
(LC) and high-throughput experiments (HT) (Cusick et al., 2009). LC refers to systematically 
collecting interaction data from thousands of small-scale studies directed at validating a single or 
a few specific hypotheses. On the other hand, HT experiments produce large-scale interaction 
maps. Because most LC data are generated by hypothesis-driven experiments, it is much easier 
to infer biological function from those studies as compared to HT experiments. On the other 
hand, although the search space of some HT experiments might be focused on certain functional 
groups, most HT experiments are not designed to detect the presence or absence of specific 
interactions. Any experiment can have two kinds of bias – “assay bias” and “sampling bias”. The 
first arises because no assay is perfect and all experiments – HT or small-scale have their own 
characteristic biases (von Mering et al., 2002). However, small-scale studies also have a 
sampling bias, i.e., they are typically focused on one or a few proteins of interest and hence 
selectively sample interactions from only a part of the search space. HT experiments are free of 
this sampling bias, i.e., the search space is scanned without a priori expectations (Venkatesan et 
al., 2009; Yu et al., 2008). Thus, for many global topological analyses, it is often necessary to 
use only the HT datasets. 
Here, we describe a publicly available protein-protein interaction database, HINT (High-quality 
INTeractomes) that directly addresses the above three issues and provides high-quality binary 
and co-complex interactions for human, S. cerevisiae and, S. pombe. The binary interactomes 
have also been divided into LC and HT subsets. Using these datasets, we show that there are 
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significant sociological sampling biases in LC datasets, i.e., well-studied proteins tend to have 
more interactions in LC datasets for both human and S. cerevisiae. Finally, using only the high-
quality HT interactions for human, we find that disease genes (i.e., genes that have a causal 
connection with one or more diseases) with more interactions tend to cause more diseases. Even 
though this result is unexpected in light of previous findings that interaction hubs are less likely 
to cause disease (Feldman et al., 2008; Goh et al., 2007), it will help understand mechanisms of 
various disease processes and develop corresponding treatments.  
 
2.3 RESULTS 
Data source for protein-protein interactions 
The set of all protein-protein interactions for the three organisms was downloaded from the 
public databases – BioGrid (Stark et al., 2011), DIP (Salwinski et al., 2004), HPRD (Keshava 
Prasad et al., 2009), IntAct (Kerrien et al., 2012), iRefWeb (Turner et al., 2010), MINT (Licata et 
al., 2012), MIPS (Mewes et al., 2011) and VisAnt (Hu et al., 2009). Not all three organisms were 
present in all the databases. Though some of the databases mentioned above store both genetic 
and physical interactions, only physical interactions were used in building the interactomes. 
Certain tools (Szklarczyk et al., 2011; Turner et al., 2010) also provide scoring schemes for 
protein-protein interactions. However, we do not include these for HINT as they integrate both 
computational predictions and experimentally determined interactions. Our goal is to provide a 
repository of only experimentally well-validated high-quality protein-protein interactions. 
Building the database 
8
Figure 2.1 summarizes how HINT was built. For each organism and each source database, a 
filter was applied to generate non-redundant lists of appropriate interactions for the two 
categories – binary and co-complex. The filter classifies interactions into the correct groups and 
removes ones that are inadequately supported by experimental evidence. The binary interactions 
were further classified as HT and LC based on the nature of the experiments that produced them. 
If the experiment in support of the interactions discovers greater than a cutoff number of 
interactions, it is classified as HT. To determine the cutoff, we calculated the distribution of 
number of interactions reported by each unique publication. The cutoff (>=100 interactions) 
corresponds to the top 0.5 percentile of studies, when all publications are ranked in decreasing 
order of interactions reported per study. For co-complex associations, there exists no such clear 
distinction between HT and LC because the average number of interactions detected in a single 
experiment is significantly higher. 
The next step was to remove low-quality interactions. For ones supported by HT publications, a 
non-redundant list of papers was compiled and each publication was manually examined to 
verify that the actual experiments used by the authors agree with the evidence codes cited by the 
curators. All papers for which there was an error in this matching process were removed. 
Moreover, papers that do not validate the interactions obtained were also not included in HINT. 
Although some HT affinity purification followed by mass spectrometry (AP/MS) experiments 
producing co-complex associations report confidence scores, most binary HT experiments do 
not. For co-complex interactions, we require all interactions to be reported by two papers or 
more to ensure quality. For HT binary experiments, some report datasets of different levels of 
confidence – usually, core vs. non-core. We always include the highest-quality dataset (i.e., the 
core set only). Moreover, we ensure that every single interaction included is high-quality (please 
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see Quality control section). Within this high-quality dataset, the users of HINT are free to 
choose their own confidence cutoff based on any combination of the number of supporting 
publications and evidence code. For LC interactions, it is not possible to replicate this process, as 
the number of papers is too high. It has been shown that a large fraction of the LC interactions 
supported by a single publication cannot be verified (Cusick et al., 2009; Turinsky et al., 2010). 
Curation is an extremely painstaking process and we acknowledge that there may be some high-
quality interactions supported by only one publication. However, it is impossible to distinguish 
them from the larger fraction that has been demonstrated to be of lower quality/erroneous 
(Venkatesan et al., 2009; Yu et al., 2008). Our goal here is to present to the community only a 
high-quality dataset that is free of potential biases due to differential curation of the same source 
publication. Only those LC interactions that are supported by two or more publications are 
preserved in our database. Table 1 provides a summary of the source databases used (version and 
download date). Table 2 reports the number of high-quality interactions in each of these 
databases in each category.  
For the binary network, we generated two sub-interactomes – the high-quality LC (HQ-LC) and 
the high-quality HT (HQ-HT) sub-interactomes. Interactions that are supported by both forms of 
evidence belong to both.  
Table 3 provides summary statistics for the different interactomes and their sub-classes. The 
numbers refer to unique entries and any interaction validated in multiple orientations (e.g., bait 
and prey in binary interaction detection experiments) or by different research groups is counted 
as a single entity. We find that the average degree for S. pombe is much lower than that of human 
or S. cerevisiae for both binary and co-complex data. This shows that the S. pombe interactome 
is still mostly unexplored. There is also a sharp increase in the average degree from binary to co-
10
complex for S. cerevisiae. This is expected given that models to generate topologies of co-
complex networks tend to include several or all possible combinations (Bader and Hogue, 2002). 
However, the same does not hold true for human. This probably indicates that the human co-
complex interactome is underexplored as compared to the S. cerevisiae one. 
Figure 2.2 depicts the binary and co-complex interactomes for human and S. cerevisiae. The 
degree distribution of each of the networks is also illustrated and these plots correspond well 
with the theoretical expectation of the networks being scale-free (Barabasi and Bonabeau, 2003). 
It is not possible to produce these plots for S. pombe as the interactome for this organism is 
severely underexplored. 
Quality control 
There has been a great deal of effort in the literature at discovering new protein-protein 
interactions in different species to gain an understanding of the entire interactome of that 
organism. However, due to experimental errors and inaccurate curation, databases often contain 
interactions that are low quality/erroneous (Cusick et al., 2009). Since accuracy is of paramount 
importance in generating new hypotheses using these interaction data, it is essential to have an 
easily accessible repository of high-quality binary protein-protein interactions. HINT is a 
repository created by combining information from commonly used databases. To ensure quality 
control, we adopt the following protocol. Since the number of HT publications is relatively low 
as compared to the vast number of small-scale studies, we manually inspect each of the HT 
studies. We ensure that high-quality HT experiments included in HINT have been verified by 
orthogonal traditional assays (e.g., co-immunoprecipitation). Some experiments that do not 
perform any validation of their screen are considered low-quality and therefore removed. More 
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recently, we developed a statistical framework to comprehensively evaluate the quality of HT 
datasets verified by orthogonal assays in both human and S. cerevisiae (Venkatesan et al., 2009; 
Yu et al., 2008). Using this framework, we can quantitatively and experimentally measure the 
quality of individual interactions, as well as the whole dataset. The quality of interactions 
reported by a HT experiment can be measured by two independent statistical parameters – the 
number of interactions validated, i.e., the “validation rate” and the number of interactions that 
could be re-tested in the validation carried out, i.e., the “retest rate”. The first parameter is a 
measure of the confidence associated with the validation carried out (i.e., more confidence can 
be associated with the results when a larger fraction of the reported interactions are validated), 
while the second one directly assays the reproducibility of the HT experiment. We carried out a 
comprehensive re-curation for all HT experiments included in HINT. Only those HT 
experiments that satisfy have a validation rate of >50% and a recuration rate of >75% are 
included in HINT. This ensures that only the highest quality HT experiments are included in 
HINT. 
On the other hand, since it is impossible to manually check all small-scale studies, we require 
two independent publications to report the same interaction for it to be included in our dataset. 
This is because while some interactions from dedicated small-scale studies are high-quality and 
have been repeated multiple times in the literature, a significant fraction of interactions from 
small-scale experiments are not easily reproducible. In fact, many of the interactions that cannot 
be reproduced are supported by only one publication, were not produced by dedicated 
experiments and were often not even mentioned in the paper (Cusick et al., 2009). More 
importantly, it has been experimentally shown that such interactions are indeed of low quality 
(Venkatesan et al., 2009; Yu et al., 2008). Thus, our repository of high-quality interactions 
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contains only manually validated HT experiments and interactions from small-scale studies that 
have been reported at least twice in the literature.  
To further validate the filtering approach used we adopted the following method. For each 
organism and interaction type, percentage overlaps between all pairs of databases that contain 
data relevant to that category were calculated before and after filtering. Since all these databases 
are curating the same information, we would expect the overlaps between any two of them to be 
high. However, that is not the case and we find low overlaps between pairs of databases. This 
supports our hypothesis that some of the information contained in these datasets is low-
quality/incorrect. However, if our filtering scheme successfully removes these low-
quality/incorrect interactions, the pairwise overlap between databases should increase 
considerably after filtering. We find that this is indeed the case. For each organism and 
interaction type, there is a significant enrichment in the average pairwise overlap between 
databases after filtering (Figure 2.3; P-values calculated using a cumulative binomial test). 
Specifically, let the maximum number of interactions for a certain organism and interaction type 
that can be common to a particular database pair before and after filtering be denoted by Mbi and 
Mai respectively, where i is an index to denote the database pair. Let the percentage overlaps 
before and after filtering for that pair be denoted by Pbi and Pai respectively. The average 
percentage overlap for that organism and interaction type before (AvPB) and after filtering 
(AvPA) are calculated as: 
€ 
AvPB =
Mbi x Pbii∑
Mbii∑  
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€ 
AvPA =
Mai x Paii∑
Maii∑
 
Querying the database 
The database has two major parts – a query interface and a batch download for the entire 
interactomes of the organisms. The pooled interactions can be queried in the following manner.  
The organism of interest is selected from a drop-down menu followed by entering the query 
proteins separated by semi-colons. Up to a maximum of 10 proteins can be entered per query. 
The database supports Entrez gene IDs (Maglott et al., 2007) and gene names for proteins in 
human and ORF names and gene names for proteins in S. cerevisiae (Cherry et al., 1997) and S. 
pombe (Matsuyama et al., 2006). The user also has the option of specifying the cutoff number of 
publications for each of the query proteins. One can also specify a particular evidence type for 
searching interactions. For each interacting protein, the gene name is listed in the first column 
followed by the list of Pubmed IDs of the papers supporting this interaction in column 2. The last 
column lists the PSI-MI evidence code (Hermjakob et al., 2004) that describes the kind of 
evidence supporting the interaction. The gene names are linked to the NCBI Entrez Gene 
database (Maglott et al., 2007) for human and S. cerevisiae and the GeneDB database (Hertz-
Fowler et al., 2004) for S. pombe. The PubMed IDs link to the NCBI website for the relevant 
abstracts. 
For batch download, separate links are provided for binary and co-complex interactomes for each 
organism. The binary interactome is also divided into the LC and HT networks. One notes here 
that the LC and HT networks are not completely mutually exclusive. There are certain protein-
14
protein interactions that have been discovered both by HT experiments and by LC. There are 
included in both interactomes. 
Using HINT, it will now be possible to analyze, visualize, and generate reliable hypotheses about 
a part of or the complete interactome of the three different organisms – human, S. cerevisiae and 
S. pombe. Future efforts may be directed at similarly collecting and filtering data for other 
organisms and also updating the current dataset based on new findings. 
Binary vs co-complex 
HINT clearly distinguishes between binary and co-complex interactions. The binary network 
represents direct interactions between two proteins. On the other hand, the co-complex network 
merely indicates membership of a group and does not necessarily imply pairwise interactions. In 
most cases, the exactly topology of the complex is unknown. Two primary methods – the spoke 
model and the matrix model are used to represent these complexes. However, both models are 
approximations and merely suggest possible topologies (Bader and Hogue, 2002). Since different 
reports base their choice of model on study-specific conditions, all co-complex associations were 
included as curated in the source databases. No re-curation was performed. Moreover, compared 
to co-complex interactome models, binary maps have a greater fraction of transient signaling 
connections and inter-complex connections (Das et al., 2012; Yu et al., 2008). Since these two 
datasets represent fundamentally different biological entities, their overlap is low and it is 
important to differentiate between them in certain studies. For example, recent studies have 
examined how mutations may either lead to complete loss of gene products or edge-specific 
changes in the interactome (Dreze et al., 2009; Zhong et al., 2009). We show in a recent study 
that the pathogenesis of human disease can be better understood by looking at the position of 
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mutations on interaction interfaces (Wang et al., 2012). These approaches are applicable to direct 
binary interactions, as it is more difficult to infer interface pairs from co-complex associations. 
The latter can be resolved using information on three-dimensional structures of protein 
complexes if these are available. Thus, based on the context, it may be more appropriate to use 
one interactome over the other. Moreover, there are significant differences in the topological 
properties of these two networks. We calculated the clustering coefficient (Watts and Strogatz, 
1998) and the edge betweenness (Girvan and Newman, 2002) for the different interaction 
networks in HINT. Clustering coefficient measures the density of clustering in an interaction 
network (Watts and Strogatz, 1998). We find that co-complex networks have a significantly 
higher clustering coefficient (P < 10-8 in both cases as calculated by a two-sample Kolmogorov-
Smirnov test) than binary networks. This shows that co-complex associations tend to be much 
more dense in terms of topological structure. Edge betweenness is used to detect community 
structure in networks. A higher betweenness value for an edge indicates that it connects different 
modules and disrupting this edge will fragment the network into disjoint components (Girvan 
and Newman, 2002). We find that binary networks for both human and S. cerevisiae have a 
significantly higher betweenness (P < 10-8 in both cases as calculated by a two-sample 
Kolmogorov-Smirnov test) than co-complex networks for the two organisms. This suggests that 
co-complex associations form tightly regulated modules and binary interactions are often used to 
form links between these modules. We did not use the S. pombe networks for our global 
topological calculations as these interactomes are highly underexplored at this stage and the 
small number of interactions available make the networks unsuitable for global analyses. 
HT protein-protein interactions in understanding human disease  
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People have realized in the last decade that a human disease is rarely the consequence of an 
isolated abnormality in a particular gene but is generally the outcome of complex perturbations 
of the underlying cellular network (Barabasi et al., 2011). This has led to systematic studies of 
interactome networks and numerous insights have been obtained from such studies. The structure 
of these networks is governed by key biological principles and changes in their global properties 
may be linked to human disease (Vidal et al., 2011). Further advances in such studies are 
expected to uncover the biological significance of disease-associated mutations discovered by 
genome-wide association studies (Manolio, 2010) and help in identifying biomarkers and novel 
drug targets (Barabasi et al., 2011). 
Previous studies have shown that protein hubs tend to be essential genes (Jeong et al., 2000; Yu 
et al., 2004). Therefore, one interesting question is whether a lot of the hubs are disease genes. 
Using the HT interactome, we examined the distribution of disease genes across number of 
protein-protein interactions. We found that disease-genes tend not to be hubs (Figure 2.4A; error 
bars correspond to standard error of the mean assuming a binomial distribution). This result is 
consistent with earlier studies that find that disease genes are usually non-essential and occupy 
peripheral positions in the human interactome (Feldman et al., 2008; Goh et al., 2007). The 
finding is logical in light of an evolutionary argument – for essential genes, mutations would be 
more likely to affect fitness to the extent of causing embryonic lethality (Feldman et al., 2008; 
Goh et al., 2007).  
However, we were unable to reproduce the same results using the LC interactome (Figure 2.4A; 
error bars correspond to standard error of the mean assuming a binomial distribution). There is a 
significant increase (P < 10-8 as calculated by a one-way ANOVA) of percentage of disease 
genes with degree for proteins that have at least one interaction. This led us to believe that the 
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difference could be due to study biases in the LC data. To systematically analyze if this is true, 
we plotted the average number of publications against the number of interactions of proteins 
separately for the HT and LC interactomes. Intuitively, there should be no strong correlation 
between these two entities as the number of publications associated with a protein should have 
no connection with its degree. The average number of publications does not vary significantly 
with degree for the HT dataset but increases dramatically for the LC interactome (see Figures 
2.4B and 2.4C). This illustrates the strong study bias in the LC data – proteins with a greater 
number of interactions tend to be revisited more often by small-scale studies. Our results are 
consistent with earlier findings that the degree of proteins in the LC interactome is strongly 
correlated with the number of publications associated with them (Pfeiffer and Hoffmann, 2007; 
Yu et al., 2008). This makes the LC interactome unsuitable for global topological analyses. The 
low overlap between the HT and LC interactomes also confirms that these are in fact two 
separate networks that need to be appropriately used based on the context. 
To further investigate whether protein interactomes can help us understand disease mechanisms 
and uncover previously unknown disease genes, we used the HT human interactome to analyze 
what fraction of disease genes are disease-hubs, i.e., genes causing multiple diseases. We 
examined the distribution of disease-hubs as a function of their degrees (Figure 2.4D; error bars 
correspond to standard error of the mean assuming a binomial distribution). We observed that 
proteins with a higher number of interactions are significantly more likely to be disease hubs (P 
< 10-8 as calculated by a one-way ANOVA). Though this may seem contradictory to earlier 
findings in Figure 2.4A, these two are in fact independent results. It is true that if a disease gene 
has more interactions, there is a higher probability of its fitness being affected. However, in 
Figure 2.4D, we focused only on disease genes. By virtue of the fact that these are observed in 
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the population as disease genes, their mutations are less likely to cause embryonic lethality. 
Therefore the evolutionary constrains in Figure 2.4A do not apply here. It is logical to expect that 
a disease protein with multiple interactions will have a greater propensity for causing multiple 
diseases. This is because a protein with more interactions is involved in more biological 
functions (Yu et al., 2004). This result also means that protein-protein interactions are important 
in the pathogenesis of many human diseases. Further studies on alteration of interactions by 
disease mutations may reveal insights into molecular mechanisms of various diseases and 
provide information about potential drug targets.  
 
2.4 DISCUSSION  
HINT is a comprehensive repository of high-quality binary and co-complex physical interactions 
in human, S. cerevisiae, and S. pombe. It establishes and implements systematic techniques for 
separating interactions based on both type (i.e., binary and co-complex) and data-source (i.e., LC 
and HT). Making these distinctions is critical for many applications. Using only the HT dataset, 
we demonstrated that human disease genes with a greater number of interactions tend to cause 
more diseases. Future directions involve implementation of the same techniques for other 
organisms of biological interest.  
 
2.5 MATERIALS AND METHODS 
Evidence codes and ID-mapping 
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As one of the primary goals of the database is to clearly distinguish binary interactions from co-
complex associations, two separate and mutually exclusive lists of evidence codes were created – 
one for each category. An evidence code is a unique number assigned by the PSI-MI initiative to 
a particular form of experimental information in support of an interaction (Hermjakob et al., 
2004). The lists used for both categories can be found in Tables 2.1, 2.2, and 2.3. Using these 
lists, all the interactions were classified into binary and/or co-complex. Interactions supported by 
evidence codes that are in neither of the two lists are excluded. Different databases use different 
gene identifiers and as this may lead to error, all gene identifiers in each database were converted 
to Entrez gene IDs for human and ORF names for S. cerevisiae and S. pombe. For each of the 
organisms, gene names are also provided in the bulk download files. Mapping files we obtained 
from Uniprot (2007) and the NCBI gene databases. 
As described earlier, for an interaction to qualify as high-quality, it has to have at least one 
manually verified HT evidence code or at least two LC evidence codes supporting it.  
Protein-protein interactions and human disease genes 
To look at the distribution of human disease genes across number of protein-protein interactions, 
the following protocol was used. The total number of human proteins is taken to be 20,000. For 
the LC and the HT interactomes, we separately calculated the number of proteins that take part in 
1, 2, 3, and >=4 interactions respectively. The difference of 20,000 and the sum of proteins in all 
these categories represents the number of proteins that have no known interactions in that 
particular network. Thus we have the number of proteins with 0, 1, 2, 3, and >=4 interactions for 
both interactomes. The mapping between human genes and diseases is obtained from OMIM 
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(Amberger et al., 2009) and HGMD (Stenson et al., 2009).Then the following formula was used 
to calculate the percentage of disease genes in each category (PGi): 
€ 
PGi =
Ni x100
Ti  
where Ni is the number of disease genes in bin i and Ti is the total number of genes in bin i. 
 
Here each bin corresponds to the number of interactions – 0, 1, 2, 3, and >=4 respectively. These 
values have been shown in Figure 2.4A. The error bars represent standard error of the mean 
assuming a binomial distribution (each gene is either involved or not involved in disease). 
To calculate the sub-percentage of disease hubs in each category (PHj), the following formula 
was used: 
€ 
PH j =
N j x100
Tj
 
where Nj is the number of disease hubs in bin j and Tj is the total number of disease genes in bin j
 
Here each bin corresponds to the number of interactions – 0, 1, and >=2 respectively and a 
disease hub is any disease gene implicated in three or more diseases. These values have been 
shown in Figure 2.4D. The error bars represent standard error of the mean assuming a binomial 
distribution (each protein is either a disease hub or it is not). 
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2.6 FIGURE AND TABLE LEGENDS 
Figure 2.1 
Flow diagram depicting the series of steps used to build HINT. 
Figure 2.2 
Binary and co-complex interactomes and degree distribution plots for human and S. cerevisiae 
Figure 2.3 
Average overlap percentage between all pairs of databases for binary and co-complex 
interactions in human, S. cerevisiae (S.c.), and S. pombe (S.p.) before and after filtering. 
Figure 2.4 
A. Percentage of disease genes within proteins that have 0, 1, 2, 3, and >=4 interactions 
respectively. 
B. Plot of average number of publications associated with a protein versus the cumulative degree 
of the protein in the HT and LC interaction networks in human. 
C. Plot of average number of publications associated with a protein versus the cumulative degree 
of the protein in the HT and LC interaction networks in S. cerevisiae. 
D. Percentage of disease hubs within disease genes that have 0,1, and >=2 interactions 
respectively. 
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Table 2.1  
List of PSI-MI evidence codes used to classify binary interactions and co-complex associations. 
 
Table 2.2 
Mapping used to convert MIPS evidence codes to PSI-MI evidence codes. 
 
Table 2.3 
Mapping used to convert VisAnt evidence codes to PSI-MI evidence codes. 
 
 
 
23
2.7 REFERENCES  
(2007). The Universal Protein Resource (UniProt). Nucleic Acids Res 35, D193-197. 
Amberger, J., Bocchini, C.A., Scott, A.F., and Hamosh, A. (2009). McKusick's Online 
Mendelian Inheritance in Man (OMIM). Nucleic Acids Res 37, D793-796. 
Bader, G.D., and Hogue, C.W. (2002). Analyzing yeast protein-protein interaction data obtained 
from different sources. Nat Biotechnol 20, 991-997. 
Bader, S., Kuhner, S., and Gavin, A.C. (2008). Interaction networks for systems biology. FEBS 
Lett 582, 1220-1224. 
Barabasi, A.L., and Bonabeau, E. (2003). Scale-free networks. Sci Am 288, 60-69. 
Barabasi, A.L., Gulbahce, N., and Loscalzo, J. (2011). Network medicine: a network-based 
approach to human disease. Nat Rev Genet 12, 56-68. 
Batada, N.N., Reguly, T., Breitkreutz, A., Boucher, L., Breitkreutz, B.J., Hurst, L.D., and Tyers, 
M. (2006). Stratus not altocumulus: a new view of the yeast protein interaction network. PLoS 
Biol 4, e317. 
Batada, N.N., Reguly, T., Breitkreutz, A., Boucher, L., Breitkreutz, B.J., Hurst, L.D., and Tyers, 
M. (2007). Still stratus not altocumulus: further evidence against the date/party hub distinction. 
PLoS Biol 5, e154. 
Bertin, N., Simonis, N., Dupuy, D., Cusick, M.E., Han, J.D., Fraser, H.B., Roth, F.P., and Vidal, 
M. (2007). Confirmation of organized modularity in the yeast interactome. PLoS Biol 5, e153. 
Cherry, J.M., Ball, C., Weng, S., Juvik, G., Schmidt, R., Adler, C., Dunn, B., Dwight, S., Riles, 
L., Mortimer, R.K., et al. (1997). Genetic and physical maps of Saccharomyces cerevisiae. 
Nature 387, 67-73. 
24
Cusick, M.E., Klitgord, N., Vidal, M., and Hill, D.E. (2005). Interactome: gateway into systems 
biology. Hum Mol Genet 14 Spec No. 2, R171-181. 
Cusick, M.E., Yu, H., Smolyar, A., Venkatesan, K., Carvunis, A.R., Simonis, N., Rual, J.F., 
Borick, H., Braun, P., Dreze, M., et al. (2009). Literature-curated protein interaction datasets. 
Nat Methods 6, 39-46. 
Das, J., Mohammed, J., and Yu, H. (2012). Genome scale analysis of interaction dynamics 
reveals organization of biological networks. Bioinformatics. 
Dreze, M., Charloteaux, B., Milstein, S., Vidalain, P.O., Yildirim, M.A., Zhong, Q., Svrzikapa, 
N., Romero, V., Laloux, G., Brasseur, R., et al. (2009). 'Edgetic' perturbation of a C. elegans 
BCL2 ortholog. Nat Methods 6, 843-849. 
Feldman, I., Rzhetsky, A., and Vitkup, D. (2008). Network properties of genes harboring 
inherited disease mutations. Proc Natl Acad Sci U S A 105, 4323-4328. 
Girvan, M., and Newman, M.E. (2002). Community structure in social and biological networks. 
Proc Natl Acad Sci U S A 99, 7821-7826. 
Goh, K.I., Cusick, M.E., Valle, D., Childs, B., Vidal, M., and Barabasi, A.L. (2007). The human 
disease network. Proc Natl Acad Sci U S A 104, 8685-8690. 
Han, J.D., Bertin, N., Hao, T., Goldberg, D.S., Berriz, G.F., Zhang, L.V., Dupuy, D., Walhout, 
A.J., Cusick, M.E., Roth, F.P., et al. (2004). Evidence for dynamically organized modularity in 
the yeast protein-protein interaction network. Nature 430, 88-93. 
Hermjakob, H., Montecchi-Palazzi, L., Bader, G., Wojcik, J., Salwinski, L., Ceol, A., Moore, S., 
Orchard, S., Sarkans, U., von Mering, C., et al. (2004). The HUPO PSI's molecular interaction 
format--a community standard for the representation of protein interaction data. Nat Biotechnol 
22, 177-183. 
25
Hertz-Fowler, C., Peacock, C.S., Wood, V., Aslett, M., Kerhornou, A., Mooney, P., Tivey, A., 
Berriman, M., Hall, N., Rutherford, K., et al. (2004). GeneDB: a resource for prokaryotic and 
eukaryotic organisms. Nucleic Acids Res 32, D339-343. 
Hu, Z., Hung, J.H., Wang, Y., Chang, Y.C., Huang, C.L., Huyck, M., and DeLisi, C. (2009). 
VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene 
ontology. Nucleic Acids Res 37, W115-121. 
Jeong, H., Tombor, B., Albert, R., Oltvai, Z.N., and Barabasi, A.L. (2000). The large-scale 
organization of metabolic networks. Nature 407, 651-654. 
Kerrien, S., Aranda, B., Breuza, L., Bridge, A., Broackes-Carter, F., Chen, C., Duesbury, M., 
Dumousseau, M., Feuermann, M., Hinz, U., et al. (2012). The IntAct molecular interaction 
database in 2012. Nucleic Acids Res 40, D841-846. 
Keshava Prasad, T.S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., 
Telikicherla, D., Raju, R., Shafreen, B., Venugopal, A., et al. (2009). Human Protein Reference 
Database--2009 update. Nucleic Acids Res 37, D767-772. 
Licata, L., Briganti, L., Peluso, D., Perfetto, L., Iannuccelli, M., Galeota, E., Sacco, F., Palma, 
A., Nardozza, A.P., Santonico, E., et al. (2012). MINT, the molecular interaction database: 2012 
update. Nucleic Acids Res 40, D857-861. 
Maglott, D., Ostell, J., Pruitt, K.D., and Tatusova, T. (2007). Entrez Gene: gene-centered 
information at NCBI. Nucleic Acids Res 35, D26-31. 
Manolio, T.A. (2010). Genomewide association studies and assessment of the risk of disease. N 
Engl J Med 363, 166-176. 
Matsuyama, A., Arai, R., Yashiroda, Y., Shirai, A., Kamata, A., Sekido, S., Kobayashi, Y., 
Hashimoto, A., Hamamoto, M., Hiraoka, Y., et al. (2006). ORFeome cloning and global analysis 
26
of protein localization in the fission yeast Schizosaccharomyces pombe. Nat Biotechnol 24, 841-
847. 
Mewes, H.W., Ruepp, A., Theis, F., Rattei, T., Walter, M., Frishman, D., Suhre, K., Spannagl, 
M., Mayer, K.F., Stumpflen, V., et al. (2011). MIPS: curated databases and comprehensive 
secondary data resources in 2010. Nucleic Acids Res 39, D220-224. 
Pawson, T., and Nash, P. (2000). Protein-protein interactions define specificity in signal 
transduction. Genes Dev 14, 1027-1047. 
Pfeiffer, T., and Hoffmann, R. (2007). Temporal patterns of genes in scientific publications. Proc 
Natl Acad Sci U S A 104, 12052-12056. 
Salwinski, L., Miller, C.S., Smith, A.J., Pettit, F.K., Bowie, J.U., and Eisenberg, D. (2004). The 
Database of Interacting Proteins: 2004 update. Nucleic Acids Res 32, D449-451. 
Stark, C., Breitkreutz, B.J., Chatr-Aryamontri, A., Boucher, L., Oughtred, R., Livstone, M.S., 
Nixon, J., Van Auken, K., Wang, X., Shi, X., et al. (2011). The BioGRID Interaction Database: 
2011 update. Nucleic Acids Res 39, D698-704. 
Stenson, P.D., Mort, M., Ball, E.V., Howells, K., Phillips, A.D., Thomas, N.S., and Cooper, D.N. 
(2009). The Human Gene Mutation Database: 2008 update. Genome Med 1, 13. 
Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A., Minguez, P., Doerks, T., 
Stark, M., Muller, J., Bork, P., et al. (2011). The STRING database in 2011: functional 
interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39, D561-
568. 
Turinsky, A.L., Razick, S., Turner, B., Donaldson, I.M., and Wodak, S.J. (2010). Literature 
curation of protein interactions: measuring agreement across major public databases. Database 
(Oxford) 2010, baq026. 
27
Turner, B., Razick, S., Turinsky, A.L., Vlasblom, J., Crowdy, E.K., Cho, E., Morrison, K., 
Donaldson, I.M., and Wodak, S.J. (2010). iRefWeb: interactive analysis of consolidated protein 
interaction data and their supporting evidence. Database (Oxford) 2010, baq023. 
Venkatesan, K., Rual, J.F., Vazquez, A., Stelzl, U., Lemmens, I., Hirozane-Kishikawa, T., Hao, 
T., Zenkner, M., Xin, X., Goh, K.I., et al. (2009). An empirical framework for binary 
interactome mapping. Nat Methods 6, 83-90. 
Vidal, M. (2005). Interactome modeling. FEBS Lett 579, 1834-1838. 
Vidal, M., Cusick, M.E., and Barabasi, A.L. (2011). Interactome networks and human disease. 
Cell 144, 986-998. 
von Mering, C., Krause, R., Snel, B., Cornell, M., Oliver, S.G., Fields, S., and Bork, P. (2002). 
Comparative assessment of large-scale data sets of protein-protein interactions. Nature 417, 399-
403. 
Wang, X., Wei, X., Thijssen, B., Das, J., Lipkin, S.M., and Yu, H. (2012). Three-dimensional 
reconstruction of protein networks provides insight into human genetic disease. Nat Biotech 30, 
159-164. 
Watts, D.J., and Strogatz, S.H. (1998). Collective dynamics of 'small-world' networks. Nature 
393, 440-442. 
Yu, H., Braun, P., Yildirim, M.A., Lemmens, I., Venkatesan, K., Sahalie, J., Hirozane-
Kishikawa, T., Gebreab, F., Li, N., Simonis, N., et al. (2008). High-quality binary protein 
interaction map of the yeast interactome network. Science 322, 104-110. 
Yu, H., Greenbaum, D., Xin Lu, H., Zhu, X., and Gerstein, M. (2004). Genomic analysis of 
essentiality within protein networks. Trends Genet 20, 227-231. 
28
Zhong, Q., Simonis, N., Li, Q.R., Charloteaux, B., Heuze, F., Klitgord, N., Tam, S., Yu, H., 
Venkatesan, K., Mou, D., et al. (2009). Edgetic perturbation models of human inherited 
disorders. Mol Syst Biol 5, 321. 
 
29
Collect interactions for the 3 organisms from 
dierent databases - BioGrid, DIP, HPRD, 
IntAct, IRefWeb, MINT, MIPS, VisAnt
Classify the interactions into binary and co-
complex and remove ones inadequately sup-
ported by experimental evidence.
Group interactions into high-throughput (HT) 
and literature-curated (LC) datasets. Map all 
gene names to unique identiers. 
Manually recheck experimental evidence for 
the HT data and use a cuto of 2 independent 
publications for LC data. 
Compile overall binary and co-
complex interactomes. Separate the 
binary interactome into HT and LC 
sub-networks.
Figure 2.1
Binary
Human: 27356
S. cerevisiae: 11936
S. pombe: 160
Co-complex
Human: 7629
S. cerevisiae: 16294
S. pombe: 417
30
Figure 2.2
100 101 102 103
10−5
10−4
10−3
10−2
10−1
100
S. cerevisiae co−complex
k
P(
k)
P(k) = 0.427k−1.405 ; R2 = 0.8282 
100 101 102 10310
−5
10−4
10−3
10−2
10−1
100
S. cerevisiae binary
k
P(
k)
P(k) = 0.591k−1.639 ; R2 = 0.8818 
100 101 102 10310
−5
10−4
10−3
10−2
10−1
100 Human binary
k
P(
k)
P(k) = 0.644k−1.695 ; R2 = 0.9036 
100 101 102 10310
−5
10−4
10−3
10−2
10−1
100 Human co−complex
k
P(
k)
P(k) = 0.442k−1.607 ; R2 = 0.8704
31
Human binary Human co−complex S.c. binary S.c. co−complex S.p. binary S.p. co−complex0
5
10
15
20
25
30
35
40
P
er
ce
n
ta
g
e 
In
cr
ea
se
 in
 O
ve
rl
ap
s 
af
te
r 
F
ilt
er
in
g
p < 10−8 p < 10−8p < 10
−8
p < 10−8 p = 1.1x10
−6
p = 2.2x10
−3
Figure 2.3
32
Figure 2.4
0 1 2 3 >=4
0
5
10
15
20
25
30
35
40
Number of Interactors
P
e
r
c
e
n
t
a
g
e
 
o
f
 
D
i
s
e
a
s
e
 
G
e
n
e
s
HT
LC
0 10 20 30 40 50 60 70 80 90 100
0
500
1000
1500
2000
2500
3000
3500
4000
4500
A
v
e
r
a
g
e
 
N
u
m
b
e
r
 
o
f
 
P
u
b
l
i
c
a
t
i
o
n
s
HT
LC
k, Degree>=k
0 1 2
0
5
10
15
20
25
30
35
40
45
Number of Interactors
P
e
r
c
e
n
t
a
g
e
 
o
f
 
D
i
s
e
a
s
e
 
H
u
b
s
0 10 20 30 40 50 60 70 80 90 100
0
100
200
300
400
500
600
700
800
900
k, Degree>=k
A
v
e
r
a
g
e
 
N
u
m
b
e
r
 
o
f
 
P
u
b
l
i
c
a
t
i
o
n
s
HT
LC p < 10-8
33
Experimental Evidence PSI-MI Evidence Code
array technology 0008
beta galactosidase complementation 0010
beta lactamase complementation 0011
bioluminescence resonance energy transfer 0012
adenylate cyclase complementation 0014
circular dichroism 0016
classical fluorescence spectroscopy 0017
two hybrid 0018
coimmunoprecipitation 0019
transmission electron microscopy 0020
cosedimentation 0027
cosedimentation in solution 0028
cosedimentation through density gradient 0029
cross-linking study 0030
protein cross-linking with a bifunctional reagent 0031
dynamic light scattering 0038
electron microscopy 0040
electron paramagnetic resonance 0042
far western blotting 0047
filamentous phage display 0048
filter binding 0049
fluorescence correlation spectroscopy 0052
fluorescence polarization spectroscopy 0053
fluorescence-activated cell sorting 0054
fluorescent resonance energy transfer 0055
isothermal titration calorimetry 0065
lambda phage display 0066
light scattering 0067
molecular sieving 0071
nuclear magnetic resonance 0077
peptide array 0081
phage display 0084
protein array 0089
protein complementation assay 0090
chromatography technology 0091
reverse ras recruitment system 0097
scintillation proyimity assay 0099
static light scattering 0104
surface plasmon resonance 0107
t7 phage display 0108
dihydrofolate reductase reconstruction 0111
ubiquitin reconstruction 0112
x-ray crystallography 0114
yeast display 0115
ion eychange chromatography 0226
reverse phase chromatography 0227
Binary Interactions
TABLE 2.1
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green fluorescence protein complementation 
assay 0229
mammalian protein protein interaction trap 0231
transcriptional complementation assay 0232
blue native page 0276
ley-a dimerization assay 0369
toy-r dimerization assay 0370
two hybrid array 0397
two hybrid pooling approach 0398
two hybrid fragment pooling approach 0399
comigration in non denaturing gel 
electrophoresis 0404
competition binding 0405
deacetylase assay 0406
electron tomography 0410
enzyme linked immunosorbent assay 0411
enzymatic study 0415
fluorescence microscopy 0416
kinase homogeneous time resolved fluorescence 0420
in-gel kinase assay 0423
protein kinase assay 0424
phosphatase assay 0434
protease assay 0435
saturation binding 0440
homogeneous time resolved fluorescence 0510
methyltransferase assay 0515
methyltransferase radiometric assay 0516
enzymatic footprinting 0605
lambda repressor two hybrid 0655
antibody array 0678
reverse two hybrid 0726
gal4 vp16 complementation 0728
luminescence based mammalian interactome 
mapping 0729
comigration in gel electrophoresis 0807
comigration in sds page 0808
bimolecular fluorescence complementation 0809
y-ray fiber diffraction 0825
y ray scattering 0826
phosphotransfer assay 0841
immunodepleted coimmunoprecipitation 0858
intermolecular force 0859
demethylase assay 0870
atomic force microscopy 0872
acetylation assay 0889
surface plasmon resonance array 0921
polymerization 0953
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Experimental Evidence PSI-MI Evidence Code
affinity chromatography technology 0004
anti bait coimmunoprecipitation 0006
anti tag coimmunoprecipitation 0007
mass spectrometry studies of complexes 0069
pull down 0096
affinity technology 0400
tandem affinity purification 0676
Co-complex Associations
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MIPS Evidence Code MIPS Description Corresponding PSI-MI Code
902.01.01.02.01.01 co-immunoprecipitation 0019
902.01.01.02.01.03 centrifugation 0027
902.01.01.02.01.05.01 cross linking, chemical 0031
902.01.01.02.01.05.02 cross linking, UV 0430
902.01.01.02.01.06 in vitro reconstitution 0492
902.01.01.02.01.07 two hybrid 0018
902.01.01.02.01.08 overlay 0047
902.01.01.02.01.09.01 FRET 0055
902.01.01.02.01.09.02 scintillation proximity assay 0099
902.01.01.02.01.10 surface plasmon resonance 0107
902.01.01.02.01.11 phage display 0084
902.01.01.02.01.13.01 electron microscopy 0040
902.01.01.02.01.13.02 NMR 0077
MIPS Evidence Code MIPS Description Corresponding PSI-MI Code
902.01.01.02.01 physical 0013
902.01.01.02.01.01.02 epitope tag co-ip 0007
902.01.01.02.01.02 affinity chromatography 0004
902.01.01.02.01.02.01 affinity chromatography, native 0004
902.01.01.02.01.02.02 affinity tag chromatography 0004
Binary Interactions
Co-complex Associations
Table 2.2
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VisAnt Evidence Code VisAnt Description Corresponding PSI-MI Code
M0010 Co-immunoprecipitation 0019
M0011 Co-sedimentation 0027
M0012 Competition binding 0405
M0013 Copurification 0025
M0014 Cross-linking studies 0030
M0015 Electron microscopy 0040
M0018 Molecular sieving 0071
M0021 Western blot 0113
M0024 Immunoprecipitation 0019
M0026 In vitro binding 0492
M0029 Monoclonal antibody 0671
M0032 Sizing Column 0071
M0033 Cosedimentation 0027
M0034 Two-hybrid 0018
M0035 X-ray 0114
M0049 Surface plasmon resonance 0921
M0050 Phage display 0084
M0051 ELISA 0411
M0052 Fluorescence technology 0051
M0053 Filter binding 0928
M0060 Far western 0047
M0061 Resonance energy transfer 0055
M0062 Electron microscopy 0040
M0066 Enzymatic study 0415
M0068 Protein array 0089
M0069 Protein complementation assay 0090
M0070 NMR 0077
M0071 X-ray crystallography 0114
M0079 Co-fractionation 0027
M0085 Chromatography 0091
M0092 Peptide array 0081
M0095 Protein kinase assay 0424
M0096 Blue native PAGE 0276
M0097 Comigration in gel electophoresis 0404
M0100 Ubiquitin reconstruction 0112
M0101 Phosphatase assay 0434
M0103 Isothermal titration calorimetry 0065
VisAnt Evidence Code VisAnt Description Corresponding PSI-MI Code
M0006 Affinity column 0400
M0028 Mass spectrometry of complex 0069
M0044 Affinity precipitation 0400
M0045 Affinity technology 0400
M0065 Anti-tag co-IP 0007
M0067 Pull down 0096
Binary Interactions
Co-complex Associations
TABLE 2.3
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M0074 Reconstituted complex 0069
M0088 Tandem affinity purification 0676
M0089 Anti-bait Co-IP 0006
M5001 Tandem affinity mass spectrometry 0032
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CHAPTER 3 
 
Elucidating common structural features of human pathogenic variations using 
large-scale atomic-resolution protein networks  
 
In the following chapter, we examine human disease mutations in the context of structurally-
resolved protein networks. I am the sole first author of the manuscript resulting from this chapter 
(Das et al Human Mutation 2014). I am also a co-first author on another related manuscript 
(Wang*, Wei*, Thijssen*, Das* et al Nature Biotechnology 2012 *=Equal contribution); I have 
not devoted a separate chapter to that paper in my thesis as the core concepts common to both 
papers are covered in this chapter. 
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3.1 ABSTRACT 
 
With the rapid growth of structural genomics, numerous protein crystal structures have become 
available. However, the parallel increase in knowledge of the functional principles underlying 
biological processes, and more specifically the underlying molecular mechanisms of disease, has 
been less dramatic. This notwithstanding, the study of complex cellular networks has made 
possible the inference of protein functions on a large scale. Here, we combine the scale of 
network systems biology with the resolution of traditional structural biology to generate a large-
scale atomic-resolution interactome-network comprising 3,398 interactions between 2,890 
proteins with a well-defined interaction interface and interface residues for each interaction. 
Within the framework of this atomic-resolution network, we have explored the structural 
principles underlying variations causing human inherited disease. We find that in-frame 
pathogenic variations are enriched at both the interface and in the interacting domain, suggesting 
that variations not only at interface “hot-spots”, but in the entire interacting domain can result in 
alterations of interactions. Further, the sites of pathogenic variations are closely related to the 
biophysical strength of the interactions they perturb. Finally, we show that biochemical 
alterations consequent to these variations are considerably more disruptive than evolutionary 
changes, with the most significant alterations at the protein interaction interface. 
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3.2 INTRODUCTION 
 
The functions of a protein are inherently bound up with its three-dimensional structure – both 
regular secondary structures and disordered elements play a role in modulating function(Lahiry 
et al., 2010). Protein structures are often so intricate that even comparatively minor structural 
alterations can cause dramatic changes in function. Since such disruptions often lead to 
disease(Celli et al., 1999; Haberle et al., 2011), a significant amount of effort has been invested 
in attempting to determine the principles underlying complex structure-function relationships in 
human proteins. To date, however, most of this effort has been directed towards understanding 
how individual folds, domains or structural motifs carry out specific cellular functions(Andreeva 
et al., 2008; Pearl et al., 2005). Furthermore, most proteins carry out their functions by 
interacting with other proteins, all of which are part of a complex cellular network termed the 
“interactome”(Vidal, 2005; Vidal et al., 2011).  
           Recently, studies have become focused on how protein networks can be used to infer 
function and how changes in these networks can lead to human disease(Barabasi et al., 2011; 
Vidal et al., 2011). However, these efforts have had only limited success because protein 
networks are still incomplete(Vidal et al., 2011) and studies to date have treated proteins as mere 
graph-theoretical points in a mathematical network rather than as biological entities with their 
own structural details and chemical properties(de Souza, 2012; Wang et al., 2012). The 
importance of structural considerations has been well-recognized in predicting protein-protein 
interactions(Tuncbag et al., 2011; Zhang et al., 2012) and functional residues for each 
interaction(Marks et al., 2012). However, although structure has been widely employed to 
understand the evolutionary impact of single nucleotide polymorphisms (SNPs) (Bao and Cui, 
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2005; David et al., 2012; Sunyaev et al., 2001), the number of studies which have examined 
pathogenic variations in a structural context has been limited(Studer et al., 2013). To address this 
deficiency, we previously used a domain-level interaction network to show that in-frame 
pathogenic variations tend to be enriched within interacting domains(Wang et al., 2012). 
However, interacting domains comprise not only interface residues that are directly involved in 
the physical interaction between the two proteins but also other non-contact residues. In our 
earlier study, we did not differentiate between these two categories of amino acid residues. Since 
it is generally considered that interface residues mediate protein-protein interactions(Jones and 
Thornton, 1996), it is of paramount importance to examine the differential distribution of 
pathogenic variations between interface and non-interface residues within interacting domains. 
Moreover, only at the resolution of individual amino acid residues is it possible to ascertain 
structural (i.e., biophysical and biochemical) principles governing pathogenic processes. 
To this end, we present here a large-scale atomic-resolution human interactome network 
by systematically identifying the interaction interfaces and corresponding residues mediating all 
interactions with available co-crystal structures in the Protein Data Bank (PDB)(Berman et al., 
2000). Using this atomic-resolution interactome network, we analyze the distribution of 
pathogenic variations in different regions of human proteins focusing on interface and non-
contact residues within interacting domains. We also explore how the locational specificity of 
these variations is directly associated with the strength of the interactions they disrupt. Finally, 
we examine biochemical properties of human pathogenic variations and compare them to their 
evolutionary counterparts.  
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 3.3 RESULTS 
 
Atomic-resolution structural analysis of pathogenic variations and their molecular 
mechanisms 
Pathogenic variations belong to two broad categories – in-frame variations (both missense 
variations and in-frame microinsertions and microdeletions) and truncating variations (both 
nonsense point variations and frameshift insertions or deletions)(Zhong et al., 2009). We 
previously found that in-frame pathogenic variations are non-randomly distributed in proteins – 
indeed, they tend to be enriched within interacting domains. On the other hand, truncating 
variations do not show any particular trend with regard to their distribution in different parts of 
the protein(Wang et al., 2012).  
It has been commonly accepted that interface residues mediate interactions between 
proteins(Hu et al., 2000; Jones and Thornton, 1996). Moreover, it is generally believed that “only 
a small portion of interface residues, the so-called hot spot residues, contribute the most to the 
binding energy of the protein complex”(Assi et al., 2010). These hot-spots are often the targets of 
drug molecules(Wells and McClendon, 2007). Owing to the limits of resolution of our previous 
study(Wang et al., 2012), we were able to perform the investigation only at the domain level, not 
at the level of individual residues. Employing the newly derived atomic-resolution interactome 
network, we set out to systematically examine whether pathogenic variations tend to specifically 
alter interface residues, as our previous results suggested might be the case. This network is 
higher resolution that other structurally resolved networks(Khurana et al., 2013; Wang et al., 
2012) as it reports not just interacting domains for 3,398 interactions, but individual amino acids 
residues mediating each interaction. We calculated the enrichment of in-frame variations at the 
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interaction interface, the remainder of the interacting domain, and the rest of the protein. We 
found that in-frame variations are enriched significantly both at the interface and in the 
remainder of the interacting domain (odds ratio = 1.67, P < 10-3 for interface residues; odds ratio 
= 1.75, P < 10-3 for the remainder of the interacting domain; Figure 1A). To confirm that the 
observed trends are robust, we performed the same calculations with only the fraction of the 
protein in the actual co-crystal, because in many cases the crystallized structure does not contain 
full-length proteins. 62.6% of all the pathogenic variations used for our calculations in Fig. 1a 
are present within co-crystal structures. Using only these variations, our results remain 
unchanged – in-frame variations are enriched at both the interface and in the remainder of the 
interacting domain even if we consider only residues depicted within the co-crystal structures. To 
assess the significance of a decrease in solvent accessibility, we used randomly chosen cutoffs – 
decreases of 0.5 Å2, 2 Å2 and 5 Å2 in solvent accessible surface area to define 3 alternate sets of 
interface residues. Using these 3 sets of residues, we repeated our calculations in Fig. 1a. We 
find that our results remain unchanged with all 3 alternate sets of residues. This shows that our 
results are robust to the choice of cutoff for decrease in solvent accessible area to define interface 
residues. In fact, the sets of interface residues are very similar for any cutoff between 0.5 Å2 to 5 
Å2. 
Our result shows that it is not simply the interface residues, but rather the interacting 
domain in its entirety that plays an important role in pathology for many disease genes. As a 
negative control, we calculated the distribution of 94,084 missense non-synonymous single 
nucleotide polymorphisms (SNPs) from ESP6500 in 2,829 genes and found that these were 
distributed randomly across the protein (Figure 1B). Most genes contain relatively few 
pathogenic variations and SNPs. Moreover, there is no significant difference (P = 0.33) in the 
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distribution of pathogenic variations and SNPs across various genes, confirming that the 
differences observed in the distribution of disease-associated variants and SNPs are not due to 
gene-specific distribution biases. To further confirm that SNPs are indeed randomly distributed 
across proteins, we repeated our calculations with only those genes that contain at least one 
disease-associated variant (i.e., those genes used for the calculations in Figure 1A) and found 
that SNPs in these genes are also randomly distributed across the length of the protein. 
Moreover, even if we consider SNPs present only within co-crystal structures, we find that they 
are still randomly distributed across proteins. 
We also note that in-frame variations outside the interface were enriched in buried 
residues (Figure 1C). The importance of buried residues in maintaining the overall stability of 
the protein is well established(Gromiha et al., 1999). It has been suggested that in-frame and 
truncating variations have distinct disruption modes – the former is likely to disrupt specific 
interactions whereas the latter usually leads to degradation of the entire protein leading to a loss 
of all interactors(Zhong et al., 2009). Our results suggest that even for in-frame variations, the 
possible molecular mechanisms by which variations at or near the interface (and distant from it) 
affect protein-protein interactions are likely to be distinct: those at the interface are more likely 
to alter specific interactions, thereby causing the mutated protein either to lose or acquire specific 
functions; by contrast, in-frame variations in other non-interacting regions are more likely to 
disrupt the core of the protein and lead to incorrect folding and/or degradation of the protein, 
resulting in the loss of all interactions for the mutated protein (Figure 1D). 
To further understand the effects of variations in the interacting domain outside the 
interface, we examined the effects of two disease-associated variants on the PTS-PTS interaction 
(Figure 2A). Using site-directed mutagenesis PCR, we introduced the two variants – R25Q and 
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R9C on PTS. Although the R25Q variant is located on the PTPS domain that mediates the PTS-
PTS interaction, it is not at an interface residue. Using yeast two-hybrid, we confirmed that wild-
type PTS interacts with itself (Figure 2B). However the R25Q variant disrupts this interaction 
(Figure 2B). On the other hand, the R9C variant lies outside the interface mediating the PTS-PTS 
interaction. Using yeast two-hybrid, we confirmed that this variant (R9C) does not affect the 
interaction (Figure 2B). This shows that variations in the interacting domain outside the interface 
can disrupt protein interactions, whereas the same interactions can remain unaffected by variants 
outside the corresponding interacting domains. 
Moreover, using Western blotting, we confirm that all three variants are stable (Fig. 2b). 
Together, these results show that the R25Q variant causes an interaction-specific disruption – the 
PTS-PTS homodimeric interaction is lost due to a local structural alteration in the corresponding 
interacting domain. It has been previously shown that the enzymatic activity of the R25Q variant 
of PTS is reduced, but not completely abolished compared to the activity of WT PTS(Oppliger et 
al., 1995; Thony et al., 1994). Our results suggest a molecular mechanistic basis for this 
reduction – since the dimerization of PTS is important for its enzymatic activity(Oppliger et al., 
1995; Thony et al., 1994), the pathogenic R25Q that disrupts the PTS homodimer reduces this 
activity. However, since the variant is stable, PTS still maintains part of its activity. 
 
Pathogenic variation loci associated with interaction strength 
To understand the biophysical mechanisms by which in-frame pathogenic variations alter 
specific interactions, we examined the relationship between the spatial distribution of the 
variations and the strength of the interactions they perturb. Here, we explored the biophysical 
strength of an interaction – the stronger the interaction, the higher the free energy difference 
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between the bound and unbound states of the proteins;(Noskov and Lim, 2001; Shi et al., 2006) 
by calculating the buried surface area of all the interactions in the atomic-resolution human 
interactome network. The most direct measure of interaction strength is the equilibrium 
association constant (Ka, inverse of the equilibrium dissociation constant Kd). However, it is 
difficult to measure Ka in a high-throughput fashion and the amount of experimental Ka data is 
limited to a handful of human protein-protein interactions.  
It has been suggested that the strength of an interaction can be measured by its buried surface 
area in the co-crystal structure(Jones and Thornton, 1996). To validate this postulate, we 
classified all interactions in the network into three distinct categories on the basis of their buried 
surface area – low, medium and high. Using a genome-wide microarray analysis that measures 
the expression levels of human genes at different time points in the cell cycle(Whitfield et al., 
2002), we calculated the enrichment in co-expression of proteins involved in these interactions. 
We found that interactions with high buried surface area are significantly more likely to be co-
expressed than interactions with low buried surface area (P = 0.015, Figure 3A). It is well known 
that strong, stable interactions are more likely to be co-expressed than weak, transient 
interactions(von Mering et al., 2002; Yu et al., 2008). Our result confirms that protein-protein 
interactions mediated by high buried surface area are indeed stronger. Moreover, we calculated 
the fraction of these binary interactions independently for the three categories detected in stable 
protein complexes. We found that interactions with high buried surface area are significantly 
enriched in stable complexes, further supporting the conclusion that these are stronger 
interactions (Figure 3B). Finally, we calculated the correlation between Ka and buried surface 
area using SKEMPI, a database of binding free energy changes for interactions with supporting 
co-crystal structures(Moal and Fernandez-Recio, 2012). For all interactions in SKEMPI 
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involving wild-type human proteins, we calculated the correlation between Ka values and the 
buried surface area. We find that there is a significant correlation (ρ = 0.63, P < 10-3 using a 
permutation test) between Ka and buried surface area, confirming that the latter is an appropriate 
surrogate for interaction strength. 
 Next, we determined the distribution of in-frame variations in different parts of the 
protein as a function of the strength of the interaction. We found that variations at the interface 
tend to disrupt strong interactions (odds ratio = 1.10, P = 0.005) whereas those in the rest of the 
protein outside the interacting domains tend to be enriched in weak interactions (odds ratio = 
1.24, P < 10-3; Figures 3C-3E). As a control, we also computed the distribution of SNPs in 
different parts of the protein as a function of interaction strength. We found that SNPs at the 
interface and away from the interface are both randomly distributed with respect to interaction 
strength. Our results therefore suggest that there is a relationship between the location of the 
disease variation and the biophysical strength of the interactions it disrupts. Because pathogenic 
variations are enriched at the interaction interface and interface variations selectively affect 
biophysically strong interactions, we surmise that many strong interactions within stable protein 
complexes involved in key cellular functions are likely to be preferentially disrupted in human 
disease. This provides a molecular-level biophysical explanation for the results of previous 
studies which have suggested that protein complexes are useful predictors for discovering 
unknown disease genes(Fraser and Plotkin, 2007). 
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Significant alterations in structural and biochemical properties of amino acids involved in 
human inherited disease 
To systematically explore the structural properties of human pathogenic variations, we analyzed 
relationships between the properties of these variations and their accessibility in the protein. 
Amino acids may be classified as either accessible or inaccessible. Using the Janin accessibility 
scale(Janin, 1979), we then calculated the proportion of accessibility-altering in-frame missense 
disease-associated variations (i.e., point variations that cause an accessible wild-type amino acid 
to be changed to an inaccessible amino acid or vice versa) in different parts of the protein. These 
variations are most likely to cause dramatic changes to the configuration of the interface because 
the local structural configuration is drastically altered. Since disease-associated variations in 
different parts of the protein may exert their effects via different pathophysiological mechanisms, 
we normalized our results by calculating the ratio of accessibility-altering in-frame variations 
against a background distribution of putatively neutral SNPs that are characterized by a similar 
change in their accessibility. Since these SNPs are uniformly distributed throughout the protein 
(Fig. 1b), this gives us an idea of the relative propensity of disease-associated variations to be 
significantly accessibility-altering. We found that at both surface and buried residues, and indeed 
in all parts of the protein, accessibility-altering variations are significantly more likely to occur in 
pathogenic variations as opposed to putatively neutral variants in the general population (P < 10-
3; Figure 4A). 
 We also examined amino acid substitutions in terms of their change in polarity. We 
calculated the proportion of polarity-altering in-frame missense disease-associated variations 
(i.e., those that cause a polar wild-type amino acid to change to a non-polar amino acid or vice 
versa). We note that these alterations also follow a similar trend – at both surface and buried 
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residues, and in all regions of the protein, polarity-altering variations are significantly more 
likely to occur in disease as opposed to putatively neutral variants in the population (P < 10-3; 
Figure 4A). This suggests that disease-associated variations are biochemically more destabilizing 
to the protein than benign variants in the population.  
To further understand how disease-associated variations differ in terms of their 
biochemical properties from changes that have been fixed over the course of evolutionary time, 
we calculated the relative enrichment of all possible pairs of amino-acid changes for disease-
associated in-frame missense variations over those that have occurred during evolution. We 
obtained the probabilities of amino acid changes occurring during evolution from a recently 
updated version of the Dayhoff matrices(Kosiol and Goldman, 2005). We compared these 
amino-acid changes to in-frame disease variations occurring throughput the protein (Figure 4B). 
We found that disease-associated variations generally tend to alter accessibility of the wild-type 
amino acid whereas evolutionary changes tend to preserve it (P = 0.010; Figure 4C). Our 
findings contrast with previous reports of significant correlations between amino acid variations 
in genetic disease and evolution(Wu et al., 2007). To further understand the specific differences 
in the distribution of variations in different parts of the protein, we determined which variations 
were enriched at least 2-fold at the interaction interface compared to other regions of the protein 
(Figure 4D). We found that these interface variations are significantly more likely to change the 
accessibility of the amino acid involved (P = 0.034), with the most dramatic changes occurring 
with those variations with the highest enrichment.  
By way of an example, a K143I variation at the interaction interface of RNASEH2B and 
RNASEH2C has been shown to be associated with a human auto-inflammatory disorder, 
Aicardi-Goutières syndrome(Reijns et al., 2011). This variation causes a major change in 
51
structural and biochemical properties, leading to a significant structural modification at the 
interface that specifically alters the wild-type interaction (Figure 4E). These results further 
validate our finding that pathogenic variations tend to be more disruptive than random 
evolutionary changes, with those occurring at the protein interface causing the most drastic 
changes, enough to perturb even strong interactions. 
 
3.4 DISCUSSION 
  
In this study, we build and use an atomic-resolution human protein interactome network to 
improve our understanding of the structural principles and molecular mechanisms of pathogenic 
variations that perturb protein-protein interactions leading to disease. We find that in-frame 
variations are significantly enriched both at the interaction interface as well as in the remainder 
of the corresponding interacting domain. Thus, it is not just the residues at the interface which 
serve as the key mediators of interactions(Hu et al., 2000; Jones and Thornton, 1996), variations 
outside the interface but within the interacting domain are capable of altering protein-protein 
interactions. Our findings suggest that it is the alteration of specific interactions by in-frame 
variations within the entire interacting domain that is a major molecular determinant of human 
inherited disease. Moreover, we show that there are important biochemical and biophysical 
differences between variations at the interface and those located in the remainder of the protein 
molecule. Specifically, we find that the locations of pathogenic variations are associated with the 
strength of interactions – those at the interface tend to selectively disrupt stronger interactions. 
One mechanistic explanation for such a phenomenon is the tendency for variations enriched at 
the interface (as compared to other parts of the protein) to cause the most dramatic changes in 
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their structural and biochemical properties. Analyses at the level of individual amino acids are 
only possible with atomic-resolution interactome networks. Our findings suggest that the 
structurally guided prioritization of pathogenic variations identified in large-scale sequencing 
studies using an atomic-resolution network might be useful in the context of informing follow-up 
experiments. 
The coverage of the atomic-resolution human protein interactome network is limited by 
the number of co-crystal structures currently available in PDB. As more co-crystal structures 
become available(Chandonia and Brenner, 2006), the same principles developed here can be 
readily applied to reveal additional specific structural mechanisms underlying pathogenic 
variations. Our work further underscores the importance of the exploration of all possible domain 
architectures by structural genomics consortia(Editorial, 2007). Using our methodology on a 
more complete set of structural folds is likely to generate reliable direct atomic-resolution target 
sites for structurally-aided rational drug design, and has the potential to overcome the difficulties 
routinely encountered due to the paucity of well-elucidated structural targets(Tanrikulu and 
Schneider, 2008; Xie and Bourne, 2011). 
 
3.5 MATERIALS AND METHODS 
 
Calculating atomic-resolution interface residues for human protein interactions 
To calculate atomic-resolution interaction interfaces, we systematically examined a 
comprehensive list of 7,340 PDB co-crystal structures and were able to determine atomic-
resolution interaction interfaces for 3,398 unique human protein-protein interactions between 
2,890 proteins. To define the interface, we used a water molecule of diameter 1.4Å as a probe 
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and calculated the relative solvent accessible surface areas of the interacting pair as well as the 
individual proteins involved in the interaction(Hubbard and Thornton, 1993). All calculations 
were performed using Naccess(Hubbard and Thornton, 1993). Residues whose relative 
accessibilities changed by more than 1Å2 were considered as potential interface residues. Amino 
acids at the interface reside on the surfaces of the corresponding proteins, but tend to become 
buried in the co-crystal structure as the two proteins bind to each other. It follows that these 
residues should experience a significant decrease in accessible surface area when the bound and 
the unbound states of the protein chains are compared (Franzosa and Xia, 2011). In most cases, 
our calculations incorporated multiple instances of the same interaction from different chains 
within the same PDB structure or entirely different PDB structures representing the same 
interaction. This allows us to accurately determine the exact interface, and normalize differences 
due to specific crystallization conditions(Chayen and Saridakis, 2008). We take the union over 
all such instances subject to the constraint that the particular protein pair contains at least five 
interface residues for both interacting proteins. This ensures that all the interfaces included in our 
calculations represent significant regions of molecular contact, eliminating potential crystal 
contacts. Furthermore, 1,689/3,398 (49.7%) interactions used in this study have been detected by 
at least one other assay and were reported independently in a separate publication. This confirms 
that interactions used in this study are not only real but also reproducible using other assays. 
To further refine the set of identified interface residues, we required that they be necessarily 
present on the surface of the protein. To determine which residues were on the surface, we 
calculated the fraction of surface area for each residue in the individual protein chains that was 
accessible to the water molecule probe defined above(Hubbard and Thornton, 1993). If more 
than 15% of the total surface area for a particular residue was accessible to the water molecule 
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probe, we defined that particular amino acid to be on the surface, otherwise it was considered to 
be buried. Using these two criteria, for each interaction we obtained a set of 141,686 residues 
that represent the interface for 3,398 interactions from 7,340 atomic-resolution co-crystal 
structures. The fraction of homomeric interactions to heteromeric interactions is ~2:1 as the PDB 
is enriched for homodimers as compared to heterodimers. 
 
Identifying interacting domains for each interaction 
We generated a list of putative interacting domains utilizing the “homology modeling approach” 
as described earlier(Meyer et al., 2013) using both 3did(Stein et al., 2011) and iPfam(Finn et al., 
2005). However, some of the domain pairs identified as interacting by 3did and iPfam for a 
particular protein pair may not have been supported by the corresponding co-crystal structure as 
they may have been inferred from other co-crystal structures. Therefore, to avoid potential false 
positives, we additionally required that these domains should contain at least one interface 
residue for them to be considered as interacting domains. Moreover, the set of interacting 
domains inferred by 3did and iPfam were not always complete. For our analysis, we took 
advantage of our own atomic-resolution interface calculations to identify a comprehensive set of 
interacting domains for each co-crystal structure, and included interacting domains not identified 
by 3did or iPfam if they had five or more interface residues. 
 
Compiling a comprehensive list of pathogenic variations and SNPs 
We compiled a comprehensive list of 94,476 pathogenic variations from HGMD(Stenson et al., 
2013; Wang et al., 2012) as described earlier (Wang et al., 2012). We updated our earlier lists 
with a newer version of the HGMD dataset [HGMD Professional v.2012.2]. Specifically, we 
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used in-frame variations (both missense variations and in-frame microinsertions and 
microdeletions) classified as ‘DM’ in HGMD. For further analysis, we employed a total of 
17,306 variations in 673 genes for which we were able to define at least one atomic-resolution 
interaction interface. We also compiled a set of non-synonymous SNPs from the Exome 
Sequencing Project (Fu et al., 2013) from which we derived a dataset of 94,084 SNPs in 2,829 
genes for which we were able to define at least one atomic-resolution interaction interface. 
Using our publicly available supplementary website, http://www.yulab.org/Supp/AtomInt,	  
researchers can query interface residues for their favorite interaction. 
 
Criteria used to choose PTS-PTS homodimeric interaction for experimental validation 
The following criteria were used to choose the PTS-PTS homodimeric interaction for 
experimental validation of the effects of pathogenic variants within and outside the interacting 
domain: 
a. the interaction is supported by a co-crystal structure 
b. the wild-type PTS clone is available in our library. 
c. the wild-type interaction (PTS-PTS) is amenable to testing in our yeast two-hybrid system 
d. there is a pathogenic variation in the interacting domain but outside interface residues. 
e. there is a different pathogenic variation outside both the interface residues and the 
interacting domain. 
 
Generation of PTS variants 
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Wild-type PTS is obtained from the human ORFeome v8.1 collection(Yang et al., 2011). To 
generate the alleles R25Q and R9C corresponding to two different pathogenic variations, 
sequence-verified single-colony wild-type PTS and corresponding mutagenic primers (designed 
according to the protocol accompanying the Stratagene QuikChange Site-Directed Mutagenesis 
Kit #200518) were aliquoted together. Mutagenesis PCR was then performed as specified by the 
New England Biolabs (NEB) PCR protocol for Phusion polymerase (M0530L), noting that PCR 
was limited to 18 cycles. The samples were then digested by DpnI (NEB R0176L) according to 
the manufacturer’s manual. After digestion, samples were transformed into competent E. coli 
and then individually streaked onto LB plates containing spectinomycin to obtain single 
colonies. The generated clones were verified by Sanger sequencing. 
Yeast two-hybrid  
Y2H was done as previously described(Wang et al., 2012). WT PTS and both pathogenic variant 
alleles were transferred by Gateway LR reactions into our Y2H pDEST-AD and pDEST-DB 
vectors. DB-X and AD-Y plasmids were transformed individually into the Y2H strains MATα 
Y8930 and MATa Y8800, respectively. Each of the DB-X MATα transformants (wild-type and 
variants) were then mated against corresponding AD-Y MATa transformants (wild-type and 
variants), including inoculation of AD-Y and DB-X yeast cultures, mating on YEPD media 
(incubated overnight at 30 °C), and replica-plating onto selective Synthetic Complete media 
lacking leucine, tryptophan, and histidine, and supplemented with 1 mM of 3-amino-1,2,4-
triazole (SC-Leu-Trp-His+3AT), SC-Leu-His+3AT plates containing 1 mg/l cycloheximide (SC-
Leu-His+3AT+CHX), SC-Leu-Trp-Adenine (Ade) plates, and SC-Leu-Ade+CHX plates to test 
for CHX-sensitive expression of the LYS2::GAL1-HIS3 and GAL2-ADE2 reporter genes. The 
plates were incubated overnight at 30 °C and replica-cleaned the following day. Plates were then 
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incubated for another three days, after which positive colonies were scored as those that grow on 
SC-Leu-Trp-His+3AT and/or on SC-Leu-Trp-Ade, but not on SC-Leu-His+3AT+CHX or on 
SC-Leu-Ade+CHX. Disruption of an interaction by a variation was defined as significant 
reduction of growth when compared to the Y2H phenotype of the wild-type PTS-PTS interaction.	  
 
Western blotting 
Wild-type and both PTS variants were cloned into MSCV-N-FLAG-HA-IRES-Puro 
vector(Behrends et al., 2010) and transfected into HEK293T cells to express HA-tagged wild-
type and mutated proteins. HEK293T cells were maintained in complete DMEM medium 
supplemented with 10% FBS. Cells were transfected with Lipofectamine 2000 (Invitrogen) at a 
5:1 (µl/µg) ratio with DNA and harvested 24 hrs after transfection. Cells were gently washed 
three times in PBS and then resuspended using 200 µl 1% NP-40 lysis buffer [1% Nonidet P-40, 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1× EDTA-free Complete Protease Inhibitor tablet 
(Roche 05056489001)] and kept on ice for 30 mins. Extracts were cleared by centrifugation for 
10 min at 13,000 rpm at 4 °C. 25 µl of extracts were mixed with 6X loading buffer and subjected 
to SDS-PAGE. Proteins were then transferred from the gel onto PVDF membranes (GE 
Healthcare RPN303F). Anti-HA (Sigma H9658) and anti-γ-tubulin (Sigma T5192) were used at 
1:3,000 dilutions for immunoblotting analysis. Blotting signal was developed with Novex ECL 
HRP chemiluminescent substrate reagent kit (Invitrogen WP20005) and captured with 
Amersham Hyperfilm MP (GE Healthcare 28906843). 
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3.6 FIGURE LEGENDS 
 
Figure 3.1 Atomic-resolution structural analysis of pathogenic variations. (a) Odds ratios for the 
distribution of in-frame variations in different locations on proteins in our atomic-resolution 
interactome network. **P < 10-3. P-values calculated using Z-tests for the log odds ratios. (b) 
Odds ratios for the distribution of non-synonymous SNPs in different locations on proteins in our 
atomic-resolution interactome network. (c) Enrichment of in-frame variations in buried residues. 
**P < 10-3 Error bars indicate ± SE. (d) Different mechanistic modes of disruption for variations 
in different structural environments – variations at the surface are likely to cause interaction-
specific disruptions, whereas those buried in the core of the protein are likely to destabilize the 
entire protein. 
 
Figure 3.2 (a) Crystal structure (PDB id: 3I2B) depicting a R25Q variation in the PTS-PTS 
interacting domain but not at an interface residue and a R9C variation outside the interaction 
interface. (b) Y2H assay illustrating that the R25Q variation disrupts the PTS-PTS interaction 
whereas the R9C variation does not affect the interaction. 
 
Figure 3.3 Loci of disease variations associated with interaction strength. (a) Co-expression 
profiles for interactions with low, medium and high buried surface areas. (b) Enrichment of 
interactions with low, medium and high buried surface areas in stable complexes. (c) Odds ratios 
for the distribution of in-frame variations at the interface in interactions with low, medium and 
high buried surface areas. *P < 10-3 (d) Odds ration of in-frame variations in the remainder of the 
interacting domain in interactions with low, medium and high buried surface areas. (e) Odds ratio 
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of in-frame variations in the rest of the protein in interactions with low, medium and high buried 
surface areas. *P < 10-3. Error bars indicate ± SE. 
 
Figure 3.4 Alterations of biochemical properties of individual amino acids in disease. (a) 
Enrichment of disease variations that alter the structural (accessibility) and biochemical 
(polarity) properties of amino acids as compared to SNPs. *P < 10-3. Error bars indicate ± SE. (b) 
Relative enrichment of all pairs of amino-acid changes in human pathological variations as 
compared to changes which occurred, and which were fixed, during the course of evolution (gray 
indicates that these pathogenic variations are not observed). (c) Pairs of amino-acid changes 
enriched in pathogenic missense variations and changes that occurred during evolution (shaded 
pairs undergo significant change in biochemical properties). (d) Pairs of amino-acid changes 
enriched at the atomic-resolution interaction interface (shaded pairs undergo significant change 
in biochemical properties). (e) An example of the alteration of the interaction interface between 
RNASEH2B and RNASEH2C by a variation (K143I) in RNASEH2C that significantly alters 
biochemical properties (in the circular panel, the blue residue is the wild-type K and the red 
residue is the pathogenic variant I).  
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CHAPTER 4 
A massively parallel pipeline to clone DNA variants and examine molecular 
phenotypes of human disease mutations 
 
In the following chapter, we describe a high-throughput site-directed mutagenesis pipeline to 
generate thousands of mutations and examine their effects on protein stability and interactions. I 
am a co-first author of the paper resulting from this chapter (Wei*, Das* et al PLoS Genetics 
2014, *=Equal contribution) and performed all computational analyses. The first author of the 
Xiaomu Wei led the experiments, along with other co-first authors Robert Fragoza and Jin Liang. 
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4.1 ABSTRACT 
 
Understanding the functional relevance of DNA variants is essential for all exome and genome 
sequencing projects. However, current mutagenesis cloning protocols require Sanger sequencing, 
and thus are prohibitively costly and labor-intensive. We describe a massively-parallel site-
directed mutagenesis approach, “Clone-seq”, leveraging next-generation sequencing to rapidly 
and cost-effectively generate a large number of mutant alleles. Using Clone-seq, we further 
develop a comparative interactome-scanning pipeline integrating high-throughput GFP, yeast 
two-hybrid (Y2H), and mass spectrometry assays to systematically evaluate the functional 
impact of mutations on protein stability and interactions. We use this pipeline to show that 
disease mutations on protein-protein interaction interfaces are significantly more likely than 
those away from interfaces to disrupt corresponding interactions. We also find that mutation 
pairs with similar molecular phenotypes in terms of both protein stability and interactions are 
significantly more likely to cause the same disease than those with different molecular 
phenotypes, validating the in vivo biological relevance of our high-throughput GFP and Y2H 
assays and indicating that both assays can be used to determine candidate disease mutations in 
the future. The general scheme of our experimental pipeline can be readily expanded to other 
types of interactome-mapping methods to comprehensively evaluate the functional relevance of 
all DNA variants, including those in non-coding regions. 
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4.2 INTRODUCTION 
 
Owing to rapid advances in next-generation sequencing technologies, tens of thousands of 
disease-associated mutations(Stenson et al., 2009) and millions of single nucleotide 
polymorphisms (SNPs)(Consortium, 2012; Fu et al., 2013) have been identified in the human 
population. With the large number of ongoing whole-exome and whole-genome sequencing 
projects(Consortium, 2012; Fu et al., 2013), hundreds of thousands of new SNPs are now being 
discovered every month. Hence, there is an urgent need to develop high-throughput methods to 
sift through this deluge of sequence data and rapidly determine the functional relevance of each 
variant. Here, we focus on coding variants, firstly because trait- and disease-associated SNPs are 
significantly over-represented in nonsynonymous sites(Hindorff et al., 2009), and secondly 
because the vast majority of disease-associated mutations identified to date reside within coding 
regions(Stenson et al., 2009). We evaluate the functional impact of coding variants by examining 
their effects on corresponding protein-protein interactions, because most proteins carry out their 
functions by interacting with other proteins(Vidal et al., 2011).  
Recent studies have begun to use large-scale protein interaction networks to understand 
human diseases and their associated mutations(Vidal et al., 2011; Zhong et al., 2009). By 
integrating structural details with high-quality protein networks, we created a 3D interactome 
network where the interface for each interaction has been structurally resolved(Wang et al., 
2012). Using this 3D network, we demonstrated that in-frame disease mutations (missense 
mutations and in-frame insertions/deletions) are significantly enriched at the interaction 
interfaces of the corresponding proteins(Wang et al., 2012). Our results indicate that alteration of 
specific interactions is very important for the pathogenesis of many disease genes, highlighting 
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the importance of 3D structural models of protein interactions in understanding the functional 
relevance of coding variants. However, many important questions still remain unanswered – for 
example, what fraction of protein-protein interactions is altered by disease mutations to cause the 
corresponding disorders? Furthermore, do structural details of the interacting proteins, especially 
the position of the mutation relative to the interaction interface, affect the ability of a given 
disease mutation to alter a specific interaction? 
To address these questions, we decided to focus on proteins with known disease mutations 
that participate in interactions with available co-crystal structures in the Protein Data Bank 
(PDB)(Berman et al., 2000). To detect the alteration of the interactions by disease mutations, it is 
necessary to first detect the interactions of the wild-type proteins using an assay of choice. This 
turns out to be a major bottleneck because all high-throughput interaction-detection assays have 
very limited sensitivity(Braun et al., 2009; Yu et al., 2008). Our assay of choice is Y2H because 
there are over 16,000 human protein interactions detected by our version of Y2H that can serve 
as the reference interactome for comparison(HI2012, 2012; Rual et al., 2005; Venkatesan et al., 
2009; Yu et al., 2011), the largest for any assay performed to date. In total, there are 217 
interactions detected by our version of Y2H with available co-crystal structures; 51 of these also 
have known missense disease mutations on corresponding proteins in the Human Gene Mutation 
Database (HGMD)(Stenson et al., 2009) and the corresponding interactions for the wild-type 
proteins can be detected in our experiments with strong Y2H-positive phenotypes (see Materials 
and Methods). Here, we focused on missense mutations because they are intrinsically more 
likely to generate interaction-specific disruptions(Zhong et al., 2009). We established a high-
throughput comparative interactome-scanning pipeline to clone disease mutations and examine 
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their molecular phenotypes (Figure 4.1). The methodologies established here can be readily 
applied to any non-synonymous variant in the coding region, including nonsense mutations.  
 
4.3 RESULTS 
 
Clone-seq: a massively parallel site-directed mutagenesis pipeline using next-generation 
sequencing 
 
The first step of our pipeline is a massively parallel approach, termed Clone-seq, designed to 
leverage the power of next-generation sequencing to generate a large number of mutant alleles 
using site-directed mutagenesis in a rapid and cost-effective manner. Current protocols for site-
directed mutagenesis require picking individual colonies and sequencing each colony using 
Sanger sequencing to identify the correct clone(Suzuki et al., 2005). This standard approach is 
both labor-intensive and expensive; therefore, it does not scale up to genome-wide surveys. In 
Clone-seq, we put one colony of each mutagenesis attempt into one pool (Figure 4.1A; in other 
words, each pool contains one and only one colony for each desired mutation) and combine 
multiple pools through multiplexing for one Illumina sequencing run(Salehi-Ashtiani et al., 
2008). Colonies for generating different mutations of the same gene can be put into the same 
pool, which can be easily distinguished computationally when processing the sequencing results. 
This is true even for mutations occurring at the same site (Figure 4.2A).  
For the 51 selected interactions, we chose 27 disease-associated mutations of residues at the 
interface (“interface residue”), 100 mutations in the rest of the interface domain (“interface 
domain”) and 77 mutations away from the interface (“away from the interface”; Figure 4.3A,B). 
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These interfaces were determined using solvent accessible surface area calculations as previously 
described(Das et al., 2014b; Khurana et al., 2013) on 7,340 co-crystal structures (Materials and 
Methods). To set up our Clone-seq pipeline, we first started with 39 mutations from these 204 
and picked 4 colonies for each mutation. As a reference, we also pooled together all the wild-
type alleles in our human ORFeome library to be sequenced together with the 4 pools of the 
mutagenesis colonies. In total, there were 40.1 million Illumina HiSeq 1×100 bp reads for our 
Clone-seq samples for an average of > 2,500× coverage on all desired mutation sites. Therefore, 
our Clone-seq pipeline has the capacity to generate > 3,000 mutations in one full lane of a HiSeq 
run with 1×100 bp reads, drastically improving the throughput and decreasing overall sequencing 
costs by at least 10-fold. 
Fig. 4.2A presents a schematic of the criteria we use to determine which clones contain the 
desired mutation and can be used for subsequent steps. For example, in pool 1, all reads 
(ignoring sequencing errors) confirm that genes I and II each contain the desired mutation – 
T116A and G298T, respectively. For gene III, we want to generate two separate clones with two 
separate mutations – IIIA41T and IIIC194T. Since half the reads contain T41 (instead of A41) and 
the other half contain T194 (instead of C194), and we normalize DNA concentrations across all 
samples, we can infer that both mutant clones were generated successfully. In contrast, for gene 
IV, we see that while half the reads contain A511 (instead of G511), all the reads are wild-type at 
C74. Thus, we infer that while the IVG511A clone is successfully generated, the IVC74T clone is 
not. For gene V, although both mutant clones are successfully generated, half the reads contain 
an additional mutation, C436G. Since it is impossible to know which of the two clones for V 
contains this unwanted mutation, neither clone is usable. Similarly, we can determine mutant 
clones IT116A, IIIA41T, IIIC194T, IVC74T, IVG511A, VT53G, and VG272A as usable clones in pool n. 
76
Based on these criteria, we developed the S score calculation and used it to determine successful 
mutagenesis attempts (Materials and Methods). Out of 156 colonies for 39 mutations, 125 of 
them contain the desired mutations (S > 0.8), an overall 80% PCR-mutagenesis success rate. In 
fact, we were able to pick correct clones for all 39 mutant alleles using only the first two pools in 
Clone-seq. All 78 clones from the first two pools, from which the correct ones were selected for 
use in subsequent steps, were also Sanger sequenced for verification. 55 Clone-seq positive 
results with S > 0.8 were all confirmed and there is a clear separation in the S scores between the 
successful and failed mutagenesis attempts (Figure 4.2B).  
One major advantage of our Clone-seq pipeline is that it allows us to carefully examine 
whether other unwanted mutations have been inadvertently introduced during PCR-mutagenesis 
in comparison with the corresponding wild-type alleles, since we obtain reads spanning the entire 
gene. We found that there are on average 4-5 unwanted mutations introduced in each pool of 39 
colonies. This corresponds to a 0.013% PCR error rate (Materials and Methods), in agreement 
with previous studies(Vandenbroucke et al., 2011). The detection of unwanted mutations, 
especially those distant from the mutation of interest, is achieved in traditional site-directed 
mutagenesis pipelines by Sanger sequencing through the gene of interest. This is costly and 
labor-intensive, especially because multiple sequencing runs are needed for one long gene. 
However, since Clone-seq yields reads spanning the entire gene, we were able to determine 
which of the generated clones definitely do not have unwanted mutations in the full length of 
their sequences as illustrated in Figure 4.2A (Materials and Methods), and we pick only these 
clones for subsequent assays.  
To further test our Clone-seq pipeline, we applied it to generate clones for 113 SNPs on 66 
genes from the recently published Exome Sequencing Project dataset(Fu et al., 2013). Using the 
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same approach as described above, we sequenced 4 colonies each for the 113 alleles of interest 
using one third of a 1×100 bp MiSeq run. We obtained 4.7 million reads for these 113 alleles. 
With a threshold of S > 0.8, we were able to determine that 370 out of the 452 colonies (82%) 
contain the desired mutation, in perfect agreement with the PCR-mutagenesis success rate 
obtained earlier. We were able to choose colonies that contain only the desired mutation for all 
113 alleles. Because the whole MiSeq run produced 17.7 million reads and we only used 4.7 
million for generating the 113 mutant clones, the capacity of our Clone-seq pipeline using one 
full lane of a 1×100 bp HiSeq run is estimated to be >3,000, exactly the same as our previous 
assessment.  
Finally, we generated the remaining 165 disease mutations (of the 204) and 717 other coding 
variants from the Exome Sequencing Project and the Catalog of Somatic Mutations in 
Cancer(Forbes et al., 2011) using a full 1×100 bp HiSeq run, including 40 mutations on a single 
gene – MLH1. Using 111.2 million reads for these 882 alleles, we found that 2,958 of the 3,528 
colonies (84%) contain the desired mutation, again in excellent agreement with our previously 
obtained PCR-mutagenesis success rate. There was at least one colony with only the desired 
mutation for all 882 alleles, including all 40 MLH1 mutations. Therefore, our Clone-seq pipeline 
can generate a large number of mutations (>40) even for a single gene. In fact, to generate even 
more mutations for one gene, we can implement a two-round barcoding approach: generate 
groups of 40 mutations and barcode them differently for one HiSeq run. Ten such groups will 
enable us to generate ~400 mutations for a single gene. Since the average coverage of these 882 
alleles is > 300×, the capacity of our Clone-seq pipeline using one full lane of a 1×100 bp HiSeq 
run is estimated to be >3,000, again in agreement with our previous two estimates. 
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Overall, our pipeline has been significantly optimized to make it very efficient. We 
established a web tool (http://www.yulab.org/Supp/MutPrimer) to design mutagenesis primers 
both individually and in batch. MutPrimer can design ~1,000 primers for ~500 mutations in one 
batch in less than one second. All of the 2,068 primers for the 1,034 mutations in this study were 
generated by MutPrimer. All mutagenesis PCRs are performed in batch using automatic 96-well 
procedures. Since single colony picking after bacterial transformation of mutagenesis PCR 
product is a rate-limiting step, we rigorously optimized this step and found that adding 10 µL 
mutagenesis PCR products to 100 µL competent cells and plating 50 µL transformed cells give 
the best transformation yield and well-separated single colonies. Furthermore, rather than 
individually streaking transformed cells onto agar plates one sample at a time, we were able to 
significantly increase throughput by spreading colonies using glass beads onto four sector agar 
plates which are partitioned into four non-contacting quadrants (Materials and Methods). In this 
manner, a 96-well plate of transformed bacteria can be plated out onto 24 four-sector agar plates 
in ~15 minutes. Traditional site-directed mutagenesis pipelines require miniprepping each of the 
selected colonies and sequencing them separately by Sanger sequencing. To drastically improve 
the throughput of our Clone-seq pipeline, we pooled together the bacteria stock of a single 
colony for each mutagenesis attempt to perform one single maxiprep, which makes the library 
construction step much more efficient and amenable to high-throughput. Furthermore, existing 
variant calling pipelines(McKenna et al., 2010) cannot be applied to our Clone-seq results 
because the expected allelic ratios built into these pipelines are a function of the ploidy of the 
organism. However, in our Clone-seq pipeline there is no concept of ploidy. We pool together 
many mutations for one gene in the same pool (e.g., 40 mutations for MLH1) and different genes 
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often have different numbers of mutations. Our S score calculation and unwanted mutation 
detection pipeline was designed according to our pooling strategy (Materials and Methods). 
In total, we have used the novel Clone-seq pipeline successfully to generate 1,034 (39 + 113 
+ 882) mutant clones without any additional unwanted mutations, confirming the scalability, 
accuracy, and throughput of our Clone-seq pipeline. 
 
A high-throughput GFP assay to determine the impact of mutations on protein stability 
 
For the 204 mutations on proteins with co-crystal structures, we first examined whether the 
mutant proteins can be stably expressed in human cells. To do this, we tagged every wild-type 
and mutant protein with GFP at the C-terminus using high-throughput Gateway cloning (Figure 
4.1B). The GFP constructs were transfected into HEK293T cells and fluorescence intensities 
were measured by a plate reader (Figure 4.3C; Materials and Methods). All fluorescence 
intensity readings were also confirmed manually under a microscope. Compared with the 
corresponding wild-type proteins, the expression levels of 3 of the 27 “interface residue” 
mutants, 8 of the 99 “interface domain” mutants and 6 of the 77 “away from the interface” 
mutants are significantly diminished (Figure 4.3C; Materials and Methods; Table 4.1). To 
validate these findings, we also performed Western blotting for 8 random mutants that are stably 
expressed and 8 random mutants with significantly diminished expression levels (Figure 4.4A). 
Western blotting results confirm our GFP intensity readings. 
 
A high-throughput Y2H assay to determine the impact of mutations on protein interactions 
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Next, we investigated whether these mutations could affect protein-protein interactions using 
Y2H (Figure 4.1C; Materials and Methods). We found that 21 of the 27 (78%) “interface 
residue” mutations, 57 of the 100 (57%) “interface domain” mutations, and only 22 of the 77 
(29%) “away from the interface” mutations disrupt the corresponding interactions, thereby 
demonstrating a clear difference (Figure 4.4B; P = 3 x 10-6 between “interface residue” and 
“interface domain” and P = 8 x 10-10 between “interface domain” and “away from the interface”) 
in terms of ability to interfere with protein-protein interactions between mutations at different 
structural loci within the same protein. Furthermore, comparing with the GFP results, we found 
that all destabilizing mutations were shown to disrupt the corresponding interactions in our Y2H 
experiments. By considering only the mutations that do not affect protein expression based on 
the GFP experiments, we found the same difference: 13 out of 18 (72%) “interface residue” 
stable mutations, 42 out of 83 (51%) “interface domain” stable mutations, and only 9 out of 52 
(17%) “away from the interface” stable mutations disrupt the corresponding interactions (Figure 
4.4B; P = 2 x 10-5 between “interface residue” and “interface domain” and P = 9 x 10-13 between 
“interface domain” and “away from the interface”; Table 4.1). Since these interfaces are obtained 
from actual co-crystal structures, our results suggest that accurate structural information can help 
determine the functional impact of mutations on protein-protein interactions. Wild-type proteins 
corresponding to 113 of the 153 stably expressed mutant proteins also interact with other 
proteins as determined by our Y2H experiments (114 interactions in total, termed “other 
interactions”); however, for these interactions, there are currently no co-crystal structures 
available in the PDB. Using these other interactions, we calculated the likelihood of a given 
mutation disrupting a specific interaction without any structural information to be 32% (Figure 
4.4B).  
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 Relationships between measured molecular phenotypes and corresponding disease 
phenotypes 
 
We then analyzed whether the molecular phenotypes measured by our high-throughput GFP and 
Y2H assays are correlated with corresponding disease phenotypes. We first examined how 
mutation pairs on the same gene affect protein stability and its relationship to their corresponding 
diseases. We find that pairs of mutations that are either both stable or both unstable cause the 
same disease in 68% and 70% of cases, respectively. However, pairs comprising one stable and 
one unstable mutation cause the same disease in only 30% of cases (P = 6 x 10-9 and 8 x 10-10, 
respectively, Figure 4.5A). For example, we find that the mutations R727C and L844F on the 
spindle checkpoint kinase Bub1b both cause the protein to become unstable and lose all its 
interactors. These mutations are both associated with the same disease, mosaic variegated 
aneuploidy, an autosomal recessive disorder that causes predominantly trisomies and 
monosomies of different chromosomes(Hanks et al., 2004; Suijkerbuijk et al., 2010). Since our 
GFP assay shows that these two mutations cause loss of protein product, our results are 
consistent with Matusuura et al.’s finding that a more than 50% decrease in Bub1b activity leads 
to abnormal mitotic spindle checkpoint function and mosaic variegated aneuploidy(Matsuura et 
al., 2006).  
We then examined whether mutation pairs on the same gene disrupt the same set or different 
sets of interactions (i.e., their interaction disruption profiles) and investigated whether their 
disruption profiles correlates with disease phenotypes. We found that mutation pairs with the 
exact same disruption profile are significantly more likely to cause the same disease than those 
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with different profiles (70% and 61% respectively, P = 3 x 10-5, Figure 4.5B). For example, we 
found that two mutations on Smad4, R361C and Y353S, disrupt its interactions with Smad3 and 
Smad9 while leaving the interactions with Lmo4 and Rassf5 unaltered (Figure 4.5C). These two 
mutations both cause juvenile polyposis coli(Houlston et al., 1998; Roth et al., 1999), a disease is 
known to be caused by disruption of the core Smad/Bmp signaling pathways(Massague, 2008). 
Our Y2H results clearly demonstrate that the R361C and Y353S mutations disrupt the Smad4-
Smad3 and Smad4-Smad9 interactions (Figure 4.5C) leading to disruption of core Smad 
signaling pathways. However, the mutation N13S on Smad4 does not disrupt any of these 
interactions (Figure 4.5C) and is associated with a different disease, pulmonary arterial 
hypertension. Our results agree with Nasim et al.’s finding that the N13S mutation does not alter 
downstream Smad signaling(Nasim et al., 2011). Our findings provide support for the hypothesis 
that the N13S mutation either impacts pathways outside the core Smad signaling network or are 
pathogenic only when combined with other environmental and genetic factors(Machado, 2012). 
Overall, these results show that mutation pairs with similar molecular phenotypes in terms of 
both protein stability and interactions are significantly more likely to cause the same disease than 
those with different molecular phenotypes. This confirms that the molecular phenotypes 
measured by our high-throughput GFP and Y2H assays are biologically relevant in vivo. 
Furthermore, by comparing the molecular phenotypes, in particular the protein interaction 
disruption profiles, of mutations/variants to those of known disease mutations, potential 
candidate mutations for a variety of diseases can be identified. 
 
A high-throughput mass spectrometry assay to determine the impact of mutations on 
protein interactions 
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 While we use only those interactions that are supported by co-crystal structures to estimate the 
fraction of interactions that are disrupted by mutations at different structural loci, the described 
procedures can also be applied to interactions with predicted interfaces and structural 
models(Meyer et al., 2013; Mosca et al., 2013; Tuncbag et al., 2011; Zhang et al., 2012). This is 
of particular importance because over 90% of known interactions do not currently have 
corresponding co-crystal structures(Das et al., 2014a; Mosca et al., 2013). For example, Mlh1 is 
known to interact with Pms2, both of which are well-studied DNA mismatch repair genes 
frequently mutated in hereditary nonpolyposis colorectal cancer(Peltomaki and Vasen, 1997). 
Although the structural basis of the Mlh1-Pms2 interaction still remains unknown, both our 
previous 3D reconstruction of the human interactome network(Meyer et al., 2013; Wang et al., 
2012) and the newly-established Interactome3D(Mosca et al., 2013) database suggest that the 
HATPase_c domain is part of the interface for Mlh1’s interaction with Pms2. Previous work has 
shown that a point mutation (I107R) on the HATPase_c domain of Mlh1 is associated with 
colorectal cancer and disrupts the Mlh1-Pms2 interaction(Kondo et al., 2003; Peltomaki and 
Vasen, 1997; Wang et al., 2012). First, using Y2H, we were able to confirm the disruption. Next, 
we developed a high-throughput-amenable mass spectrometry pipeline using Stable Isotope 
Labeling by Amino acids in Cell culture (SILAC)(Ong et al., 2002; Ong and Mann, 2006), which 
was designed to reveal both lost/weakened and gained/enhanced interactions of the target 
proteins (Figure 4.1D)(Ohouo et al., 2010). We added an HA-tag to the N-terminus of both wild-
type and mutant Mlh1, as well as to GFP as a control, and performed four SILAC experiments: 
wild-type Mlh1 (heavy) vs. GFP control (light), mutant Mlh1 (heavy) vs. GFP control (light), 
wild-type (heavy) vs. mutant (light) Mlh1, and mutant (heavy) vs. wild-type (light) Mlh1 (Figure 
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4.6A; Materials and Methods). Interactors of wild-type/mutant Mlh1 are defined as those that 
bind wild-type/mutant Mlh1 more than 2× stronger than GFP control (Materials and Methods). 
For a lost/weakened interaction, we required that the interaction be more than 2× stronger with 
wild-type Mlh1 than with mutant Mlh1 as confirmed both in wild-type (heavy) vs. mutant (light) 
and in mutant (heavy) vs. wild-type (light) experiments; we further required that the interaction 
be detected in the wild-type vs. control experiment (Figure 4.6A; Materials and Methods). For a 
gained/enhanced interaction, we required that the interaction be more than 2× stronger with 
mutant Mlh1 than with wild-type Mlh1 as confirmed both in wild-type (heavy) vs. mutant (light) 
and in mutant (heavy) vs. wild-type (light) experiments; we further required that the interaction 
be detected in the mutant vs. control experiment (Figure 4.6A; Materials and Methods). We were 
able to detect Pms2 as the only specifically weakened interactor caused by the mutation (Figures 
4.6B,C; E = -1.77; P = 3 x 10-4), in agreement with our Y2H results and previous studies(Kondo 
et al., 2003; Wang et al., 2012). Additionally, we were able to detect Hspa8 as the only 
specifically enhanced interactor of the mutant protein (Figures. 4.6B,C; E = 2.71; P = 7 x 10-8). 
Two other known interactors of Mlh1, Pms1 (Figures 4.6B,C; E = -0.32; P = 0.21)(Leung et al., 
2000) and Brip1 (Figures 4.6B,C; E = 0.18; P = 0.32)(Peng et al., 2007), were also detected, 
although their interactions with Mlh1 are not affected by this particular mutation (Materials and 
Methods).  
Hspa8 was not previously known to interact with Mlh1 and the impact of the Mlh1 I107R 
mutation on its interactions with Pms1 and Brip1 has not been reported in the literature. To 
verify our SILAC results, we performed in vivo co-immunoprecipitation using HA-tagged wild-
type and mutant Mlh1 and tagged Hspa8 and Brip1 with V5 (Materials and Methods). Our co-
immunoprecipitation results confirm that Hspa8 only weakly interacts with wild-type Mlh1, but 
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the interaction is dramatically enhanced by a single amino acid substitution (I107R) (Figure 
4.6D, lanes 3 and 4), whereas the interaction between Mlh1 and Brip1 is not affected by this 
mutation (Figure 4.6D, lanes 6 and 7; Materials and Methods). Hspa8 is a constitutively 
expressed member of the heat shock protein 70 family(Goldfarb et al., 2006). It functions as a 
chaperone to facilitate protein folding(Goldfarb et al., 2006) and also functions as an ATPase in 
the disassembly of clathrin-coated vesicles during membrane trafficking(DeLuca-Flaherty et al., 
1990). A recent study reported that Hspa8 is specifically recruited to reovirus viral factories, 
independent of its chaperone function(Kaufer et al., 2012). Therefore, our SILAC results suggest 
that Hspa8 may play an important role in colorectal cancer and that its function could be 
independent of its role as a chaperone. 
 
4.4 DISCUSSION 
 
We have successfully developed the first massively parallel site-directed mutagenesis pipeline, 
Clone-seq, using next-generation sequencing. Our Clone-seq pipeline is entirely different from 
previously described random mutagenesis approaches(Araya et al., 2012; Fowler et al., 2010; Pitt 
and Ferre-D'Amare, 2010; Starita et al., 2013). Clone-seq is used to generate a large number of 
specific mutant clones with desired mutations; each individual mutant clone has a separate stock 
and different clones can therefore be used separately for completely different downstream 
assays. In random mutagenesis, a pool of sequences containing different mutations for one gene 
is generated using error-prone PCR or error-prone DNA synthesis. Therefore, it is not possible to 
separate one mutant sequence from another and the whole pool can only be used for the same 
assay(s) together. Furthermore, it is not possible to control which or how many mutations are 
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generated on each DNA sequence. In fact, to improve coverage, most random mutagenesis 
pipelines generate on average two or more mutations on each DNA sequence(Fowler et al., 
2010), which makes it impossible to distinguish the functional impact of each individual 
mutation on the same sequence. Site-directed mutagenesis and random mutagenesis are designed 
for different goals: if one wants to generate all possible mutations for a certain protein without 
the need to separate different clones, it would be more favorable to use random mutagenesis; 
whereas if one needs to have separate clones for each mutation, site-directed mutagenesis is 
required. As a result, the two approaches are complementary and not comparable. 
While there are highly efficient methods for random mutagenesis(Araya et al., 2012; Fowler 
et al., 2010; Pitt and Ferre-D'Amare, 2010; Starita et al., 2013), current protocols for site-directed 
mutagenesis are low-throughput and become prohibitively expensive if a large number of clones 
needs to be generated. Clone-seq directly addresses the necessity for a high-throughput site-
directed mutagenesis pipeline. It is a robust, cost-effective and efficient method that can be used 
to generate a total of ~3,000 distinct mutant clones in one full lane of a 1×100 bp HiSeq run. 
Clone-seq is suitable both for generating mutations across many genes as well as a large number 
of mutations on a few genes. The former situation is applicable when one wants to generate 
many mutations/variants from large-scale studies (e.g., whole-genome or whole-exome 
sequencing) since they typically identify mutations/variants on a large number of genes(Atlas, 
2012; Stransky et al., 2011). The latter situation usually arises in a study focused on a single 
pathway with a few genes of interest (e.g., an alanine-scanning mutagenesis to determine 
functional sites on a gene of interest(Cunningham and Wells, 1989)).  
Integrating with Clone-seq, we also established a comprehensive comparative interactome-
scanning pipeline, including high-throughput GFP, Y2H, and mass spectrometry assays, to 
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systematically evaluate the impact of human disease mutations on protein stability and 
interactions. We examine each mutation individually, rather than looking at their combinatorial 
effects because these inherited germline disease mutations are extremely rare. Therefore, the 
probability of having even two of these in the same individual becomes infinitesimally small. 
Our results reveal that the overall likelihood of a given disease mutation disrupting a specific 
interaction is 32%. Accurate structural information of these interactions obtained from co-crystal 
structures greatly improves our understanding of the impact of disease mutations: 13 out of 18 
(72%) “interface residue” stable mutations, 42 out of 83 (51%) “interface domain” stable 
mutations, and only 9 out of 52 (17%) “away from the interface” stable mutations disrupt the 
corresponding interactions, unveiling a clear dependence of the molecular phenotypes of disease 
mutations on their structural loci. These estimates are not affected by the false negative rate of 
our Y2H assay as we only use those interactions for which we can detect the wild-type 
interaction with strong Y2H phenotypes. Thus, any observed disruption is due to the mutation of 
interest and not an assay false negative. Furthermore, our Y2H pipeline has been shown to be of 
high quality and has an experimentally measured false positive rate of ~5% or lower in different 
organisms(Consortium, 2011; Das et al., 2013; Venkatesan et al., 2009; Yu et al., 2008). In 
addition, the interactions used to understand the relationship between molecular phenotypes and 
structural loci of disease mutations are all supported by co-crystal structures, therefore these 
interactions are not assay false positives. We also find that the molecular phenotypes detected by 
our GFP and Y2H assays correlate with known disease phenotypes, confirming the in vivo 
biological significance of our measurements. 
Moreover, as shown by the Mlh1 example (Fig. 6), our comparative interactome-scanning 
pipeline can also be used with predicted structural models(Meyer et al., 2013; Mosca et al., 2013; 
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Tuncbag et al., 2011; Zhang et al., 2012). The consequent experimental results will clearly be 
affected by the quality of these predictions, which is not part of our pipeline. In fact, our 
experimental interactome-scanning pipeline can be applied to evaluate or improve these 
predicted models by testing mutations at different loci of a protein of interest and examining how 
these mutations disrupt different interactions of this protein.  
Our comparative interactome-scanning pipeline described and validated here can be applied 
to experimentally determine in a high-throughput fashion the impact on protein stability and 
protein-protein interactions for thousands of DNA coding variants and disease mutations, which 
can directly lead to hypotheses of concrete molecular mechanisms for follow-up studies. 
Furthermore, the elucidation of molecular phenotypes of disease mutations is also vital for 
selecting actionable drug targets and ultimately for making therapeutic decisions. Finally, the 
general scheme of our pipeline can be readily expanded to other interactome-mapping methods, 
particularly other protein-protein(Braun et al., 2009), protein-DNA(Berger et al., 2006; Reece-
Hoyes et al., 2011), protein-RNA(Yakhnin et al., 2012), and protein-metabolite interaction 
assays(Bandyopadhyay et al., 2012), to comprehensively evaluate the functional relevance of all 
DNA variants, including those in non-coding regions. 
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4.5 MATERIALS AND METHODS  
 
Selecting interactions with mutations on and away from the interface 
 
To calculate atomic-resolution interaction interfaces, we systematically examined a 
comprehensive list of 7,340 PDB co-crystal structures. To define the interface, we used a water 
molecule of diameter 1.4 Å as a probe and calculated the relative solvent accessible surface areas 
of the interacting pair as well as the individual proteins involved in the interaction. Residues 
whose relative accessibilities change by more than 1 Å2 are considered as potential interface 
residues, because amino acids at the interface reside on the surfaces of the corresponding 
proteins, but will tend to become buried in the co-crystal structure as the two proteins bind to 
each other(Franzosa and Xia, 2011). So, for these residues, there should be a significant decrease 
in accessible surface area when we compare the bound and unbound states of the protein chains.  
 
To identify interface domains, we required at least one of the following criteria to hold: 
 
1. 3did(Stein et al., 2011) or iPfam(Finn et al., 2005) have identified the domain pair as 
interacting and each of the interface domains contains at least one interface residue based 
on our calculations. 
2. The domain pair contains 5 or more interface residues for each protein according to our 
calculations. 
We then identified the subset of these interactions that contain at least one disease mutation and 
are amenable to our version of Y2H(HI2012, 2012; Rual et al., 2005; Venkatesan et al., 2009; 
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Yu et al., 2011). Subsequently, we performed a pairwise retest of all these interactions and 
selected the ones that yield strong Y2H phenotypes, because subsequent steps involve detecting a 
significant decrease in these phenotypes. 
 
Primer design for site-directed mutagenesis 
 
Primers for site-directed mutagenesis were selected based on a customized version of the 
protocol accompanying the Stratagene QuikChange Site-Directed Mutagenesis Kit (200518). 
The following criteria are used: 
 
1. The primer should be of length 30-50 bp and should contain the mutation of interest in 
the center or one base away. 
2. The GC content of the primer should be ≥ 40% and the primer should start and end with a 
G or a C. 
3. The Tm for the primer should be ≥ 78 °C. Tm was calculated using the following 
expression: 
 
€ 
Tm = 81.5 + 0.41× (%GC) −
675
N −%mismatch  
 
where N is the primer length in bases, %GC is the percentage of G or C nucleotides in the 
primer, and %mismatch is the percentage of mismatched bases in the primer. Values for 
%GC and %mismatch are whole numbers. 
 
91
For cases where no primer satisfies all three criteria simultaneously, we relaxed criterion 2 to GC 
content ≥ 30%. 
 
We established a supplementary web tool (http://www.yulab.org/Supp/MutPrimer) to design 
mutagenesis primers individually or in bulk. 
 
Construction of mutant alleles using high-throughput site-directed mutagenesis PCR 
 
All wild-type clones were obtained from the human ORFeome v8.1 collection(Yang et al., 
2011). To generate mutant alleles, sequence-verified single-colony wild-type clones and their 
corresponding mutagenic primers were aliquoted into individual wells of 96-well PCR plates. 
Mutagenesis PCR was then performed as specified by the New England Biolabs (NEB) PCR 
protocol for Phusion polymerase (M0530L), noting that PCR was limited to 18 cycles. The 
samples were then digested by DpnI (NEB R0176L) according to the manufacturer’s manual. 
After digestion, samples were transformed into competent E. coli. Since single colony picking 
after bacterial transformation of mutagenesis PCR product is a rate-limiting step, we rigorously 
optimized this step. First, we tried different volumes of competent cells for transformation and 
found that single colony yields peak when ~100 µL of competent cells are used. It is also 
necessary to use ~10 µL of mutagenesis PCR product: any lower volume of PCR product results 
in significantly reduced colony yields, while higher volumes of PCR product do not increase 
yield. Finally, colony picking was done using four-sector agar plates (VWR 25384-308) that are 
partitioned into four non-contacting quadrants with glass beads poured onto each plate quadrant. 
Each bead-filled quadrant was inoculated with ~50 µL of transformed bacteria. This was then 
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spread by lightly shaking the four-sector agar plate. Our optimized transformation protocol 
results in a large number of well-separated single colonies that can be easily picked the next day. 
Upon recovery, single colonies from each quadrant were then picked and arrayed into 96-
deepwell plates filled with 300 µL of antibiotic media. Four colonies per allele were picked for 
next-generation sequencing. 
 
DNA library preparation for Illumina sequencing 
 
DNA library preparation was performed using NEBNext DNA Library Prep Master Mix Set for 
Illumina (NEB E6040S) according to the manufacturer’s manual. Briefly, 5 µg of pooled 
plasmid DNA (~100 µL, all samples were normalized to the same concentration) was sonicated 
to ~200 bp fragments. The fragmented DNA was first mixed with NEBNext End Repair Enzyme 
for 30 mins at 20 °C. Blunt-ended DNA was then incubated with Klenow Fragment for 30 mins 
at 37 °C for dA-Tailing. Subsequently, NEBNext Adaptor was added to dA-Tailed DNA. 
Adaptor-ligated DNA (~300 bp) was size-selected on a 2% agarose gel. Size-selected DNA was 
then mixed with one of the NEBNext Multiplex Oligos (NEB E7335S) and Universal PCR 
primers for PCR enrichment. At each step, DNA was purified using a QIAquick PCR 
purification kit (Qiagen 28104). Multiplexed DNA samples were combined and analyzed in one 
lane of a 1×100 bp run by Illumina HiSeq 2500. 
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Identifying successful instances of site-directed mutagenesis based on next-generation 
sequencing 
 
The mutant colonies were barcoded and pooled as shown in Fig. 1a. The multiplexed colonies 
were then run on an Illumina sequencer (2 HiSeq runs and 1 MiSeq run) to give 1×100 bp reads. 
These reads were then de-multiplexed and mapped to the genes of interest using the BWA “aln” 
algorithm(Li and Durbin, 2009). For each allele, we identified all reads that mapped to the 
position of the mutation of interest (Rall) and those that actually contained the desired mutation 
(Rmut). We then calculated a normalized score (S) that quantifies the fraction of reads containing 
the desired mutation: 
 
€ 
S = Rmut1
k Rall
=
k × Rmut
Rall
 
 
where k is the number of different mutations for the same gene.  
 
For 39 mutations, we Sanger sequenced two mutant colonies per mutagenesis attempt to quantify 
the correlation between S and observation of the desired mutation. We found that all clones with 
S > 0.44 are confirmed to be correct via Sanger sequencing with a clear separation between those 
that are correct and those that are not (Figure 4.2b). However, to further ensure that the clones 
we picked were correct, we require S > 0.8 for a colony to be scored as containing the desired 
mutation. 
 
Identifying unwanted mutations 
94
 One major advantage of our Clone-seq pipeline over traditional site-directed mutagenesis 
protocols using Sanger sequencing(Suzuki et al., 2005) is that we can now carefully examine 
whether there are other unwanted mutations inadvertently introduced during the PCR process, in 
comparison with the corresponding wild-type alleles. It is essential to use clones with no 
unwanted mutations for downstream experiments, as the presence of these will make it 
impossible to determine whether the observed disruption is due to the desired or other 
undesirable mutation(s). 
We use samtools “mpileup”(Li et al., 2009) to obtain read counts for different alleles at each 
nucleotide for all the clones. We calculate the background sequencing error rate by calculating 
the average fraction of non-reference alleles across all nucleotides where we did not attempt to 
introduce a mutation. Any site that has a significantly higher fraction of non-reference alleles 
(using a P value cutoff of 0.2 from a cumulative binomial test) is considered to have an 
unwanted mutation. A lenient P value cutoff (0.2 as opposed to the more traditionally used 0.05 
or 0.01) implies more stringent filtering in this case because we want to eliminate type II errors 
i.e., we want to identify all unwanted mutations at the cost of discarding a few clones that 
actually do not have any unwanted mutations. 
We identified an average of 4-5 unwanted point mutations per pool. The overall per-base 
point mutation rate of Phusion polymerase was calculated to be ~ 10-4. NEB’s advertised error 
rate for Phusion polymerase varies from 4.4 – 9.5 x 10-7 per PCR cycle. Since we perform 18 
PCR cycles, the expected overall error rate is ~ 10-5. Our calculated mutation is within an order 
of magnitude of this advertised error rate. It is slightly higher than the advertised rate as we use 
stringent filtering criteria as described above. 
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GFP assay 
 
All wild-type and mutant clones were moved into the pcDNA-DEST47 vector with a C-terminal 
GFP tag using automated Gateway LR reactions in a 96-well format. After bacterial 
transformation, minipreps were prepared on a Tecan Freedom Evo 200, and DNA concentrations 
were determined by OD 260/280 with a Tecan Infinite M1000 plate reader in 96-well format. A 
100 ng aliquot of each expression clone plasmid was used for transfection into HEK293T cells in 
96-well plates using Lipofectamine 2000 (Invitrogen 11668019) according to the manufacturer’s 
instructions. At approximately 48 hrs post-transfection, cells were processed with Tecan M1000. 
Fluorescence intensities were measured at 395 nm for excitation and 507 nm for emission, 
according to Invitrogen’s manual. As negative controls, the fluorescence intensities 
corresponding to cells transfected with the empty vector were measured. The normalized 
fluorescence intensity was calculated as:  
 
€ 
Inorm = I − Ibackground  
 
where I corresponds to the measured intensity and Ibackground corresponds to the average intensity 
of the empty vector controls for each plate. All Inorm values greater than K are considered to 
correspond to stable protein expression. K corresponds to the range (maximum – minimum) of 
background fluorescence intensities of the empty vector controls for each plate. For this study, 
all fluorescence intensity readings were also confirmed manually under a microscope. All 
transfection and GFP experiments were repeated 3 times. 
 
96
Y2H assay 
 
Y2H was performed as previously described(Wang et al., 2012). All wild-type/mutant clones 
were transferred by Gateway LR reactions into our Y2H pDEST-AD and pDEST-DB vectors. 
All DB-X and AD-Y plasmids were transformed individually into the Y2H strains MATα Y8930 
and MATa Y8800, respectively. Each of the DB-X MATα transformants (wild-type and mutants) 
were then mated against corresponding AD-Y MATa transformants (wild-type and mutants) 
individually using automated 96-well procedures, including inoculation of AD-Y and DB-X 
yeast cultures, mating on YEPD media (incubated overnight at 30 °C), and replica-plating onto 
selective Synthetic Complete media lacking leucine, tryptophan, and histidine, and supplemented 
with 1 mM of 3-amino-1,2,4-triazole (SC-Leu-Trp-His+3AT), SC-Leu-His+3AT plates 
containing 1 mg/l cycloheximide (SC-Leu-His+3AT+CHX), SC-Leu-Trp-Adenine (Ade) plates, 
and SC-Leu-Ade+CHX plates to test for CHX-sensitive expression of the LYS2::GAL1-HIS3 and 
GAL2-ADE2 reporter genes. The plates containing cycloheximide select for cells that do not 
have the AD plasmid due to plasmid shuffling. Growth on these control plates thus identifies 
spontaneous auto-activators(Walhout and Vidal, 2001). The plates were incubated overnight at 
30 °C and “replica-cleaned” the following day. Plates were then incubated for another three days, 
after which positive colonies were scored as those that grow on SC-Leu-Trp-His+3AT and/or on 
SC-Leu-Trp-Ade, but not on SC-Leu-His+3AT+CHX or on SC-Leu-Ade+CHX. Disruption of 
an interaction by a mutation was defined as at least 50% reduction of growth consistently across 
both reporter genes, when compared to Y2H phenotypes of the corresponding wild-type allele as 
benchmarked by 2-fold serial dilution experiments. All Y2H experiments were repeated 3 times. 
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Construction of plasmids  
 
Wild-type MLH1, HSPA8, and BRIP1 entry clones are from the human ORFeome v8.1 
collection(Yang et al., 2011). Using Gateway LR reactions, wild-type MLH1, mutant MLH1 
(I107R), and GFP were transferred into the pMSCV-N-FLAG-HA-PURO vector(Behrends et al., 
2010); HSPA8 and BRIP1 were transferred into the pcDNA-DEST40 vector that contains a C-
terminal V5 tag (Invitrogen 12274-015).  
 
Analysis of interacting proteins by SILAC and LC-MS/MS  
 
HEK293T cells were grown in SILAC media comprising SILAC DMEM (Thermo Scientific) 
and 10% dialyzed FBS (JR Scientific) supplemented with either 0.1 mg/ml L-lysine and L-
arginine (light media) or 0.1 mg/ml L-lysine 13C6, 15N2 and L-arginine 13C6, 15N4 (heavy 
media). Heavy- or light-media cultured HEK293T cells were transfected using Lipofectamine 
2000 (Invitrogen) in three 10 cm plates. 48 hrs after transfection, cells were washed three times 
in cold PBS and then resuspended in 5 ml RIPA buffer [1% NP-40, 50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 5 mM EDTA, 1× EDTA-free Complete Protease Inhibitor tablet (Roche)]. Cells were 
lysed for 30 mins on ice before centrifuging at 13,000 rpm for 10 mins. Cell lysates were 
incubated with 60 µL EZview Red Anti-HA Affinity Gel (Sigma-Aldrich) for 3 hrs. After 3 
washes with RIPA buffer, bound proteins were eluted with 3 resin volumes elution buffer (100 
mM Tris-HCl pH 8.0, 1% SDS). Eluted proteins from light and heavy media were mixed 
together, reduced with 5 mM DTT, alkylated with 15 mM of iodoacetamide, and then 
precipitated with 3 volumes PPT solution (50% acetone, 49.9% ethanol, 0.1% acetic acid). 
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Proteins from pull-down experiments were solubilized with 50 µL Urea/Tris solution (8 M Urea, 
50 mM Tris-HCl pH 8.0) and 150 µL NaCl/Tris (50 mM Tris-HCl pH 8.0, 150 mM NaCl) 
followed by the addition of 1 µg Trypsin Gold (Promega). Protein digestion was performed 
overnight at 37 °C after which trifluoroacetic acid and formic acid were added to a final 
concentration of 0.2%. Peptides were de-salted with Sep-Pak C18 columns (Waters 
Corporation), dried in a speed-vac, and reconstituted in 85 µL of a solution containing 80% 
acetonitrile and 1% formic acid. Samples were fractionated by Hydrophilic Interaction LIquid 
Chromatography (HILIC) using a TSK gel Amide-80 column (Tosoh Bioscience). HILIC 
fractions were dried in a speed-vac, reconstituted in 0.1% trifluoroacetic acid, and analyzed by 
LC-MS/MS using a 125 µM ID capillary column packed in-house with 3 µm C18 particles 
(Michrom Bioresources) and a Q-Exactive mass spectrometer (Thermo Fisher Scientific) 
coupled with a Nano LC-Ultra system (Eksigent). Xcalibur 2.2 software (Thermo Fischer 
Scientific) was used for the data acquisition and Q-Exactive was operated in the data-dependent 
mode. Survey scans were acquired in the Orbitrap mass analyzer over the range of 380 to 2000 
m/z with a mass resolution of 70.000 (at m/z 200). Up to the top 10 most abundant ions with a 
charge state higher than 1 and less than 5 were selected within an isolation window of 2.0 m/z. 
Selected ions were fragmented by Higher-energy Collisional Dissociation (HCD) and the tandem 
mass spectra were acquired in the Orbitrap mass analyzer with a mass resolution of 17.500 (at 
m/z 200). The fragmentation spectra were searched by using the SEQUEST software on a 
SORCERER system (Sage-N Research) and a human database downloaded from the 
International Protein Index (version 3.80). In all database searches, trypsin was designated as the 
protease, allowing for one non-tryptic end and two missed-cleavages. The following parameters 
were used in the database search: a mass accuracy of 15 ppm for the precursor ions, differential 
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modification of 8.0142 Daltons for lysine and 10.00827 Daltons for arginine. Results were 
filtered based on probability score to achieve a 1% false positive rate. The Xpress software, part 
of the Trans-Proteomic Pipeline (Seattle Proteome Center), was used to process the raw data and 
quantify the light/heavy peptide isotope ratios. Results were also manually inspected. 
 
Identifying loss and gain of interactors for Mlh1 
 
We performed four SILAC experiments using both wild-type and mutant Mlh1, as well as GFP 
as a control: wild-type (heavy) vs. control (light) [WT_Control]; mutant (heavy) vs. control 
(light) [Mutant_Control]; wild-type (heavy) vs. mutant (light) [WT_Mutant]; and mutant (heavy) 
vs. wild-type (light) [Mutant_WT].  
 
We use the following variables and define four ratios for all subsequent calculations. In the 
WT_Control experiment, the relative abundance of protein p pulled down by wild-type Mlh1 to 
protein p pulled down by GFP (WTp) is quantified by the inverse of the geometric mean of rwc 
reads with Xpress values Xi. In the Mutant_Control experiment, the relative abundance of protein 
p pulled down by mutant Mlh1 (I107R) to protein p pulled down by GFP (Mutp) is quantified by 
the inverse of the geometric mean of rmc reads with Xpress values Yi. In the WT_Mutant 
experiment, the relative abundance of protein p pulled down with mutant Mlh1 (I107R) to 
protein p pulled down by wild-type Mlh1 is quantified by the geometric mean of rwm reads with 
Xpress values Pi. The amount of mutant Mlh1 (I107R) to wild-type Mlh1 is quantified by the 
geometric mean of twm reads with Xpress values Cj. In the Mutant_WT experiment, the relative 
abundance of protein p pulled down with mutant Mlh1 (I107R) to protein p pulled down by wild-
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type Mlh1 is quantified by the inverse of the geometric mean of rmw reads with Xpress values Qj. 
The amount of mutant Mlh1 (I107R) to wild-type Mlh1 is quantified by the inverse of the 
geometric mean of tmw reads with Xpress values Di. 
 
WTp =
1
Xii=1
rwc
∏rwc
 
 
Mutp =
1
Yii=1
rmc
∏rmc
 	  
FCwm =
Pi
i=1
rwm
∏rwm
Cj
j=1
twm
∏twm  
 
FCmw =
Di
i=1
tmw
∏tmw
Qj
j=1
rmw
∏rmw  
 
where both FCwm and FCmw denote the fold change in protein abundance as the normalized ratio 
of the amount of protein pulled down with mutant Mlh1 to that with wild-type Mlh1. 
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To identify interactors that are lost/weakened due to the I107R mutation, we required the 
following criteria to hold simultaneously: 
 
1. The protein has to be identified as an interactor of wild-type Mlh1: WTp > 2, rwc ≥ 5. 
2. The protein has to be identified as a lost interactor based on both Mutant_WT: FCmw < 
0.5, rmw ≥ 5, and WT_Mutant: FCwm < 0.5, rwm ≥ 5. 
 
The first criterion ensures that the protein identified is a true interactor of wild-type Mlh1. The 
second criterion ensures that the loss of interaction is significant and reliably observed across 
both WT_Mutant and Mutant_WT experiments. 
 
Similarly, to identify interactors that are gained/enhanced due to the I107R mutation, we 
required the following criteria to hold simultaneously: 
 
1. The protein has to be identified as an interactor of mutant Mlh1 (I107R): Mutp > 2, rmc ≥ 
5. 
2. The protein has to be identified as a gained interactor based on both Mutant_WT: FCmw > 
2, rmw ≥ 5, and WT_Mutant: FCwm > 2, rwm ≥ 5. 
 
The first criterion ensures that the protein identified is a true interactor of the I107R mutant of 
Mlh1. The second criterion ensures that the gain of interaction is significant and reliably 
observed across both WT_Mutant and Mutant_WT experiments. 
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We also identify interactors of Mlh1 that are unaffected by the I107R mutation using the 
following criteria: 
 
1. The protein has to be identified as an interactor of both wild-type Mlh1: WTp > 2, rwc ≥ 5, 
and mutant Mlh1 (I107R): Mutp > 2, rmc ≥ 5. 
2. The protein has to be identified as an unchanged interactor based on both Mutant_WT: 
0.5 < FCmw < 2, rmw ≥ 5, and WT_Mutant: 0.5 < FCwm < 2, rwm ≥ 5. 
 
Integrating both WT_Mutant and Mutant_WT experiments, we calculated a weighted average of 
the individual fold changes: 
 
E = rmw × log2(FCmw )+ rwm × log2(FCwm )rmw + rwm  
 
P values are calculated using a two-sided Kolmogorov-Smirnov test (with bootstrapping). 
 
Cell culture, co-immunoprecipitation, and Western blotting 
 
HEK293T cells were maintained in complete DMEM medium supplemented with 10% FBS. 
Cells were transfected with Lipofectamine 2000 (Invitrogen) at a 6:1 (µL/µg) ratio with DNA in 
6-well plates and were harvested 24 hrs after transfection. Cells were gently washed three times 
in PBS and then resuspended using 200 µL 1% NP-40 lysis buffer [1% Nonidet P-40, 50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1× EDTA-free Complete Protease Inhibitor tablet (Roche)] and 
kept on ice for 20 mins. Extracts were cleared by centrifugation for 10 mins at 13,000 rpm at 4 
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°C. 15 µL EZview Red Anti-HA Affinity Gel (Sigma-Aldrich) and 100 µL protein lysate were 
used for each co-immunoprecipitation reaction. The samples were rotated gently at 4 °C for 2 
hrs. HA beads were then washed three times with protein lysis buffer, treated with 6× protein 
sample buffer, and subjected to SDS-PAGE. Proteins were then transferred from the gel onto 
PVDF (Amersham) membranes. Anti-HA (Sigma H9658), anti-V5 (Invitrogen 46-0705), anti-β-
tubulin (Promega G7121), and anti-GFP (Santa Cruz sc-9996) antibodies were used at 1:3,000 
dilutions for immunoblotting analysis. 
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4.6 FIGURE AND TABLE LEGENDS 
 
Figure 4.1. Schematic of our comparative interactome-scanning pipeline. 
Our pipeline begins with Clone-seq (a), a massively-parallel low-cost site-directed mutagenesis 
pipeline leveraging next-generation sequencing. This is followed by a high-throughput GFP 
assay (b) to determine protein stability, and a high-throughput Y2H assay (c), along with SILAC-
based mass spectrometry (d) to determine the impact of DNA coding variants on protein 
interactions.  
 
Figure 4.2. Identifying usable clones from Clone-seq. 
(a) Schematic illustrating criteria used to determine which of the clones generated by our Clone-
seq pipeline are usable for further assays – green ticks indicate usable clones, while red crosses 
indicate clones that cannot be used. (b) Variation of S across different mutagenesis attempts that 
either contain or do not contain the desired mutation as confirmed by Sanger sequencing.  
 
Figure 4.3. Examples of disease mutations in different structural loci of protein-protein 
interactions and examples of our GFP assay results. 
(a) Crystal structure (PDB id: 3W4U) depicting a D100Y mutation (on Hbb) at an interface 
residue and a F104L mutation in the interface domain for the Hbb-Hbz interaction. (b) Crystal 
structure (PDB id: 1G3N) depicting a V31L mutation (on Cdkn2c) away from the Cdkn2c-Cdk6 
interaction interface. (c) GFP assays that determine the stability of wild-type Rrm2b and the 
R41P and L317V mutations on Rrm2b that are at an interface residue and away from the 
interface for the Rrm2b-Rrm2b interaction; GFP assays that determine the stability of wild-type 
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Hprt1 and the C206Y mutation on Hprt1 that is away from the interaction interface of Hprt-
Hprt1. Empty vector was used as a negative control.  
 
Figure 4.4. Effect of disease mutations on protein stability and protein-protein interactions.  
(a) Western blotting with anti-GFP antibody confirming the protein expression levels of wild-
type Rrm2b, Actn2, Hprt1, Pnp, Tpk1, Gnmt, Gale, Fbp1, Klhl3, Tp53, Pnp, Smad4, and 
corresponding mutant alleles. β-tubulin and γ-tubulin were used as loading controls. Red denotes 
“interface residue” mutations, orange denotes “interface domain” mutations and blue denotes 
“away from the interface” mutations. (b) Likelihood of disruption of interactions by “interface 
residue”, “interface domain” and “away from the interface” mutations – overall and for stable 
mutants only; likelihood of a disease mutation disrupting a given interaction in the absence of 
structural information. Error bars indicate +SE. (N = 204 mutations) 
 
Figure 4.5. Relationships between molecular phenotypes and disease phenotypes. 
(a) Fraction of mutation pairs on the same gene that cause the same disease: for the same and 
different effects on protein stability. (b) Fraction of mutation pairs on the same gene that cause 
the same disease: for the same and different interaction disruption profiles. Error bars indicate 
+SE. (c) Crystal structure (PDB id: 1U7F) depicting the Y353S and R361C mutations (on 
Smad4) at interface residues for the Smad4-Smad3 interaction. (d) Y2H analysis of the effects of 
Smad Y353S, R361, and N13S mutations on its interactions with Smad3, Lmo4, Rassf5, and 
Smad9. Western blotting with anti-GFP antibody confirming the protein expression levels of 
wild-type Smad4 and its 3 mutant alleles – Y353S, R361C and N13S. γ-tubulin was used as a 
loading control. 
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 Figure 4.6. Identifying interactions of Mlh1 that are affected by the I107R mutation using 
SILAC-based mass spectrometry. 
(a) Schematic illustrating criteria used to identify interactions that are lost/weakened, unchanged, 
and gained/enhanced due to the I107R mutation on Mlh1. Blue denotes samples cultured in light 
media and black denotes samples cultured in heavy media. (b) Scatter plot illustrating fold 
change (FC; log scale) in the amount of protein pulled down by wild-type Mlh1 and mutant 
Mlh1 (I107R). Values are computed based on the wild-type (heavy) vs. mutant (light) (X-axis) 
and mutant (heavy) vs. wild-type (light) (Y-axis) experiments. Green denotes enhancement of 
interaction, red denotes weakening of interaction, and gold denotes no change. Mlh1 is shown in 
grey. (c) Fold changes and read counts (r) for interactors of Mlh1 that can be reliably identified 
as weakened, unchanged, and enhanced due to the I107R mutation. (d) Anti-HA 
immunoprecipitation followed by Western blotting with anti-V5 antibody confirming that the 
Mlh1-Brip1 interaction remains unchanged and that the Mlh1-Hspa8 interaction is dramatically 
enhanced due to the I107R mutation. 
 
Table 4.1. Summary of GFP and Y2H assay results for all the mutations tested in our 
interactome-scanning pipeline. For the GFP assay: “1” indicates a stable mutation, “0” indicates 
an unstable mutation, and “–” indicates inconclusive results due to weak signal for the wild-type 
protein. For the Y2H assay: “1” indicates no disruption and “0” indicates disruption of the 
corresponding interaction. 
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Table 4.1
Interface 
residue
TargetProt_ent
rez Target_uniprot
Interactor_entr
ez Mutation GFP score Y2H score
60 P60709 60 R196C 1 0
95 Q03154 95 R197W 1 0
95 Q03154 95 R378W 1 1
1967 Q14232 1967 V183F 1 0
1967 Q14232 1967 P278R 1 0
2203 P09467 2203 N213K 1 0
2582 Q14376 2582 D103G 1 0
2582 Q14376 2582 R169W 1 1
2752 P15104 2752 R324C 1 1
3043 P68871 3050 D100Y - 0
3043 P68871 3050 P101A - 0
3043 P68871 3050 E102Q - 0
3043 P68871 3050 N103Y - 1
3251 P00492 3251 P38S 0 0
3945 P07195 3945 R172P 1 0
4088 P84022 9372 T330A 1 1
4089 Q13485 4088 G352R 0 0
4089 Q13485 4088 Y353S 1 0
4089 Q13485 4088 R361C 1 0
4089 Q13485 4088 L533R 1 0
4860 P00491 4860 F159V 0 0
5631 P60891 5631 D183H 1 0
5805 Q03393 5805 T106M - 0
7329 P63279 7341 V25M 1 0
50484 Q7LG56 50484 R41P 1 0
50484 Q7LG56 50484 R121H 1 1
51135 Q9NWZ3 4615 R12C - 0
Interface 
domain
TargetProt_ent
rez Target_uniprot
Interactor_entr
ez Mutation GFP score
60 P60709 60 E364K 1 1
60 P60709 60 N12D 1 0
60 P60709 60 L65V 1 1
60 P60709 60 E117K 1 0
60 P60709 60 R183W 1 0
88 P35609 88 T495M 1 1
88 P35609 88 Q349L 1 1
88 P35609 88 E583A 1 1
95 Q03154 95 E233D 1 0
95 Q03154 95 R386C 1 0
95 Q03154 95 R393H 1 1
435 P04424 435 R12Q 1 1
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875 P35520 875 G85R 1 0
875 P35520 875 L101P 1 0
875 P35520 875 K102Q 1 1
875 P35520 875 C109R 1 0
875 P35520 875 A114V 1 1
875 P35520 875 G116R 1 0
1019 P11802 595 S52N 1 1
1019 P11802 595 R24H 1 1
1019 P11802 595 N41S 1 1
1967 Q14232 1967 N208Y 1 0
1967 Q14232 1967 Y275C 1 1
2203 P09467 2203 G164S 1 0
2203 P09467 2203 A177D 1 0
2203 P09467 2203 F194S 1 0
2203 P09467 2203 G260R 1 0
2203 P09467 2203 E281K 1 1
2512 P02792 2512 Q26L 1 0
2512 P02792 2512 A27V 1 0
2512 P02792 2512 T30I 1 0
2512 P02792 2512 A96T 1 0
2582 Q14376 2582 T150M 1 1
2582 Q14376 2582 K161N 1 1
2582 Q14376 2582 E165K 1 0
2582 Q14376 2582 D175N 1 1
2752 P15104 2752 R341C 1 0
3043 P68871 3050 S10C - 0
3043 P68871 3050 F104L - 0
3251 P00492 3251 Y105C 1 1
3251 P00492 3251 S110L 1 1
3251 P00492 3251 T124S 1 1
3611 Q13418 55742 A262V - 1
3939 P00338 3939 K222E 1 1
4085 Q13257 9587 L84M 1 0
4088 P84022 9372 E239K 1 1
4088 P84022 9372 T261I 1 1
4088 P84022 9372 P263L 1 1
4088 P84022 9372 R279K 1 1
4088 P84022 9372 R287W 1 1
4089 Q13485 4088 C324R 0 0
4089 Q13485 4088 E330K 0 0
4089 Q13485 4088 V350D 0 0
4598 Q03426 4598 N301T 1 0
4615 Q99836 51135 L93P 1 0
4830 P15531 4830 S120G 1 0
4860 P00491 4860 G71E 0 0
4860 P00491 4860 A117T 0 0
4860 P00491 4860 D128G 0 0
4860 P00491 4860 P146L 0 0
4860 P00491 4860 G156A 0 0
124
5723 P78330 5723 D32N 1 1
5723 P78330 5723 M52T 1 1
5805 Q03393 5805 R25Q - 0
5805 Q03393 5805 F100V - 0
5805 Q03393 5805 A101V - 0
5805 Q03393 5805 V103A - 1
5805 Q03393 5805 A111T - 0
6898 P17735 6898 R119W 1 0
6898 P17735 6898 C151Y 1 0
6898 P17735 6898 L201R 1 0
6898 P17735 6898 P220S 1 1
6898 P17735 6898 L273P 1 0
6898 P17735 6898 G362V 1 0
7128 P21580 7128 A125V 1 1
7157 P04637 7159 G105C 1 0
7157 P04637 7159 S106R 1 1
7157 P04637 7159 R110L 0 0
7157 P04637 7159 V122G 1 1
7157 P04637 7159 Y126C 1 0
7454 P42768 998 I294T 1 0
8772 Q13158 8772 C105W 1 0
8815 O75531 2010 A12T 1 1
11144 Q14565 11144 M200V 1 1
23568 Q9Y2Y0 402 M45R 1 0
27010 Q9H3S4 27010 N219S 1 0
27010 Q9H3S4 27010 L40P 1 1
27010 Q9H3S4 27010 N50H 1 1
27232 Q14749 27232 N141S 1 0
27232 Q14749 27232 H177N 1 0
50484 Q7LG56 50484 R110C 1 1
50484 Q7LG56 50484 F123S 1 0
50484 Q7LG56 50484 E131K 1 1
50484 Q7LG56 50484 T144I 1 1
64802 Q9HAN9 64802 R66W 1 0
64802 Q9HAN9 64802 A13T 1 1
64802 Q9HAN9 64802 A147P 1 1
64802 Q9HAN9 64802 V151F 1 0
64802 Q9HAN9 64802 L153V 1 0
64802 Q9HAN9 64802 D173G 1 0
Away from the 
interface
TargetProt_ent
rez UniprotID
Interactor_entr
ez AA_mut GFP score
88 P35609 88 A119T 1 1
88 P35609 88 Q9R 1 1
88 P35609 88 V115M 1 1
88 P35609 88 E628G 1 1
88 P35609 88 H775Y 1 1
125
331 P98170 842 G188E - 1
331 P98170 842 R166I - 1
331 P98170 842 W173G - 1
331 P98170 842 V198M - 1
331 P98170 842 C203Y - 1
331 P98170 842 L207P - 1
701 O60566 991 L1012P 0 0
701 O60566 991 R36Q 1 1
701 O60566 991 Y155C 1 1
701 O60566 991 R727C 0 0
701 O60566 991 L844F 0 0
875 P35520 875 L456P 1 0
875 P35520 875 R379W 1 1
875 P35520 875 K384E 1 1
875 P35520 875 M391I 1 1
875 P35520 875 P422L 1 1
875 P35520 875 P427L 1 1
958 P25942 7186 C83R 1 0
1026 Q6FI05 5111 R67L 1 1
1026 Q6FI05 5111 R84Q 1 1
1031 Q6ICV4 1021 V31L 1 1
2010 P50402 8815 P183T - 1
2010 P50402 8815 S54F 1 1
2010 P50402 8815 D72V 1 1
2582 Q14376 2582 P293L 1 1
2582 Q14376 2582 G302D 1 1
2582 Q14376 2582 L313M 1 1
2582 Q14376 2582 G319E 1 1
2582 Q14376 2582 R335H 1 1
3043 P68871 3050 V114E - 0
3043 P68871 3050 L115P - 0
3043 P68871 3050 H118Y - 0
3043 P68871 3050 E122V - 0
3043 P68871 3050 F123S - 0
3043 P68871 3050 V127G - 0
3251 P00492 3251 C206Y 0 0
3251 P00492 3251 I10S 1 0
3251 P00492 3251 D12A 1 0
3251 P00492 3251 E14K 1 0
3251 P00492 3251 R167M 0 0
3251 P00492 3251 T168I 1 0
3945 P07195 3945 K7E 1 1
4088 P84022 9372 A112V 1 1
4088 P84022 9372 N197I 1 1
4089 Q13485 4088 N13S 1 1
4598 Q03426 4598 H20Q 1 0
4615 Q99836 51135 R196C 1 0
5631 P60891 5631 E43D 1 1
5805 Q03393 5805 R9C - 1
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6829 O00267 6827 E455D 1 1
7157 P04637 7159 R290L 1 1
7157 P04637 7159 K292I 1 1
7157 P04637 7159 G293W 1 1
7157 P04637 7159 K305M 1 1
7157 P04637 7159 R306P 1 1
7157 P04637 7159 P309S 1 1
7454 P42768 998 E131K 1 1
8504 P56589 5824 D347Y - 1
26249 Q9UH77 8452 C164F 0 0
26249 Q9UH77 8452 R228G 1 0
27232 Q14749 27232 L50P 1 1
50484 Q7LG56 50484 L317V 1 1
51135 Q9NWZ3 4615 G298D - 0
51135 Q9NWZ3 4615 A428T - 1
55737 Q96QK1 51699 R524W - 1
55737 Q96QK1 51699 D620N - 1
64802 Q9HAN9 64802 N273D 1 1
64802 Q9HAN9 64802 V9M 1 1
64802 Q9HAN9 64802 H251P 1 1
64802 Q9HAN9 64802 E257K 1 1
124590 Q495M9 10083 L16V 1 1
124590 Q495M9 10083 L48P 1 1
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CHAPTER 5 
Genome-scale analysis of interaction dynamics reveals organization of 
biological networks  
In the following chapter, we explore the concept of “interaction dynamics” and how it can be 
used to understand the topological and biological properties of networks. I am the first author of 
the paper resulting from this chapter (Das et al Bioinformatics 2012) and led all computational 
analyses. Jaaved Mohammed made a significant contribution to several of the analyses in the 
paper. 
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5.1 ABSTRACT 
Analyzing large-scale interaction networks has generated numerous insights in systems biology. 
However, such studies have primarily been focused on highly co-expressed, stable interactions. 
Most transient interactions that carry out equally important functions, especially in signal 
transduction pathways, are yet to be elucidated and are often wrongly discarded as false 
positives. Here, we revisit a previously described Smith-Waterman-like dynamic programming 
algorithm and use it to distinguish stable and transient interactions on a genomic scale in human 
and yeast. We find that in biological networks, transient interactions are key links topologically 
connecting tightly regulated functional modules formed by stable interactions and are essential to 
maintaining the integrity of cellular networks. We also perform a systematic analysis of 
interaction dynamics across different technologies and find that high-throughput yeast two-
hybrid (Y2H) is the only available technology for detecting transient interactions on a large 
scale. 
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5.2 INTRODUCTION 
The protein-protein interactome of an organism is the network of all biophysically possible 
interactions of different proteins in that organism (Yu et al., 2008).  It is of key importance to 
accurately map this network as most proteins function by interacting with other proteins (Pawson 
and Nash, 2000). Moreover, a better understanding of genotype to phenotype relationships in 
human disease require modeling of how disease-causing mutations might affect protein 
interactions and interactome properties (Goh et al., 2007; Wang et al., 2011). Currently, there are 
two main high-throughput technologies to generate high-quality protein-protein interactomes on 
a large-scale: yeast two-hybrid (Y2H), where a protein interaction reconstitutes a transcription 
factor which then activates expression of reporter genes (Fields and Song, 1989); and affinity 
purification followed by mass spectrometry (AP/MS), where proteins bound to tagged baits are 
co-purified and identified (Rigaut et al., 1999). High-throughput Y2H maps have been generated 
for yeast, fly, worm, and human, while large-scale AP/MS datasets have been generated for 
yeast, worm and human (Jensen and Bork, 2008; Yu et al., 2008). An alternative approach, 
adopted by most databases, is to obtain literature-curated (LC) interactions (Cusick et al., 2009).  
It has been shown that well-controlled Y2H and AP/MS experiments are both of high quality, but 
of complementary nature – Y2H identifies direct binary interactions whereas AP/MS determines 
co-complex associations (Jensen and Bork, 2008; Yu et al., 2008). Moreover, gene expression 
and other functional genomics datasets are routinely integrated with protein-protein interactions 
to validate their biological relevance - for example, interactions between proteins encoded by co-
expressed genes are often considered to be of high quality (Ge et al., 2001; Suthram et al., 2006; 
von Mering et al., 2002). In these analyses, gene co-expression is normally determined by a high 
Pearson correlation coefficient (PCC), which really means that the expression levels of the two 
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genes are correlated over most conditions i.e., they are globally co-expressed (Figure 5.1A). 
Previous studies have shown that interacting proteins within stable complexes also tend to be 
encoded by globally co-expressed gene pairs (Jansen et al., 2002; Yu et al., 2008). On the other 
hand, the regulation and coordination of the sub-cellular machinery is achieved by dynamic 
transient interactions for example in signal transduction pathways (Jansen et al., 2002). Proteins 
involved in transient interactions are not globally co-expressed. Rather, they share local blocks 
of co-expression. Transient interactions and their dynamics have significant biological 
importance but most genes in these pathways are often co-expressed only under certain 
conditions (Figure 5.1B). As a result, these are usually discarded as false positives (Ge et al., 
2001; Suthram et al., 2006). Here, we take advantage of a novel measurement of expression 
relationships (Qian et al., 2001) to directly distinguish stable from transient interactions on a 
genome-wide scale in human and yeast and systematically analyze their topological and 
biological significance. We also evaluate different technologies in terms of their sensitivity in 
detecting interaction dynamics on a genomic scale.  
 
5. 3 RESULTS 
Expression dynamics: global vs. local co-expression 	  
For our analysis, we created compendiums of gene expression and high-quality large-scale 
protein-protein interaction datasets for human and yeast. We decided to use time course datasets 
because four distinct kinds of expression relationships - co-expression, time-shifted, inverted, 
and inverted time-shifted can be determined using such datasets (Qian et al., 2001). As the cell is 
in a different state at each of these time points, we are in fact measuring expression under 
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different intra-cellular conditions. All datasets are carefully normalized to remove potential noise 
(Irizarry et al., 2003; Johnson et al., 2007; Luscombe et al., 2003; Yu et al., 2007b). We also 
compiled high-quality large-scale protein-protein interaction datasets for human and yeast 
spanning both high-throughput technologies  - Y2H and AP/MS. We consolidated high-quality 
binary interactions in the literature from various databases. Although traditionally these LC 
interactions are considered to be of high quality, recent studies have shown that many of them, 
especially those supported by only one publication, in fact tend to be false positives (Cusick et 
al., 2009). To remove unreliable interactions from our analysis, we carefully compiled 
comprehensive sets of high-quality binary LC interactions supported by multiple publications 
(named “LC-multiple”) for human and yeast. High-quality LC co-complex associations were 
obtained from MIPS (Mewes et al., 2011) for yeast and Reactome (D'Eustachio, 2011) for 
human - two databases generally considered as gold standards for complexes in the 
corresponding organisms (Jansen et al., 2002; Lage et al., 2007).   
From these datasets, we first calculated the PCC for expression profiles corresponding to 
interacting protein pairs in the high-quality interaction datasets described above. For a pair of 
gene expression profiles, PCC reports the global correlation of expression levels across all 
conditions (Qian et al., 2001). A PCC value close to one indicates the pair of genes is globally 
co-expressed  (Figure 5.1A), whereas values close to zero indicate random, uncorrelated 
expression patterns. We find that the different interaction datasets for both human and yeast are 
significantly enriched for global co-expression as opposed to random gene pairs (Figures 5.2A 
and 5.2B). Since PCC is a linear correlation coefficient and certain co-expression relationships 
could be non-linear, we also used the maximal information coefficient (MIC) (Reshef et al., 
2011) to explore global expression dynamics of the different interaction datasets in human and 
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yeast. MIC belongs to a class of maximal information-based nonparametric exploration (MINE) 
statistics and has been shown to be very robust in detecting a wide range of associations both 
linear and not (Reshef et al., 2011). Using MIC, we re-validate the global expression dynamics 
captured by PCC – all the high-quality interaction datasets in both human and yeast have 
significantly enriched global co-expression as opposed to random gene pairs. Interacting protein 
pairs that have PCC greater than a certain cutoff are defined as stable interactions. However, 
gene pairs that are only co-expressed under certain conditions could have low and non-
significant global PCC/MIC values. These often go undetected in the global nature of the 
computation, making global correlation an ineffective method for identifying condition-specific 
characteristics of transient interactions.  To define dynamic co-expression relationships, we 
employed a Smith-Waterman-like dynamic programming algorithm as described previously 
(Qian et al., 2001). For each pair of genes and their expression profiles, this algorithm calculates 
local expression-correlation scores (LES) to find subsets of conditions with correlated expression 
levels  (Figure 5.1B). Interacting proteins that do not pass the global PCC cutoff but have high 
LES are defined as transient interactions (see Methods). 
 
Interaction dynamics: stable vs. transient  
Next, in order to explore interaction dynamics across different technologies, we compared how 
successful different experimental techniques were in detecting stable and transient interactions. 
In agreement with previous studies, stable interactions within sub-cellular complexes show a 
strong enrichment of proteins encoded by globally co-expressed genes  (Figures 5.2a and 5.2B). 
On the other hand, although statistically significant, the enrichment of these globally-co-
expressed pairs is much less for binary interactions from both large-scale Y2H and LC sources. 
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This lack of global co-expression has often been used as an argument to suggest that high-
throughput Y2H interactions are of low quality (Ge et al., 2001; Suthram et al., 2006; von 
Mering et al., 2002). However, a recent study applied orthogonal assays to experimentally 
confirm that these binary interactions are in fact highly reliable (Yu et al., 2008). Figures 5.2C 
and 5.2D show that in both human and yeast, Y2H is the only technology consistently able to 
identify transient interactions significantly more than random expectation. Surprisingly, binary 
interactions from the literature are not enriched with transient ones. Given the sociological biases 
within interactions from the literature (Cusick et al., 2009; Yu et al., 2008), there might be many 
compounding factors for this result. Stable interactions are easier to recapitulate under different 
experimental conditions whereas transient interactions can only be tested under specific 
conditions. Therefore, transient interactions are more likely to be considered as false positives 
and not reported in the literature. Additionally, in the post-genomic era, many candidate 
interaction partners are first identified based on gene expression and other genomic features 
favoring selection of stable interactions over transient ones. This result further highlights the 
importance of high-throughput Y2H because it is the only technology available to detect 
transient interactions, confirming that different protein interaction detection technologies capture 
different modes of biochemical interactions (Jensen and Bork, 2008; Yu et al., 2008). 
 
Biological significance of transient interactions 
To assess the biological significance of transient interactions as defined by our algorithm, we 
computed functional similarity of protein pairs involved in these interactions. We find that 
transient interactions are significantly enriched for proteins with similar functions and the fold 
enrichment is comparable to that of stable interactions in both human and yeast. These results 
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confirm the validity of our definition of transient interactions. We therefore provide the first 
method to systematically detect transient interactions on a genomic scale. Although our method 
might miss certain transient interactions, especially extremely transient ones that are virtually 
impossible to distinguish from random, our results confirm that those detected by our method are 
high-quality and share significant functional similarity.  
A good example of transient interactions identified by Y2H is the interaction between Sfb2 and 
Sec23. This interaction has been confirmed in vivo (Peng et al., 2000). Sec23 is a subunit of the 
COPII complex, required for the budding of transport vesicles from endoplasmic reticulum 
(Miller et al., 2003). SFB2 has a 56% sequence identity with SEC24, an essential component of 
COPII involved in cargo selection (Miller et al., 2003). Over-expression of SFB2 can rescue the 
sec24 null mutant cells (Kurihara et al., 2000). Furthermore, it has been suggested 
experimentally that Sfb2 may recognize different export signals from those of Sec24 and may be 
used under non-normal growth conditions (Miller et al., 2003; Peng et al., 2000). These results 
agree with the expression dynamics revealed by our new analysis – SFB2 and SEC23 are only 
co-expressed during stress response (Figure 5.3A). 
 
Transient interactions key in maintaining network integrity 
Traditionally, in network analysis, the focus has been on nodes. Hubs are crucial in maintaining 
the integrity of biological networks (Albert et al., 2000; Barabasi and Albert, 1999; Jeong et al., 
2000 ). Interaction networks have two broad categories of hubs. Date hubs have low average 
PCCs with their interactors and hold the key in maintaining the integrity of cellular networks 
while party hubs have high average PCC with their interactors and are often contained in tightly 
organized modules (Han et al., 2004). We find that date hubs have a significant propensity to be 
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involved in transient interactions (Figures 5.3B and 5.3C) suggesting that these play an important 
role in maintain the integrity of the networks. To validate this result, we compared the edge 
“betweenness” of global and transient interactions. Edge betweenness can be used to detect 
community structure within networks (Girvan and Newman, 2002). Clusters detected by this 
approach tend to share similar functions (Dunn et al., 2005). We find that transient interactions 
for both human and yeast have a significantly higher betweenness than stable interactions 
(Figure 5.3D). This implies that transient interactions hold the key in maintaining the integrity of 
the underlying cellular network. Disrupting these will partition the interactome into disjoint 
clusters, unable to perform temporally and spatially well-regulated processes. 
To further explore topological properties of transient interactions, we examined connectivity in 
response to progressive edge removal and found that selectively removing transient interactions 
increased characteristic path length much more sharply than selectively removing stable or 
random interactions (Figures 5.3E and 5.3F). Biological interactomes are small-world networks 
and removing a random edge is unlikely to significantly alter connectivity, as most random edges 
are not essential in maintaining network integrity (Albert et al., 2000). However, selectively 
disrupting key edges disrupts network structure and increases the characteristic path length 
significantly. Since removal of transient interactions causes the sharpest increase in path length, 
these are indeed critical for network integrity. 
 
 
5.4 DISCUSSION 
Here, we utilize a previously described Smith-Waterman-like dynamic programming algorithm 
to segregate transient interactions from stable complexes on a genomic scale directly from gene 
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expression data. For the first time, we distinguish their biological roles and show that though 
transient interactions are currently underexplored, they perform key biological functions and are 
essential to maintaining the integrity of cellular networks. Moreover, we find that Y2H is 
currently the only technology that is able to determine transient interactions on a large scale. Our 
findings are likely to generate significant interest in designing experiments to detect transient 
interactions to further explore their properties. 
5.5 MATERIALS AND METHODS 
Calculating PCC, MIC and LES 
PCC was calculated in a massively parallel, Java program utilizing the Parallel Java framework 
(Kaminsky, 2010). MIC was calculated using a Java implementation provided by Reshef et al. 
(Reshef et al., 2011). Transient interactions for human and yeast were identified with a similar 
Parallel Java implementation of a Smith-Waterman-like dynamic programming algorithm to 
calculate LES (Qian et al., 2001). 
Calculating betweenness and functional similarity 
Edge betweenness was calculated using the Girvan-Newman algorithm (Girvan and Newman, 
2002). Functional similarity was studied using total ancestry measure – a metric that takes the 
entire biological process tree and calculates the association of each gene with a biological 
process. For each protein pair query, it computes what fraction of all possible protein pairs that 
share the same set of Gene Ontology (GO) (Ashburner et al., 2000) biological pathway terms as 
the query pair (Yu et al., 2007a). The calculations are performed using a massively Parallel Java 
program (Kaminsky, 2010). 
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5.6 FIGURE LEGENDS 
Figure 5.1. Cartoon depiction of protein–protein interaction dynamics. (A) Gene expression 
profiles for two proteins that are highly correlated under all conditions indicating a stable or 
globally co-expressed interaction. (B) Two contiguous blocks of significant co-expression 
indicate this pair of proteins is transiently interacting or locally co-expressed. 
Figure 5.2. (A, B) Enrichment of PCC of co-expression of interacting proteins (detected by 
different technologies) as opposed to random gene pairs in human and yeast respectively. (C, D) 
Comparison of transient interactions detected per technology in human and yeast, respectively. 
The dashed line indicates the overall average detection of transient interactions. 
Figure 5.3. (A) The expression profiles of SFB2 and SEC23 (co-expression only in the final 
yellow block). (B, C) Transient interactions in human are enriched in “date hubs”. These have 
previously been shown to be vital in forming important topological links between stable 
functional modules. (D) Transient interactions in human and yeast have a significantly higher 
betweenness value–they hold the key in maintaining the integrity of cellular networks. (E, F) 
Characteristic path length as a measure of network connectivity after successive removal of 
edges of the network. Each data point represents the removal of a fixed percentage of overall 
nodes of the graph from each interaction type. Random removal occurs on all interactions in the 
network, which may include other interactions that are still uncategorized as transient or stable. 
Removal of transient interactions increases path length more sharply than disturbing random or 
stable interactions. 
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CHAPTER 6 
ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for 
human cancers 
In the following chapter, we explore how expression data can be combined with protein 
networks to predict cancer outcome. I am the first author of the paper resulting from this chapter 
(Das et al BMC Genomics 2015) and led all computational analyses. Kaitlyn Gayvert made a 
significant contribution to several of the analyses in the paper. 
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6.1 ABSTRACT 
 
With the explosion of genomic data over the last decade, there has been a tremendous 
amount of effort to understand the molecular basis of cancer using informatics approaches. 
However, this has proven to be extremely difficult primarily because of the varied etiology 
and vast genetic heterogeneity of different cancers and even within the same cancer. Thus, 
one particularly challenging problem is to predict prognostic outcome of the disease for 
different patients. Here, we present ENCAPP, an elastic-net-based approach that combines 
the reference human protein interactome network with gene expression data to accurately 
predict prognosis for different human cancers. Our method identifies functional modules 
that are differentially expressed between patients with good and bad prognosis and uses 
these to fit a regression model that can be used to predict prognosis for breast, colon and 
ovarian cancers. Using this model, ENCAPP can also identify prognostic biomarkers with a 
high degree of confidence, which can be used to generate downstream mechanistic and 
therapeutic insights. ENCAPP is a robust method that can accurately predict prognostic 
outcome and identify biomarkers for different human cancers.  
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6.2 INTRODUCTION 
The genetic complexity of cancer and its widely varying etiology and outcome make it extremely 
difficult to treat. It has been realized that rather than being a single disease, different cancers 
have widely diverse molecular bases (Hanahan and Weinberg, 2011; Lawrence et al., 2014). 
There has been a tremendous amount of effort in the literature to understand molecular 
signatures underlying cancer (Hanahan and Weinberg, 2011). A significant number of these 
efforts have been informatics-based approaches that try to leverage genomic information such as 
expression alterations, mutations in genomes, copy number changes and epigenetic modifications 
to elucidate the mechanistic basis of cancer (Chin et al., 2011). Global collaborative research 
endeavors such as The Cancer Genome Atlas (TCGA) (Weinstein et al., 2013) and the 
International Cancer Genome Consortium (ICGC) (Hudson et al., 2010) are trying to assimilate 
these genome-scale datasets for different kinds of cancers across many countries. 
One of the key challenges has been to use genomic information to understand the basis for 
different outcomes for the same cancer. However, this has been difficult because it is unclear as 
to which parameters contain the most information regarding disease outcome. One of the first 
attempts at predicting cancer prognosis using genome-scale transcriptomic datasets was 
undertaken by van de Vijver et al (van de Vijver et al., 2002). Using microarrays, they obtained 
tissue-specific gene-expression profiles for breast cancer patients. They then clustered these 
expression profiles and correlated them with prognostic outcome to identify a 70-gene ‘prognosis 
profile’ for breast cancer. One of the key limitations in using only expression datasets to predict 
cancer prognosis is the assumption of independence between genes in hypotheses testing. 
However, the protein products encoded by these genes are not independent but part of a complex 
interactome network. The dependencies of this network have been shown to be of great 
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importance in understanding the genetic and molecular bases of disease (Das et al., 2014a; Das et 
al., 2014b; Guo et al., 2013; Vidal et al., 2011; Wang et al., 2012). Chuang et al (Chuang et al., 
2007), Taylor et al (Taylor et al., 2009) and Wu and Stein (Wu and Stein, 2012) used a 
functional interactome network to predict breast cancer prognosis. Recently, Hofree et al 
reported a network-based stratification approach that can use somatic mutations to predict cancer 
subtypes (Hofree et al., 2013). However, their method is primarily designed to work with 
mutation data and is less accurate for expression data (Hofree et al., 2013). Given the much 
wider availability of expression datasets as compared to whole genome or exome sequences, it is 
of paramount importance to have a robust method that can use gene expression to accurately 
predict prognosis across different types of cancer. To this end, in this manuscript, we report 
ENCAPP, an elastic-net-based cancer prognosis prediction method. We use tissue-specific gene 
expression data from patients along with the reference human protein interaction network to 
construct a regression model that can predict disease outcome for breast, colon and ovarian 
cancers. Our approach outperforms previous methods in terms of accuracy of prognosis 
prediction. Moreover, ENCAPP can also accurately identify genes that can serve as prognostic 
biomarkers for different cancers. 
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6.3 RESULTS 
ENCAPP – a schematic  
A reference high-quality human protein interactome was constructed as described earlier (Das 
and Yu, 2012). Our interactome comprises a total of 42,604 binary and co-complex interactions 
between 9,985 proteins. We include both kinds of interactions as they capture orthogonal layers 
of information – binary interactions represent direct contacts between two proteins, while co-
complex associations capture co-membership of a protein complex. This network is clustered 
into different functional modules. We then overlay tissue-specific gene expression data from 
cancer patients onto these functional modules to generate ‘expression modules’. We then identify 
ones that are differentially expressed between patients with good and bad prognosis (Figure 6.1). 
We use the expression modules that show the maximum difference between the prognostic 
outcome classes as decision boundaries to build a regression model that can predict disease 
prognosis (Figure 6.1). Our regression approach attempts to estimate the conditional probability 
of having good or bad prognosis given the patient’s expression modules. 
Since the data is inherently high dimensional (i.e., the number of expression modules is greater 
than the number of patients), ordinary least squares regression cannot be used and a 
regularization term is essential (see Methods). While ridge regression (L2 regularization term) 
(Hoerl and Kennard, 1970) uses all input variables to fit the model, the least absolute shrinkage 
and selection operator (LASSO, L1 regularization term) (Tibshirani, 1996) attempts to find the 
most optimal sparse fit. Ridge regression can lead to inflated variance but has low bias, while 
LASSO can have high bias but ensures low variance. To optimize the bias-variance tradeoff, the 
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elastic net (Bunea, 2008; Zou and Hastie, 2005) has been proposed and is our choice of 
regression model (see Methods). 
Prognosis prediction using differentially expressed functional modules 
We first examined expression data from a cohort of breast cancer patients (van de Vijver et al., 
2002). Here, prognosis was defined as five-year disease-free survival. Using five-fold cross 
validation, we first measured prognosis prediction accuracy using only expression values from 
all genes and found it to be a suboptimal predictor (median AUC = 0.747, 95% CI for AUC = 
0.743-0.751 Figure 6.2A, see Methods). Since proteins carry out their function by interacting 
with other proteins, we then used only expression values from genes whose corresponding 
proteins have at least one known interaction to predict prognosis. This did not significantly alter 
performance (median AUC = 0.745, Figure 6.2A). Taylor et al used hub groups as a measure of 
network topology, however we choose modules for two reasons (Figure 6.2B). First, hub groups 
only include interactions between the hub protein and its interactors, not those between the 
interactors themselves. Thus, modules contain more information. Second, in Taylor et al’s 
model, each protein is assigned to one and only one hub group. However, since network modules 
can be overlapping (Ahn et al., 2010; Ravasz et al., 2002), the same protein may be assigned to 
multiple modules if it has multiple functions. Since numerous proteins carry out biological 
functions in a pleiotropic fashion, our approach captures such relationships while hub groups do 
not. 
To identify functional modules, we tried three separate algorithms – hierarchical clustering 
(Ward, 1963), affinity propagation clustering (Frey and Dueck, 2007) and ClusterOne (Nepusz et 
al., 2012). We constructed modules from all three algorithms using default parameters (the 
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module creation is independent of any expression data). Using expression values from the van de 
Vijver dataset, we used modules generated by all three algorithms to construct expression 
modules and used them to predict prognosis. We find that ClusterOne has the best performance 
(Figure 6.2C; see Methods). One possible reason for this is that the protein interactome network 
is binary (1 corresponding to an interaction between two proteins, while 0 corresponds to no 
interaction between the two proteins) and sparse. Thus, the number of discrete values (equal to 1 
+ the graph diameter) the graph distance used for hierarchical clustering can take is limited. 
Affinity propagation clustering is more suited to identifying hub-group-like topological 
structures as hubs fit the definition of exemplars. On the other hand, ClusterOne was designed to 
identify functional modules that capture pleiotropic relationships. Thus, ClusterOne was used for 
all further analyses.  
We then explored the contribution of the three different datasets – clinical covariates, gene 
expression and the protein network to predicting prognosis. Figure 6.3 presents a flowchart of 
our ENCAPP algorithm. We find that expression and network in combination are the most 
informative (Figure 6.4A, median AUC = 0.777; 95% CI for AUC = 0.773-0.780; P < 10-3; 
Table 6.1) and the addition of clinical data only marginally improves the performance (Figure 
6.4A, AUC = 0.786; 95% CI for AUC = 0.783-0.789; P < 10-3; Table 6.1). ENCAPP also 
performs much better than an approach that just uses differential approach; we trained a 
generalized linear model with differentially expressed genes selected using the LIMMA package 
(Ritchie et al., 2015) and found that the median AUC is 0.685, significantly lower than ENCAPP 
(P < 10-3). These results confirm that using interaction dynamics, a combination of gene 
expression data with the topological structure of the network, is a key predictor of prognosis. Our 
results also confirm that ENCAPP will work efficiently even in the absence of clinical 
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information, which can be hard to collect and thus is often unavailable. Furthermore, while we 
used ‘death’ as the outcome variable for the prognosis prediction described above, we find that it 
is robust to using other variables as outcome labels. 
To compare the performance of our method to previous attempts, we first compared our 
classification accuracy (i.e., the fraction of patients for which we were able to accurately predict 
prognosis, see Methods) and AUC to Taylor et al (Figure 6.4B) and Chuang et al et al. Using 
expression data in conjunction with the protein network, ENCAPP achieves a median AUC of 
0.777, significantly higher than the value of 0.71 reported by Taylor et al (P < 10-3). We then 
compared the performance of ENCAPP to that of Chuang et al. At a ﬁxed sensitivity of 90%, 
ENCAPP has a significantly higher accuracy (75.1% vs 70.1%, P = 0.025). Finally, we 
compared ENCAPP to the results reported by Wu and Stein (Wu and Stein, 2012). Since they do 
not directly report ROC curves, we adopted a slightly different approach for this comparison. We 
trained a generalized linear model (GLM) using expression values from Wang et al Lancet 2005 
for the significant modules identified by them and attempted to predict prognosis for the Wang 
dataset. We found that the median AUC is 0.510. We then used the same modules and 
constructed the features that ENCAPP uses to train a GLM. The median AUC goes up to 0.561, 
significantly higher (P < 10-3) than the earlier median AUC.  
We then sought to assess the changes that cause the performance boost over previous methods. 
We used ENCAPP on an experimentally verified subset of the Ophid interactome used in the 
Taylor et al. study. We obtained a median AUC of 0.750, which is significantly higher (P = 
0.040) than the AUC of 0.71 obtained by them. This confirms that a large portion of the increase 
in performance is solely due to the core methodology underlying ENCAPP – our approach 
captures more information regarding the topology of the protein interactome than Taylor et al 
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because of the differences in hub groups and modules outlined earlier. The rest of the increase is 
due to a higher quality protein network used in our study. The improvement in the protein 
network can be attributed to two factors – a methodological enhancement: we employ a series of 
stringent filtering steps (Das and Yu, 2012) to identify a set of high-quality interactions and an 
increase in the available data. Thus, ENCAPP is a robust and reliable method that combines 
expression data with protein network modules to accurately predict cancer prognosis; it works 
efficiently even in the absence of clinical data. 
Robustness of ENCAPP 
Is ENCAPP robust to changes of the response variable or the incompleteness of the reference 
protein network? To systematically test this, we first focused on how the performance of 
ENCAPP changes when the response variable is altered. For the van de Vijver dataset, he 
outcome variable (survival) is right censored, i.e., if a patient survives for >=5 years, she is 
considered to have good prognosis, else bad prognosis. To test the robustness of ENCAPP to the 
right censoring cutoff, we varied it from 3-14 years i.e, a patient is defined to have good 
prognosis if she survived for >=k years, where k varies from 3 to 14. We find that ENCAPP 
performs consistently well for all values of k (Figure 6.4C), with the highest median AUC being 
0.778 and the lowest median AUC being 0.730. This confirms that ENCAPP is robust across a 
wide range of cutoff values for right censoring. 
 To further validate the robustness of ENCAPP to alternate definitions of prognosis, we modified 
the outcome definition. We defined a patient to have a good prognosis, if she does not have 
metastases for >= k years, where k varies from 3 to 10. Here too, ENCAPP performs consistently 
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well (Figure 6.4D), with the highest median AUC being 0.744 and the lowest median AUC being 
0.652, confirming that it is also robust across prognosis definitions. 
To address the robustness of ENCAPP to incompleteness of the protein network, we generated 
sets of 50 random networks for each of the following scenarios:  5%, 10%, 15% and 20% of the 
total edges randomly removed. We then generated modules for all these random networks using 
the same ClusterOne parameters as the original network. We then re-calculated the performance 
of ENCAPP on the van de Vijver dataset for each of these networks with a certain fraction of the 
edges removed. We find that ENCAPP still performs well, with median AUCs of 0.744, 0.740, 
0.743 and 0.742 at 5%, 10%, 15% and 20% edge deletions respectively (Figure 6.4E), 
confirming that it highly robust to network incompleteness. 
Pan-cancer prognosis prediction 
A major challenge of prognosis prediction algorithms is to make them generically applicable to 
different human cancers. To examine the applicability of ENCAPP for other cancer types and 
sub-types, we first used it on a dataset of lymph-node negative breast cancer patients (Wang et 
al., 2005). Although, van de Vijver et al also examined breast cancer patients, the consensus gene 
signature identified was very different. Wang et al stated that the results vary so much “because 
of differences in patients, techniques, and materials used” (Wang et al., 2005). The van de Vijver 
dataset included node-negative and node-positive patients and women less than 53 years old. 
Moreover, prognosis for the Wang dataset is defined as metastasis-free survival. However, 
ENCAPP is still able to accurately predict (median AUC = 0.690; 95% CI for AUC = 0.684-
0.695; P < 10-3; Table 6.1) cancer prognosis for these patients (Figure 6.5A), confirming that its 
robustness across cancer sub-types. 
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Another key goal of prognosis prediction algorithms is to be applicable across data collected 
from different cohorts of patients. To test whether ENCAPP can be trained on a certain dataset 
and then used to predict outcome for a completely different set of patients, we used the Wang et 
al dataset to train the model and then predicted outcomes for the van de Vijver dataset using it. 
While we originally analyzed the van de Vijver dataset in terms of overall survival, clinical 
information on metastasis was available. Since, the Wang et al dataset uses metastasis-free 
survival as the prognostic outcome, we used this as the outcome for the cross-dataset prediction. 
ENCAPP was accurate in predicting outcomes (median AUC = 0.649; 95% CI for AUC = 0.649-
0.650; P = 0.019; Table 6.1), showing that our approach is highly robust and successful in 
incorporating major differences in clinical parameters (Figure 6.5B). Here too, we perform better 
than Chuang et al who report a classification accuracy of 55.8% at 90% sensitivity (for 
predictions on the Wang dataset using the van de Vijver sub-network markers). ENCAPP 
achieves a significantly higher classification accuracy of 62.6% at 90% sensitivity (P = 0.009).  
We then used ENCAPP to analyze other kinds of cancer – a colon cancer (Atlas, 2012) and an 
ovarian cancer (Atlas, 2011) expression dataset published by the TCGA. The ovarian cancer 
dataset that we analyzed consisted of platinum-resistant cancer patients, which occurs in 
approximately 25% of patients within 6 months of therapy. For each dataset, we looked to see 
how well our method could predict overall survival. ENCAPP was able to predict prognostic 
outcome successfully for both colon and ovarian cancer (median AUCs = 0.666 and 0.766 
respectively; 95% CIs for AUC = 0.658-0.674 and 0.760-0.771 respectively; P = 0.001 and 
0.097 respectively; Table 6.1) confirming that it works robustly across different cancers (Figures 
6.5C, 6.5E). 
Finally, we tried using ENCAPP to predict prognosis across cancer types when they are related. 
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We tried predicting rectal cancer prognosis (Atlas, 2012) having trained ENCAPP using colon 
cancer data (Atlas, 2012). ENCAPP is very successful (median AUC = 0.803; 95% CI for AUC 
= 0.782-0.823; Figure 6.5D; P < 10-3; Table 6.1) at predicting rectal cancer prognosis showing 
that ENCAPP is able to predict prognosis across related cancers. 
Identifying prognostic markers using ENCAPP 
Since our elastic net approach is a combination of LASSO and ridge regression, the number of 
coefficients with significant regression coefficients is relatively low (Figure 6.6A, Table 6.2; see 
Methods). The modules whose corresponding coefficients are mathematically significant are 
termed ‘significant modules’. To test the robustness of these ‘significant’ modules, we calculated 
the Spearman rank correlation coefficient of these significant modules across cross-validation 
runs and folds. We find that they are highly stable: 99.1% have a rank correlation coefficient >= 
0.98. To see if these modules are also biologically significant, we examined the distribution of 
known cancer genes in these modules (see Methods). We found that these modules are 
significantly enriched for cancer genes (Figure 6.6B; P < 0.01 for all 4 datasets). The fact that the 
enrichment extends to the level of entire modules shows that the differences in expression 
patterns extend to the level of the modules themselves. This is conceptually consistent with 
previous findings that gene sets rather than genes themselves better explain dysregulation in 
cancer (Subramanian et al., 2005). Thus differential co-expression of these modules is a 
molecular determinant of different outcomes for different patients.  
We also compared the average degree of proteins in these significant modules with that of 
cancer-associated proteins (11.2) and all proteins in the network (8.2). The average degree of 
proteins in significant modules is not, in general, skewed towards the average degree of cancer-
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associated proteins. For the van de Vijver and Wang breast cancer datasets, the average degree of 
proteins in significant modules are 12.0 and 10.5 respectively, similar to the average degree of 
cancer-associated proteins. However, for the colon and ovarian cancer datasets, they are 8.3 and 
8.8 respectively, similar to the overall average degree. These findings are also consistent with 
Figure 6B, which shows that the enrichment of cancer genes in significant modules for the 2002 
and 2005 breast cancer datasets is higher than the enrichment for the colon and ovarian cancer 
datasets. This could be due to higher noise for the colon and ovarian cancer datasets or due to the 
list of cancer genes being incomplete with varying degrees of incompleteness for different tissue 
types. 
To examine whether the significant modules that we find agree with what has been previously 
reported, we compared the significant modules that we obtained for the van de Vijver dataset 
with the significant modules that Wu and Stein (Wu and Stein, 2012) obtained for the same 
dataset. 29/85 (34.1%) of the modules are overlapping. Thus, ENCAPP does find a large number 
of signatures concordant with what has been reported earlier, but it also finds a significant 
number of potentially novel signatures. We then compared the significant modules that we 
obtained for the Wang dataset with the significant modules that Wu and Stein obtained for the 
van de Vijver dataset. This is a comparison both across methods and cancer sub-types. 25/268 
(9.3%) of the modules are still overlapping, showing that there are a number of stable signatures 
across cancer sub-types. We also find that 3 significant modules for the van de Vijver dataset 
contain 13 proteins of which 5 have been previously implicated in cancer (Figure 6.6C) and 3 
significant modules for the colon cancer dataset contain 9/21 known cancer genes (Figure 6.6C). 
A number of these genes are known to be good prognostic markers.  
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As a further validation, we examined prognostic biomarkers detected by ENCAPP that were 
unknown at the time of publication of the expression dataset, but have since been clinically 
validated. Conceptually, these correspond to novel biomarkers detected by ENCAPP. For 
example, we detected NFKB2 and BCL3 in a significant module for the breast cancer (2002) 
dataset (Figure 6.6C). In 2005, it was shown that the NFκB complex, of which NFKB2 is one of 
the subunits, can be used a well-known prognostic marker for breast cancer (Zhou et al., 2005). 
More recently, it has also been shown that suppression of the NFκB co-factor BCL3 correlates 
with poor prognosis as it inhibits apoptosis of mammary cells (Wakefield et al., 2008). GATA2 
was present in a significant module for the colon cancer (published in 2011) dataset (Figure 6C). 
In 2013, GATA2 was shown to be a useful prognostic marker for colorectal cancer – patients 
with high expression levels of GATA2 are likely to have worse disease-free survival outcomes 
than those with lower expression levels of GATA2 (Chen et al., 2013). These confirm that the 
significant modules identified by ENCAPP contain numerous prognostic markers.  
We also found a number of modules with proteins that have not yet been validated as prognostic 
biomarkers but are excellent candidates for hypothesis-driven follow-up experiments. For 
example, one of the significant modules for the breast cancer (2002) dataset contains CKS1B, 
SKP2 and DUSP1 (Figure 6.6D). It has been shown that CKS1B is required for the SKP2-
mediated ubiquitination of PSMD9 (p27) (Ganoth et al., 2001). A recent study shows that 
PSMD9 expression is altered in breast cancer patients irrespective of the BRCA mutation state 
(Dressler et al., 2013). Together, these results suggest that this module and especially CKS1B and 
SKP2 could be reliable prognostic markers across breast cancer subtypes as altered expression of 
these genes will lead to mis-regulation of PSMD9, whose expression is altered in breast cancer 
patients with or without mutations in BRCA1. 
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For the colon cancer dataset, one of the significant modules contains FAM175B, BARD1, CSTF1, 
BRE, and UIMC1 (Figure 6.6D). It is well known that BARD1 interacts with BRCA1 to form a 
ubiquitin ligase complex (Brzovic et al., 2003; Hashizume et al., 2001) and the interaction can be 
disrupted by breast cancer mutations on BRCA1 (Brzovic et al., 2003; Hashizume et al., 2001). A 
blood test based on BARD1 has been proposed as a potential way to diagnose breast cancer 
(Irminger-Finger, 2010). FAM175B (ABRO1) and BRE are two of the 4 subunits of the BRISC 
deubiquitinating enzyme complex (Cooper et al., 2009). BRE has already been shown to be a 
reliable prognostic marker for acute myeloid leukemia (Noordermeer et al., 2012; Noordermeer 
et al., 2011). In the context of these studies, our results suggest that this module and especially 
FAM175B, BARD1 and BRE can be potential prognostic markers for colon cancer as altered 
expression of these genes can modify ubiquitination activity in the cell. 
160
6.4 DISCUSSION 
Here we have described ENCAPP, a robust prognosis predictor of different human cancers. 
Since ENCAPP uses differentially expressed modules between patients with good and bad 
prognosis to accurately predict disease outcome, the decision boundaries used to make this 
prediction correspond to functional changes in the cell. This is potentially extremely useful in 
generating mechanistic hypotheses regarding cancer causation and progression that can then be 
experimentally tested. Conceptually, the ENCAPP algorithm uses interaction dynamics, a 
combination of gene expression data with the topological structure of the network, to predict 
prognosis. Previous studies have shown that interaction dynamics is also useful in understanding 
the organization and evolutionary modes of biological networks (Das et al., 2012; Das et al., 
2013). Together, these suggest that approaches using interaction dynamics may be successful in 
elucidating the mechanistic basis of a wide range of biological phenomena, by combining two 
discrete layers of information – gene expression and protein networks. 
Another key feature of ENCAPP is its ability to identify prognostic markers from the regression 
model itself. While some previous methods show examples of prognostically relevant genes 
identified by their method (Hofree et al., 2013; Taylor et al., 2009), the key difference is that 
such detections are typically anecdotal. On the other hand, we demonstrate that the significant 
modules in ENCAPP are systematically enriched for cancer genes. Thus, our model identifies 
biologically relevant genes and uses these for determining prognostic outcome. We also show 
that significant modules identified by ENCAPP contain known prognostic markers and 
hypothesize that they may contain novel biomarkers. Follow-up studies may want to validate 
these putative prognostic markers. Since ENCAPP identifies modules containing these genes, 
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any positive results emerging from such studies will directly tie in to a pathway-level 
understanding of the mechanistic basis of that specific cancer type.  
One limitation of ENCAPP is that the accuracy of the prognosis prediction is highly dependent 
on the quality of the expression dataset, which is why the AUCs vary across the different 
cancers. Future approaches may want to combine gene expression and protein networks with 
other data such as somatic mutations, epigenetic modifications and copy number alterations to 
make the overall prediction accuracy less dependent on the quality of an individual dataset. 
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6.5 MATERIALS AND METHODS 
Expression data and the human protein interactome network 
Sample size, number of good and bad prognosis patients, and breakdown by stage and grade for 
the different expression datasets used are available in Table 6.3. Expression data were RMA-
normalized. High-quality binary and co-complex human protein interactome networks were 
obtained from HINT (Das and Yu, 2012). The final network used for this study was the union of 
the binary and co-complex networks. It comprises 42,604 interactions between 9,985 proteins. 
All datasets used in this study are obtained from papers that have already been published and 
required no ethics approval. 
Identifying functional modules using clustering 
ClusterOne identifies overlapping functional modules based on the topological properties of the 
protein interactome network (Nepusz et al., 2012). We did a sweep for the ‘s’ (size) and ‘d’ 
(minimum cluster density) parameters in ClusterOne (Nepusz et al., 2012). The default 
parameters are s = 3 and d = 0.35. We examined the parameter space around these values. Since 
the modules were identified independently of the expression datasets, situations occasionally 
arose in which some modules had missing gene expression values. In these cases, a module was 
included only if at least 1/3 of the genes in that module had corresponding expression values. For 
each cancer type, we report the highest AUC value obtained in the parameter sweep.  
The elastic-net-based regression model 
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The elastic net (Zou and Hastie, 2005) is a regularized regression model that uses a linear 
combination of the L1 penalty term from LASSO (Tibshirani, 1996) and the L2 penalty term 
from ridge regression (Hoerl and Kennard, 1970). The objective function is given by:  
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where, yi corresponds to the prognostic outcome for the ith patient (0 or 1 corresponding to good 
and bad prognosis respectively). xi is a vector of a vector of features for the ith patient (please see 
below for a detailed description of xi). The β’s are regression coefficients that we estimate. The 
tuning parameter λ is the weight of the regularization term and is chosen to minimize mean 
square error. The regularization term Pα(β) is given by: 
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Here, α is a number between 0 and 1 with α = 0 corresponding to ridge regression alone and α = 
1 corresponding to LASSO alone. We choose the best α using cross validation. 
For our first analysis (Figure 6.2a) that used only expression data, xi is a vector of dimension n 
containing expression values for n genes for the ith patient (The entire set of expression values 
for d patients will be a matrix of size d x n, where each row is the transpose of xi.). For ENCAPP, 
xi is a vector of dimension 2n containing expression values for n modules for the ith patient. Each 
functional module m contributes 2 values – Gim and Bim to xi: 
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Here, sm is the number of genes in module m. Eik corresponds to the expression value of the kth 
gene for the ith patient. < Ekg > and < Ekb > represent the average (mean) expression values of the 
kth gene across all patients with good and bad prognosis respectively. σkg and σkb represent the 
standard deviation of the expression values of the kth gene across all patients with good and bad 
prognosis respectively. For all the cross-validations, < Ekg >, < Ekb >, σkg and	  σkb are calculated 
using only the samples in the training set. However, while using Gim and Bim as features derived 
from every module generally gives the most optimum performance, we noticed that in certain 
cases it is possible to obtain a slight increase in performance by not averaging over each module. 
There all Pik and Qik values are used as input. While training the ENCAPP classifier, it is 
necessary to check which of the two approaches performs better. 
For the datasets where clinical information was also available, we incorporated it using a logistic 
regression model. Since the clinical data is not high dimensional, elastic net regression is not a 
suitable choice for it. The final predicted outcome was a weighted linear combination of the two 
outputs – one predicted by the elastic-net-based model (using expression and protein network 
data) and the other predicted by the logistic regression model. Thus, Y1 = f(X1) and Y2 = g(X2) 
and Y = k x Y1 + (1 - k) x Y2. Here, X1 is the set of expression derived features, f the function 
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obtained from the elastic-net based classifier and Y1 the corresponding outcome variable, X2 the 
set of clinical features, f the function obtained from the logistic-regression based classifier and Y2 
the corresponding outcome variable. Y is the final outcome obtained by a linear combination of 
Y1 and Y2. An optimal value of k, the relative weight parameter is obtained by grid search. 
Evaluating performance  
The performance of our model is evaluated in a five-fold cross validation framework. We split 
the patients into five subsets such that four subsets are used for training and the fifth one is the 
test set. The prognostic outcomes for the training set were used to determine the regression 
coefficients. These coefficients were then used to predict outcomes for patients in the test set. 
We repeated this procedure five times so that each subset served as a test set. The predicted 
outcomes were compared to the actual outcomes using a receiver operating characteristic (ROC) 
curve (Hastie et al., 2009). The area under the ROC curve (AUC) and classification accuracy 
were used as measure of the quality of the prediction (Hastie et al., 2009). The cross validation is 
process was repeated 50 times with a set of random seeds. For all comparisons, each method was 
run with the same set of random seeds, which ensured that the cross-validation dataset splits 
were identical across methods. Thus, all observed differences are solely due to one method being 
superior to the other and not because of how the dataset was split into the 5 folds. P-values 
evaluating the significance of difference in performance between different methods (two sets of 
AUC values) were calculated using a Mann-Whitney U test. 
Classification accuracy is measured at the optimum point on the ROC curve. This is usually the 
point where the slope of the curve (S) is given by: 
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S = c(P |N) − c(N |N)c(N |P) − c(P |P) ×
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Here, c(I|J) represents the cost of assigning class I to class J. Here, P = true positives + false 
negatives and N = true negatives + false positives are the total counts in the positive and negative 
classes, respectively. For our calculations, we chose c(P|P) = c(N|N) = 0. And c(N|P)=c(P|N). 
Substituting these values, we get, 
  
S = NP  
Enrichment of cancer genes in modules with significant regression coefficients 
To identify modules with significant regression coefficients, we examined the distribution of 
coefficients and chose the highest and lowest two percentile of coefficients as significant (Figure 
6A). We then examined the genes in these modules and compared them to known cancer genes. 
A list of known cancer genes was obtained from the Cancer Gene Census (Futreal et al., 2004). 
This is a high-confidence list of manually curated cancer genes with orthogonal layers of 
evidence, including but not limited to mutation information from COSMIC (Forbes et al., 2011). 
The expected fraction of cancer genes identified by random is given by: 
€ 
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where Ci is the number of cancer genes and Ti the total number of genes in modules in the ith 
expression dataset. The observed fraction of cancer genes in modules with significant regression 
coefficients is given by: 
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where Xi is the actual number of cancer genes and Ni the total number of unique genes in these 
modules. Thus, the enrichment of cancer genes in modules with significant regression 
coefficients is given by: 
€ 
En = OfiEfi
 
P-values were calculated using a cumulative binomial test. 
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6.6 FIGURE AND TABLE LEGENDS 
Figure 6.1. Schematic of ENCAPP. 
ENCAPP begins by overlaying tissue-specific gene expression data with the reference 
interactome network. Modules that have significant differential co-expression between patients 
with good and bad prognosis are used to build a regression model that can predict prognostic 
outcome. 
Figure 6.2. Integrating gene-expression data with protein interactome networks 
(A) Receiver operating characteristic (ROC) curves for prognosis prediction using expression 
data alone.  
(B) Illustration of hub groups and networks modules. 
(C) ROC curves comparing the performance of three module-detection algorithms – 
hierarchical clustering, affinity propagation clustering and ClusterOne. 
Figure 3. Flowchart illustrating the different steps in ENCAPP. 
The inputs to ENCAPP are RMA-normalized expression data and modules from a reference 
human protein interactome network. These are then combined into features that are input to an 
elastic-net based regression model. The performance of the model is evaluated using cross-
validation. 
Figure 4. Predicting breast cancer prognosis using differentially expressed functional modules 
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(A) ROC curves for prognosis prediction of patients in the breast cancer (2002) dataset using 
clinical data alone, expression data alone, expression data with the protein network and 
all 3 datasets together. 
(B) Comparison of the performance of ENCAPP with Taylor et (values shown are those 
obtained in the absence of clinical information).  
(C) Boxplots showing performance of ENCAPP at different right censoring cutoffs k used for 
determining prognostic outcome: for each boxplot, good prognosis is defined as survival 
for >=k years and bad as death within k years. 
(D) Boxplots showing performance of ENCAPP at different right censoring cutoffs k used for 
determining prognostic outcome; here a different outcome definition is used: for each 
boxplot, good prognosis is defined as no metastasis for >=k years and bad as metastasis 
within k years. 
(E) Boxplots showing performance of ENCAPP using random networks that have 5%, 10%, 
15% and 20% of the total edges in the original network randomly removed. 
 
Figure 5. Prognosis prediction for different cancer types and subtypes 
(A) ROC curves for prognosis prediction of patients in the breast cancer (2005) dataset using 
expression data alone and expression data with the protein network. 
(B) ROC curves for prognosis prediction of patients in the breast cancer (2002) dataset using 
data from the breast cancer (2005) dataset.  
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(C) ROC curves for prognosis prediction of patients in the colon cancer dataset using clinical 
data alone, expression data alone, expression data with the protein network and all 3 
datasets together. 
(D) ROC curves for prognosis prediction of patients in the rectal cancer dataset using data 
from the colon cancer dataset. 
(E) ROC curves for prognosis prediction of patients in the ovarian cancer dataset using 
expression data alone and expression data with the protein network. 
Figure 6. Prognostic biomarker discovery using ENCAPP. 
(A) Distribution of regression coefficients for different human cancers. The red shaded area 
corresponds to the top 10 percentile. Significant modules are defined as those with 
coefficients in the red shaded area.  
(B) Enrichment of known cancer genes in the significant modules for the breast cancer 
(2002), breast cancer (2005), colon cancer and ovarian cancer datasets. 
(C) Examples of significant modules for the breast cancer (2002) and colon cancer datasets. 
Known cancer genes are depicted in red. 
(D) Examples of novel biomarker prediction for the breast cancer (2002) and colon cancer 
datasets. 
Table 6.1. Summary of AUCs and p values for the different datasets. 
Table 6.2. Number of different modules identified by each clustering method and list of 
significant modules identified by ENCAPP for the breast cancer (2002), breast cancer (2005), 
171
colon cancer and ovarian cancer datasets. All genes in a particular module are listed in a single 
row. Each module is listed in a separate row. 
Table 6.3. Sample size, number of good and bad prognosis patients, breakdown by stage and 
grade for the different datasets.. 
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genes in module, and σkg ,σkb ,<Ekg>,<Ekb> are as defined above.  
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- yi = prognostic outcome for the ith patient 
         (0 or 1 corresponding to good and bad prognosis respectively)
- xi = vector of features for the ith patient
- β’s = estimated regression coefficients
- λ = weight of the regularization term 
         (chosen to minimize mean square error)
- α is a number between 0 and 1 with α = 0 corresponding to ridge 
   regression alone and α = 1 corresponding to LASSO alone.
  (The best α is chosen using cross validation.)
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Table 6.1
Dataset median AUC
p-value 
(expression 
vs expression 
+ network)
median AUC
p-value 
(clinical vs 
clinical + 
expression +  
network)
2002BreastCancer 0.778 < 0.001 0.786 < 0.001
2005BreastCancer 0.690 < 0.001 - -
Cross-prediction (trained 
using 2005BreastCancer, 
tested on 
2002BreastCancer)
0.649 0.019 - -
ColonCancer 0.666 0.053 0.649 < 0.001
Cross-prediction (trained 
using clon cancer, tested 
on rectal cancer)
0.803 < 0.001 - -
OvarianCancer 0.766 0.097 - -
Without clinical data With clinical data (when available)
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Table	  6.2
2002BreastCancer
Total	  number	  of	  modules
Modules	  a8er	  ﬁltering	  
out	  those	  where	  the	  
majority	  of	  expression	  
values	  are	  not	  available
Aﬃnity	  propaga-on	  
clustering 151 57
Hierarchical	  clustering 200 120
ClusterOne 350 234
2005BreastCancer
Total	  number	  of	  modules
Modules	  a8er	  ﬁltering	  
out	  those	  where	  the	  
majority	  of	  expression	  
values	  are	  not	  available
ClusterOne 584 63
ColonCancer
Total	  number	  of	  modules
Modules	  a8er	  ﬁltering	  
out	  those	  where	  the	  
majority	  of	  expression	  
values	  are	  not	  available
ClusterOne 584 104
OvarianCancer
Total	  number	  of	  modules
Modules	  a8er	  ﬁltering	  
out	  those	  where	  the	  
majority	  of	  expression	  
values	  are	  not	  available
ClusterOne 2221 241
Note:	  The	  total	  number	  of	  modules	  also	  varies	  by	  dataset	  (for	  ClusterOne)	  as	  
we	  have	  reported	  the	  number	  of	  modules	  corresponding	  to	  op-mal	  
performance.	  We	  did	  a	  parameter	  sweep	  around	  the	  default	  recommended	  
parameters	  for	  ClusterOne	  and	  found	  that	  the	  s	  and	  d	  parameters	  need	  to	  be	  
varied	  in	  the	  neighbourhood	  of	  the	  default	  recommended	  parameters	  for	  
op-mal	  performance.
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Table 6.3
2002Breast Cancer GRADE: GRADE:
I:    61 I:    14
II:   76 II:   25
III:  79 III:  39
2005Breast Cancer Grade/Stage Grade/Stage
Not Available Not Available
ColonCancer STAGE: STAGE:
I:        26 I:        2
IIA:    50 IIA:    5
IIB:    4 IIB:    1
IIIB:  18 IIIB:  1
IIIC:  13 IIIC:  3
IV:     19 IV:     3
Unknown: 2
OvarianCancer STAGE: STAGE:
IIC:   0 IIC:   1
IIIB: 0 IIIB: 1
IIIC: 14 IIIC: 61
IV:    3 IV:    10
GRADE: GRADE:
G2: 2 G2: 6
G3: 15 G3: 66
Unknown: 1
90 17 73
152 137 15
286 179 107
Dataset Sample Size Positive Outcome (=0)
#patients
Negative Outcome (=1)
#patients
293 215 78
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CHAPTER 7 
Cross-Species Protein Interactome Mapping Reveals Species-Specific Wiring of Stress-
Response Pathways 
 
In the following chapter, we explore concepts of network evolution and how stress-response 
pathways have evolved across different yeast species. I am the first author of the paper resulting 
from this chapter (Das et al Science Signaling 2013) and performed all computational analyses. 
Experimental analyses described in the chapter were led by graduate student Tommy Vo. 
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 7.1 ABSTRACT 
 
The fission yeast Schizosaccharomyces pombe has more metazoan-like features than the 
budding yeast Saccharomyces cerevisiae, yet it has similarly facile genetics. Here, we 
present a large-scale verified binary protein-protein interactome network, “StressNet”, 
based on high-throughput yeast two-hybrid screens of interacting proteins classified as 
part of stress-response and signal transduction pathways in S. pombe. We performed 
systematic, cross-species interactome mapping using StressNet and a protein interactome 
network of orthologous proteins in S. cerevisiae. With cross-species comparative network 
studies, we detected a previously unidentified component (Snr1) of the S. pombe mitogen-
activated protein kinase Sty1 pathway. Coimmunoprecipitation experiments showed that 
Snr1 interacted with Sty1 and that deletion of snr1 increased the sensitivity of S. pombe 
cells to stress. Comparison of StressNet with the interactome network of orthologous 
proteins in S. cerevisiae showed that the majority of interactions among these stress-
response and signaling proteins are not conserved between species, but are “rewired;” 
orthologous proteins have different binding partners in both species. In particular, 
transient interactions connecting proteins in different functional modules were more likely 
to be rewired than conserved. By directly testing interactions between proteins in one yeast 
species and their corresponding binding partners in the other yeast species with yeast two-
hybrid assays, we found that about half of the interactions traditionally considered 
“conserved” form modified interaction interfaces that may potentially accommodate novel 
functions. 
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 7.2 INTRODUCTION 
 
A crucial step towards understanding properties of cellular systems is to map networks of DNA-
protein, RNA-protein, and protein-protein interactions, or the “interactome network,” of an 
organism. Over the last decade, large-scale binary protein-protein interactome datasets have been 
produced for several eukaryotes – Saccharomyces cerevisiae (Ito et al., 2001; Uetz et al., 2000; 
Yu et al., 2008), Drosophila melanogaster (Formstecher et al., 2005; Giot et al., 2003), 
Caenorhabditis elegans (Li et al., 2004; Simonis et al., 2009), Arabidopsis thaliana (Consortium, 
2011), and human (Rual et al., 2005; Stelzl et al., 2005), among which we produced a high-
quality whole-proteome interactome network in S. cerevisiae using a high-throughput yeast two-
hybrid (HT-Y2H) system (Yu et al., 2008). However, due to large evolutionary distances among 
these species [the last common ancestor of fungi and human is over 1 billion years ago (Sipiczki, 
2000; Wood et al., 2002)] and extremely low coverage (most protein interactions are yet to be 
detected) of available interactome maps outside of S. cerevisiae, the overlap among these 
networks is sparse (Gandhi et al., 2006). This makes it difficult to extract meaningful 
information about evolutionary relationships from these interactomes. Thus, to bridge this gap, it 
is essential to construct a high-coverage interactome network for an intermediate species. The 
fission yeast, Schizosaccharomyces pombe, has an easily manipulatable genome and is estimated 
to have diverged from the budding yeast, S. cerevisiae, approximately 400 million years ago 
(Sipiczki, 2000; Wood et al., 2002). Furthermore, fission yeast is more similar to metazoans than 
is budding yeast, especially in its gene regulation by chromatin modification and RNA 
interference, mechanisms that are differently regulated and absent, respectively, in budding yeast 
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(Roguev et al., 2008). A high-quality map of the protein-protein interactome network of S. 
pombe will enable analysis of biological properties of many complex pathways common in 
metazoan species but missing in S. cerevisiae (Shevchenko et al., 2008). 
The two yeasts live in highly disparate ecological niches and have varied mechanisms 
of responding to external stimuli. Therefore, in this study, we focus on 658 S. pombe genes 
involved in key regulatory processes of stress response and cellular signaling. Because these 
pathways control how organisms sense and adapt to their immediate environments, they are 
likely to have diverged between the two species. Using our HT-Y2H pipeline (Yu et al., 2008), 
we obtained a binary interactome network among these 658 genes, which we named “StressNet”. 
All interactions were verified with two orthogonal assays to ensure their quality. By comparing 
with their S. cerevisiae counterparts, we measured the conservation rate of these StressNet 
interactions between fission and budding yeasts using a Bayesian method. We found species-
specific wiring of stress-response and signaling pathways beyond what was expected by 
sequence orthology, indicating that rewiring of protein interactome networks in related species is 
likely to be a major factor for divergence. We also identified a previously unknown component 
Snr1 of the Sty1 mitogen-activated protein kinase (MAPK) pathway and experimentally 
validated that Snr1 has gained functions, through rewiring of its interactions, compared to the 
orthologous protein in S. cerevisiae. Furthermore, to better understand the evolution of proteins 
and their interactions, we developed a large-scale cross-species interactome mapping approach to 
directly test interactions between S. pombe proteins and the S. cerevisiae orthologs of their 
partners. Such analysis is only possible with the availability of two well-controlled high-
coverage interactome maps generated with the same technology. We found that, for many 
conserved interactions, both partners had co-evolved to accommodate new interactions and 
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functions, and their interaction interfaces can no longer be recognized by their S. cerevisiae 
counterparts.  
 
7.3 RESULTS 
Comparison of known interactions in S. cerevisiae and S. pombe 
The number of known protein-protein interactions in S. pombe is disproportionately lower than 
in other model eukaryotic organisms and human. We estimated the number of all known 
interactions in S. cerevisiae and S. pombe by analyzing seven commonly-used databases – 
BioGRID (Stark et al., 2011), DIP (Salwinski et al., 2004), IntAct (Kerrien et al., 2012), 
iRefWeb (Turner et al., 2010), MINT (Ceol et al., 2010), MIPS (Mewes et al., 2011), and 
VisANT (Hu et al., 2007). There identified 110,443 interactions for budding yeast, but only 
4,038 for fission yeast, from these databases. Furthermore, only those interactions or interaction 
sets that have been validated by at least two independent assays are reliable and defined as “high 
quality” (Cusick et al., 2009; Das and Yu, 2012). Based on this criterion, 519 fission yeast 
interactions are of high quality, as opposed to 25,335 high-quality interactions known in budding 
yeast. Of these, only 160 S. pombe interactions are binary (a direct biophysical interaction 
between the two proteins), as opposed to 11,936 in S. cerevisiae. These numbers indicate the 
extent to which the fission yeast interactions are underexplored and necessitate the systematic 
mapping of its interactome network.  
 
StressNet: A large-scale high-quality protein interactome network for stress response and 
cellular signaling in S. pombe 
The subset of 658 genes for this study was selected using Gene Ontology (GO) (Ashburner et al., 
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2000) “Biological Process” (BP) functional annotations for fission yeast (Figure 7.1A). To 
generate a high-quality high-coverage stress-response interactome map for S. pombe, we 
screened all possible protein pairs (>430,000) in this space three times using a high-quality HT-
Y2H system, as we had done for S. cerevisiae (Yu et al., 2008). The resulting protein 
interactome network, StressNet (Figure 7.1B), comprises 235 high-quality binary interactions 
among 200 proteins (Table 7.1). Of these, 218 interactions were previously unknown. To 
validate our experimental pipeline and the quality of StressNet, from the 160 high-quality binary 
interactions we selected a set of 54 well-documented protein interactions from the literature and 
[“positive reference set” (PRS); Table 7.2] and 43 random protein pairs that have never been 
reported or predicted to interact [“random reference set” (RRS); Table 7.3]. 20 PRS interactions 
were successfully confirmed in our pipeline, whereas none of the RRS pairs were detected as 
positives (Figure 7.1C). Therefore, the sensitivity [fraction of detected true positives among all 
possible true positives (Yu et al., 2008)] of our Y2H assay is 37.0%. 
To directly measure the quality of our Y2H-identified interactions (Braun et al., 2009; Yu et al., 
2008), we re-tested all 235 interactions detected in our HT-Y2H screen by two orthogonal 
assays: the protein complementation assay (PCA) (Remy and Michnick, 2006) and the well-
based nucleic acid programmable protein array (wNAPPA) (Ramachandran et al., 2004), 
producing a fully-verified large-scale interactome map. The confirmation rates of our 
interactions with both orthogonal assays were similar to those of the PRS, further validating the 
high quality of StressNet (Braun et al., 2009; Yu et al., 2008) (Figure 7.1C). Using the results of 
the validating assays, we calculated the precision of StressNet as 95.3
€ 
± 4.7% (Eq. 8 and 9 in 
Materials and Methods).  
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To assign a confidence score to each interaction in StressNet, we implemented a random 
forest algorithm to integrate results from the three orthogonal assays (figs. S1 and S2 and 
Materials and Methods). Every detected interaction had a confidence score >0.76 (Table 7.1). 
This value represents a normalized probability on a scale of 0 to 1 and indicated that all the 
interactions in StressNet were of high quality. Finally, to evaluate the topological properties of 
our network, we plotted the degree (number of interactions each protein has) distribution of 
StressNet (Figure 7.1D). Protein interactomes are small-world scale-free networks (Barabasi and 
Albert, 1999; Jeong et al., 2000) and our stress-response interactome for S. pombe exhibited 
similar topological properties to other large-scale biological networks.  
To assess the biological relevance of this network, we investigated overall relationships 
between protein pairs using expression and genetic interaction profile similarities (Roguev et al., 
2008; Rustici et al., 2004), subcellular colocalization (Matsuyama et al., 2006), and GO 
functional similarities (Ashburner et al., 2000). We found significant enrichment of interactions 
in StressNet of protein pairs that colocalized or were functionally similar, and that were encoded 
by coexpressed genes or genes that exhibited similar genetic interaction profiles [calculated 
using the Pearson Correlation Coefficient (PCC)], relative to random expectation (Figure 7.2A-
D). Furthermore, the enrichment of StressNet in all four categories was similar to that of high-
quality literature-curated binary interactions. These results confirmed the high quality of 
StressNet and indicated that these interactions are likely to be functionally relevant. 
 
Evolutionary relationships in StressNet 
For biological networks, evolutionary relationships are commonly measured in terms of 
conservation and rewiring: If a pair of interacting proteins in one species has corresponding 
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orthologs in another that also interact, then the interaction is considered to be conserved (an 
interolog); otherwise, the interaction is considered to be rewired (Matthews et al., 2001; Shou et 
al., 2011; Yu et al., 2004) (Figure 7.3A). To understand key principles governing the evolution 
of protein-protein interactions, especially for those in stress-response and signaling pathways, we 
compared the interactions in StressNet to their corresponding ortholog pairs in S. cerevisiae. We 
experimentally tested all corresponding S. cerevisiae protein pairs of the 235 interactions in 
StressNet and found that for 35 interactions, the corresponding budding yeast ortholog pairs were 
detected as interacting by our Y2H experiments. We developed a Bayesian framework to 
calculate the percentage of conserved interactions based on three parameters – the proportion of 
observed conserved interactions (35/235 = 14.9%), the precision (95.3
€ 
±4.7%), and the 
sensitivity (37.0%
€ 
± 4.4%) of our Y2H assay (see Eq. 12 and 13 in Materials and Methods). 
Substituting appropriate values, the percentage of conserved interactions between S. pombe and 
S. cerevisiae is calculated as 36.3 ± 2.9% (Figure 7.3B). 
Using an orthogonal approach, we supplemented S. cerevisiae interactions detected in our 
Y2H experiments with high-quality known S. cerevisiae interactions curated from the literature 
to obtain 55 more StressNet interactions for which the corresponding budding yeast orthologs 
were reported to interact in the literature (Das and Yu, 2012). There are 90 (35 + 55) conserved 
interactions in total and the conservation is 38.3% ± 3.2%, consistent with the conservation 
calculated using the Bayesian framework (Figure 7.3B). Furthermore, this agreement shows that 
after combining our Y2H experimental results with high-quality literature-curated interactions, 
the number of known interactions in our search space in S. cerevisiae is nearly complete, because 
if there were still a large number of unidentified interactions, the observed proportion of 
conserved interactions based on literature-curated interactions would have been much lower. 
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Because it is always difficult to determine a negative interaction (Ben-Hur and Noble, 2006; Yu 
et al., 2008), to ensure the set of rewired interactions is of high quality, we used a stringent set of 
criteria to define them as those StressNet interactions without corresponding S. cerevisiae 
ortholog pairs and those interactions whose corresponding S. cerevisiae ortholog pairs have other 
high-quality interactions but have never been reported as interacting in the literature or tested 
positive in our Y2H experiments, and these ortholog pairs are known to have different cellular 
localizations (Huh et al., 2003).   
Proteins encoded by essential genes, those when deleted cause lethality, tend to have 
more interacting partners (hubs) and also evolve more slowly than non-essential ones (Fraser et 
al., 2002; Hirsh and Fraser, 2001). We found that essential and non-essential genes (Kim et al., 
2010) in our interactome were equally likely to be involved in conserved interactions (Figure 
7.3C), contrary to previous studies (Fraser et al., 2002). Stress-response and signal-transduction 
pathways play a crucial role in the process of adaptation to distinct ecological environments. As 
measured by the ratio of nonsynonymous to synonymous substitution rates (dN/dS) (Nei and 
Gojobori, 1986; Rhind et al., 2011), we found that the essential genes in these pathways evolve 
at the same rate as the non-essential genes in the pathways evolve, although on average all 
essential genes in the genome evolve significantly slower than non-essential genes. To ensure 
that this is not an artifact of the calculation method, we also calculated dN/dS values for all 
essential and non-essential genes. Consistent with earlier findings (Das and Yu, 2012), we 
observed that overall, the essential genes had a significantly lower average dN/dS. The average 
dN/dS for all stress-response genes is not significantly different from that for the entire genome. 
The dN/dS distributions for these two species are highly similar. This finding is consistent with 
analyses that suggest that these species are at comparable evolutionary distances from S. pombe 
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and confirm that there are no inherent biases in our dN/dS calculations. Thus, our findings 
suggest that essential genes in stress-response and signal transduction pathways are under less 
negative selection such that their interactions are rewired for adaptive advantages through 
evolution.  
To better understand the mechanisms underlying conservation and rewiring of 
interactions, we examined the relationship between sequence similarity of orthologous pairs and 
interaction conservation rates. Consistent with expectation (Yu et al., 2004), interactions 
involving proteins with higher overall sequence similarity or identity were more likely to be 
conserved (Figure 7.3D). However, proteins interact through specific domains (Finn et al., 
2010); therefore, we examined the role of sequence similarity of these interfaces in determining 
the conservation of corresponding interactions. Previous studies have established a homology 
modeling approach (Kim et al., 2006; Wang et al., 2012) to locate interaction interfaces using co-
crystal structures in PDB (Berman et al., 2000) and have found that analysis of these interfaces 
provides insights into their evolutionary rate (Kim et al., 2006). The conservation of an 
interaction depends on the conservation of the interfaces involved (Espadaler et al., 2005). Using 
a similar approach, we inferred interaction interfaces for proteins involved in 161 interactions in 
our network (Materials and Methods). We found no significant correlation between the similarity 
or identity of interaction interfaces and the conservation of the corresponding interactions 
(Figure 7.3E). Examination of the average dN/dS ratios for proteins with different numbers of 
rewired interactions showed that the selection pressure on the gene did not affect the degree to 
which the interactions of the corresponding protein were rewired (Figure 7.3F), further indicating 
that the rewiring of interactome networks and the divergence of related species are not 
completely dictated by evolution detected at the sequence level. 
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 Functional profile of conserved and rewired interactions 
To investigate whether gene pairs encoding proteins involved in conserved and rewired 
interactions are differently regulated at the transcriptional level, we measured global 
coexpression between these pairs using the PCC. Global coexpression means that the pattern of 
gene expression of both genes is the same. Whereas conserved interactions had the highest 
fraction of coexpressed pairs, gene pairs encoding proteins involved in rewired interactions were 
also significantly more coexpressed than random in S. pombe (Figure 7.4A). We also calculated 
coexpression relationships for the corresponding budding yeast pairs. By definition, the 
conserved pairs also interact in budding yeast, but the rewired pairs do not. The enrichment in 
gene expression is consistent with this distinction:  Gene pairs encoding proteins involved in 
conserved interactions were coexpressed, genes encoding rewired pairs were not significantly 
enriched than random expectation in S. cerevisiae (Figure 7.4A).  
PCC captures only global coexpression relationships, but cannot capture local or transient 
coexpression that occurs only under certain conditions. Furthermore, gene pairs encoding 
proteins involved in stable interactions tend to be globally coexpressed, whereas those in 
transient interactions are often only locally coexpressed without significant PCC values (Das et 
al., 2012). Stable and transient interactions both have important biological functions – the former 
constitute tightly connected modules, whereas the latter form key links between modules, 
especially in signal transduction pathways, and are more important than the stable ones or 
random interactions in maintaining the integrity of cellular networks (Das et al., 2012). To detect 
transient interactions, we used the Local Expression-correlation Scores (LES) (Das et al., 2012; 
Qian et al., 2001). Rewired interactions in fission yeast had significantly higher LES values 
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(Figure 7.4B) than both conserved interactions and random expectation, suggesting that transient 
interactions are more likely to be rewired through evolution. Rewired pairs in budding yeast had 
LES values lower than random pairs (Figure 7.4B), indicating that gene regulation for these pairs 
is also rewired.  
Next, we examined GO functional similarities between interacting proteins involved in 
conserved and rewired interactions. Whereas conserved interactions had higher functional 
similarity than rewired interactions in fission and budding yeast, interacting protein pairs in both 
categories were significantly more functionally similar than random (Figure 7.4C). This is in 
agreement with previous findings that conserved interactions tend to be in modules with specific 
functions, whereas rewired interactions tend to be inter-modular and have greater diversity in 
function (Das et al., 2012).  
In our analysis of rewired interactions above, we focused on those that are present in 
fission yeast but lost in budding yeast. Because the S. pombe interactome is still considerably 
underexplored in the literature and the sensitivity of our Y2H assay is 37.0%, it is not yet 
possible to determine non-interacting pairs in S. pombe reliably. Therefore, although it is 
possible to define lost interactions in S. cerevisiae by combining literature-curated interactions 
with our Y2H-detected ones, the same cannot be done to define lost interactions in S. pombe. 
However, there are 1,638 S. cerevisiae interactions where one protein has a corresponding S. 
pombe ortholog in the space of the 658 open reading frames (ORFs) that we explored and 
another protein has no S. pombe ortholog. Thus, there can be no corresponding S. pombe 
interactions and these are rewired interactions in S. cerevisiae by definition. We found that these 
interactions had significantly higher PCC, LES, and functional similarity as compared to 
random. The trend is comparable to that of rewired interactions in S. pombe (Figure 7.4), further 
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confirming the robustness of our results. We performed PCC and LES analysis of coexpression 
and functional similarity of conserved and rewired interactions defined at different confidence 
levels and obtained similar results, indicating that the analysis is robust and reliable. 
 
Modes of rewiring uncovered by cross-species interactome mapping  
To further understand the meaning of “conservation” of interactions and experimentally explore 
the molecular mechanisms through which interaction interfaces evolve, we performed a 
systematic cross-species interactome mapping by testing all conserved interactions between 
corresponding S. cerevisiae and S. pombe proteins. Using orthologous pairs of interacting 
proteins in the two yeast species, we examined whether a protein in one species interacted with 
the ortholog of its partner in the other (Figure 7.5A). Because we could detect the original 
interacting pairs from the same species with our Y2H experiments, we know that all four 
proteins are correctly expressed, folded, and are amenable to detection by our Y2H approach, 
thereby avoiding technical false negatives. The traditional definition of “conservation” implies 
the notion of conserved interfaces across different species. However, there are many examples 
where proteins with conserved interactions form new interactions and carry out new functions 
that are not conserved. The interface of a conserved interaction in fission yeast is considered 
“intact” if the proteins involved could also interact with the corresponding orthologs of their 
partners in budding yeast; otherwise, the interface is considered “co-evolved” (Figure 7.5A). We 
found that these conserved interactions were equally likely result from an intact interface or co-
evolved interface that formed new interaction interfaces that were unrecognizable by their 
orthologous counterparts in the other species (Figure 7.5B). Earlier studies have suggested that 
interacting proteins may co-evolve to maintain structural complementarity and binding 
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specificity (Goh et al., 2000; Hakes et al., 2007; Kim et al., 2004). In this calculation, we used a 
lenient definition for an intact interface: We considered the interface intact if one or both of the 
cross-species interactions was positive, which provides a lower bound estimation of co-evolution 
between interacting proteins. 
 
Divergence of the Sty1 stress-response pathway through interaction conservation and 
rewiring  
In S. pombe, Sty1 is activated in response to various stresses, including oxidative and osmotic 
stress, starvation, and other conditions (Gasch, 2007; Shiozaki and Russell, 1996). Sty1 has 
orthologs in S. cerevisiae (Hog1, with 89% sequence similarity) and human (p38, with 69% 
sequence similarity). Both p38 and Sty1 respond to a wide range of stresses and both are 
different from Hog1 in terms of function (Bone et al., 1998). With our stress-response 
interactome, we detected key interactions at every step of the MAPK signal transduction 
pathway and, therefore, completely recapitulated the entire Sty1 pathway. This confirmed the 
sensitivity and accuracy of our HT-Y2H method, especially for discovering transient interactions 
in signaling pathways. Among all Sty1 interactions in StressNet, those with its activator (Wis1) 
and inhibitor (Pyp2) were both conserved between the two yeast species, and the Sty1-Wis1 
interaction interface was intact. By contrast, the interaction between Sty1 and its known target in 
fission yeast, Atf1, represented a rewired interaction (Figure 7.5C). We also identified a 
previously unknown interactor of Sty1: SPBC2D10.09, a protein that we named Snr1 (Sty1-
interacting stress-response protein). To confirm this interaction in vivo, we performed co-
immunoprecipitation of tagged proteins expressed in S. pombe (Figure 7.5D). The amount of 
Snr1 pulled down in the presence of Sty1 was greater than that pulled down in the absence of 
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Sty1, indicating that the interaction with Sty1 stabilizes Snr1 (Figure 7.5D). The corresponding 
orthologous pair of Hog1 and Ehd3 in S. cerevisiae did not interact by Y2H (Figure 7.5E). Cells 
lacking snr1 (snr1∆ cells) grew slower under stress, similar to sty1∆ cells (Figure 7.5F), whereas 
growth of ehd3∆ cells was not compromised. These results suggested that Snr1 is a component 
of the Sty1 pathway and that its functions diverged from its budding yeast counterpart. 
Moreover, snr1 also has a human ortholog, HIBCH, further investigation of which may expand 
our knowledge of the human p38 MAPK pathway.  
 
7.4 DISCUSSION 
 
We generated StressNet – a high-quality high-coverage binary interactome for stress-response 
and signal-transduction pathways in the fission yeast, S. pombe. All interactions were verified by 
three orthogonal assays and assigned probabilistic confidence scores. We performed comparative 
network analysis to study the evolution of protein interactomes between the fission and budding 
yeast species. Even though 84% of StressNet interactions have corresponding orthologous pairs 
in S. cerevisiae, only about 40% of these interactions are conserved, indicating considerable 
evolutionary changes beyond simple sequence orthology. Thus, the interolog concept should be 
used with caution to infer interactions across species, especially if the two are not closely related. 
Furthermore, our results suggested that rewiring of protein interactome networks in related 
species is likely a major factor for divergence. Surprisingly, we found no significant correlation 
between the similarity of interaction interfaces and the conservation of corresponding 
interactions. This demonstrates that conservation of interactions is more complex than previously 
expected – domains that are not part of the interaction interface also play some indirect role in 
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making the interaction possible. Even if the interface is conserved, the corresponding interaction 
could still be rewired because of steric hindrance due to altered overall structure or loss of nearby 
structural scaffolds that make the interaction thermodynamically favorable (Kastritis et al., 
2011). We also experimentally explored the evolution of interaction interfaces and our analysis 
indicated that interactions traditionally considered “conserved” are equally likely to have intact 
interfaces as to have co-evolved ones that are different from their orthologous counterparts. 
These results suggest a molecular mechanism by which the interactome network is rewired 
through evolution: Many proteins have co-evolved with their partners to form modified 
interfaces that can, therefore, accommodate new interactions and functions.  
Our results indicated that conserved interactions tended to be stable and rewired ones were 
more likely to be transient. Therefore, our finding provides a molecular-level mechanistic 
explanation for previous studies showing that genetic cross talk between functional modules can 
differ substantially (Frost et al., 2012; Roguev et al., 2008; Ryan et al., 2012). However, our 
results also suggest that, overall, proteins tend not to rewire all of their interactions; thus, even if 
they acquire novel interactions, they still generally conserve at least some of the original 
functions. 
Our results indicate that substantial evolutionary changes, both rewiring and co-evolution, 
of stress-response pathways could be a major mechanism by which different organisms adapt to 
diverse living environments. Conservation of interactions in other pathways might be different 
from what we observed here. Therefore, similar cross-species interactome mapping and 
comparative network analyses of more pathways and species will provide a more comprehensive 
understanding of underlying principles that help shape distinct characteristics of individual 
organisms through evolution. 
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7.5 MATERIALS AND METHODS 
 
Selection of genes for the study 
This study focused on stress response and signal transduction proteins (based on GO Biological 
Process annotations) and their known interactors in S. pombe. We also include S. pombe 
orthologs of S. cerevisiae proteins that are known to interact with orthologs of fission yeast 
stress-response and signal transduction proteins. While selecting the 658 ORFs, we also ensured 
that a set of PRS interactions in S. pombe could be constructed with genes from our space, a 
limiting criterion because there are only 160 binary high-quality S. pombe interactions reported 
in the literature. 
 
Yeast two-hybrid (Y2H)  
Y2H experiments were carried out as described (Yu et al., 2011). Briefly, 658 S. pombe ORFs in 
Gateway entry vectors were transferred into AD and DB vectors using Gateway LR reactions. 
After bacterial transformation, plasmids of all AD-Y and DB-X clones were transformed into 
yeast two-hybrid strains MATa Y8800 and MATα Y8930 (genotype: leu2-3, 112 trp1-901 
his3Δ200 ura3-52 gal4Δ gal80Δ GAL2-ADE2 LYS2::GAL1-HIS3 met2::GAL7-lacZ cyh2R), 
respectively. The MATa Y8800 strain was obtained from the MATa Y550 strain after mutating 
CYH2 to introduce cycloheximide resistance. MATα Y8930 was generated by crossing MATa 
Y8800 with MATα Y1541 (3), followed by sporulation and identification of the MATα 
cycloheximide-resistant yeast strain by tetrad analysis. After AD-Y and DB-X were transformed 
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into Y8800 and Y8930, respectively, autoactivators were screened by spotting onto synthetic 
complete media (SC) lacking histidine and tryptophan (AD-Y) or histidine and leucine (DB-X). 
These autoactivators were excluded from all further screenings. Each unique DB-X was mated 
with pools of ~188 unique AD-Y by co-spotting onto yeast extract peptone dextrose (YEPD) 
plates. Diploids were selected by replica plating onto SC plates without leucine and tryptophan 
(SC–Leu–Trp). To select for positive interactions, Y2H screening was performed by replica 
plating the diploids onto SC plates with 1 mM 3-amino-1,2,4-triazole (3-AT) and without 
leucine, tryptophan, and histidine (SC–Leu–Trp–His+3-AT). SC-Leu-Trp-His plates were used 
for the HT-Y2H screen in S. cerevisiae (Yu et al., 2008). We used 1 mM 3-AT, because this 
concentration greatly reduces background and improves the quality of the screens (Consortium, 
2011; Venkatesan et al., 2009; Yu et al., 2011). Newly occurring autoactivators were determined 
by concurrently replica plating the diploids onto SC media with cyclohexamide (CHX) and 1 
mM 3-AT and lacking leucine and histidine (SC–Leu–His+3-AT+CHX). Screening for these 
autoactivators relies on CHX to select for cells that do not have the AD plasmid, due to plasmid 
shuffling. Thus, growth on the latter plate identifies spontaneous autoactivators; these were 
removed from further analyses. All plates were replica cleaned the following day and scored 
after three additional days. The space was screened three times. 
Y2H positives were grown two to three days at 30°C and then spotted onto four plates for 
secondary phenotype confirmation (phenotyping II) (SC–Leu–Trp–His+3-AT; SC–Leu–His+3-
AT+CHX; SC–Leu–Trp–adenine; SC–Leu–adenine+CHX). Colonies that either grew on SC–
Leu–Trp–His+3-AT but not on SC–Leu–His+3-AT+CHX or on SC–Leu–Trp–adenine but not on 
SC–Leu–adenine+CHX were identified as positives. 
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  For colonies that scored positive in phenotyping II, the identities of DB-X and AD-Y 
were determined by the Stitch-seq approach (Yu et al., 2011) using Illumina sequencing. All 
identified interacting pairs were retested by pairwise Y2H. 
 
Construction of PRS and RRS 
The PRS and RRS are representatives of true positive interactions and negative pairs, 
respectively, and we used the PRS and the RRS to optimize the assay performance and they may 
be interpreted as positive and negative controls. The PRS comprises a set of 54 protein 
interactions from the literature, each of which is supported by at least two independent assays 
from two different publications (Table 7.2). RRS pairs were generated from a random selection 
out of all possible protein pairs within our search space for which no interaction has yet been 
detected by any method (Table 7.3). Because fission yeast interactions are underexplored, we 
also required that their corresponding budding yeast ortholog pairs have never been reported to 
interact.  
Another way to construct the RRS is to consider protein pairs with different cellular 
localizations because these are unlikely to interact. 31 out of the 43 RRS pairs are indeed 
localized in different cell compartments. Using the whole RRS (Figure  7.1C), we estimate the 
false positive rate for Y2H, PCA, and wNAPPA are 0/43, 2/43 (4.7% ± 3.2%), and 2/43 (4.7% ± 
3.2%), respectively. If we only use the 31 RRS pairs localized in different cell compartments 
(named “RRS_DiffLocal”), the false positive rates for the three assays are 0/31, 2/31 (6.5% ± 
4.4%), and 1/31 (3.2% ± 3.2%). Therefore, the false positive rates for all three assays used in our 
experiments do not change whether we use the complete RRS or RRS_DiffLocal. 
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With these controls, we found that 20 of the 54 PRS were detected in our screen and none 
of the RRS set. We calculated the sensitivity of our assay as 20/54 (37.0% ± 4.4%) . 
 
Protein Complementation Assay (PCA) 
S. pombe ORFs available in Gateway entry vectors were transferred by Gateway LR reactions 
into vectors encoding the two fragments of YFP (Venus variant) fused to the N-terminus of the 
tested proteins. Baits were fused to the F1 fragment (amino acids 1-158 of YFP) and preys to the 
F2 fragment (amino acids 159-239 of YFP). After bacterial transformation, plasmid DNA was 
prepared on a Tecan Freedom Evo bio-robot, and DNA concentrations are determined by 
OD260nm with a Tecan M1000 in a 96-well format. A 50 ng aliquot of each vector encoding the 
two proteins was used for transfection into HEK 293T cells in 96-well plates, using 
Lipofectamine 2000 (Invitrogen) reagent according to the instructions of the manufacturer. At 
approximately 48 hrs post-transfection, cells were processed with a Tecan M1000. A pair is 
considered interacting if the YFP fluorescence intensity was ≥2 fold higher over background. 
 
Well-based nucleic-acid programmable protein array (wNAPPA) 
ORFs encoding the interacting proteins were cloned into Gateway-compatible pCITE-HA and 
pCITE-GST vectors by LR reactions. After bacterial transformation, growth, DNA minipreps, 
and determination of DNA concentration, ~0.5µg of each plasmid were added to Promega TnT 
coupled transcription-translation mix (catalog number: L4610) and incubated for 90 minutes at 
30°C to express proteins. During this time anti-GST antibody-coated 96-well plates (Amersham 
96-well GST detection module, catalog number: 27-4592-01) were blocked at room temperature 
with PBS containing 5% dry milk powder. After protein expression, the expression mix was 
207
diluted in 100µl blocking solution, and added to the emptied pre-blocked 96-well plates. 
Expression mix was incubated in the 96-well plates for two hours at 15°C with agitation to allow 
for protein capture. After capture, plates were washed three times and developed by incubation 
with primary and secondary antibodies. Signal was visualized using chemiluminescence 
(Amersham ECL Reagents, catalog number: RPN2106) with a Tecan M1000. Wells with ≥3 fold 
higher intensity over background in either configuration were considered positives. 
 
Measuring the precision of our assay 
The precision of the Y2H assay was calculated using PCA and wNAPPA as orthogonal 
validation assays. Using Bayes’ rule we can build relationships between true and false positive 
rates of Y2H and observed positive interactions by a validating assay as: 
 
€ 
Pr(A+ |Y+) = Pr(A+ |Y+,T+) × Pr(T+ |Y+) +Pr(A+ |Y+,T−) × Pr(T− |Y+)   Eq. 1 
 
where A+ corresponds to observing a positive interaction using the validating assay, Y+ 
corresponds to observing a positive interaction using Y2H, and T+ (T−) corresponds to an 
interaction being a real positive (negative) interaction. The precision of the Y2H is the term 
Pr(T+|Y+) [which is also equal to 1− Pr(T −|Y +)].  
 Assuming conditional independence between the validating assay and Y2H based on 
previously defined reasons (Yu et al., 2008), we can write: 
 
€ 
Pr(A+ |Y+) = Pr(A+ |T+) × Pr(T+ |Y+) +Pr(A+ |T−) × Pr(T− |Y+)  Eq. 2 
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Solving for the precision of the Y2H assay yields: 
 
€ 
Pr(T+ |Y+) = Pr(A+ |Y+) −Pr(A+ |T−)Pr(A+ |T+) −Pr(A+ |T−)      Eq. 3 
 
Pr(A+|T+) and Pr(A+|T–) were measured in the PRS and RRS experiments. So, for our Y2H 
assay we can write precision as: 
 
€ 
Precision = FStressNet − FRRSFPRS − FRRS
       Eq. 4 
 
where FStressNet is the fraction positive by an assay for StressNet, which is the best estimator for 
Pr(A+|Y+). FPRS is the fraction positive by the assay for the PRS, which is an estimator for 
Pr(A+|T+). FRRS is the fraction positive by the assay for the RRS, which is an estimator for 
Pr(A+|T-). 
The standard errors of FStressNet, FPRS, and FRRS are calculated using the standard error for 
binomial distributions: 
 
€ 
StdErr = F(1− F)N         Eq. 5 
 
where F is the fraction positive by the assay (FStressNet, FPRS, or FRRS and N is the total number of 
pairs tested. 
To estimate the standard error for the precision, we used the standard delta method: 
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€ 
σX
2 = (∂f
∂AσA )
2
+ (∂f
∂BσB )
2
+ (∂f
∂CσC )
2
+ ...       Eq. 6 
 
where X = f(A, B, C, …). A, B, C, … are independent random variables. 
Here, the standard error of the precision is calculated as: 
 
€ 
σprecision = (
1
FPRS − FRRS
)2 ×σStressNet2 +
(FStressNet − FRRS )
(FPRS − FRRS )4
2
×σPRS
2 +
(FStressNet − FPRS )2
(FPRS − FRRS )4
×σRRS
2  Eq. 7 
 
We have two validating assays, and we can incorporate the precision rates from these 
assays by calculating the average precision: 
 
€ 
Average Precision = PrecisionPCA + PrecisionwNAPPA2      Eq. 8 
 
The standard error for the average precision is calculated by the delta method as: 
 
€ 
σaverage precision =
σPCA
2
4 +
σwNAPPA
2
4         Eq. 9 
 
Using this framework, we estimate the precision of our Y2H assay to be 95.3
€ 
±4.7%. 
 
Calculating confidence scores for interactions 
Using the random forest algorithm (Breiman, 2001), we integrate results from Y2H, PCA, and 
wNAPPA and calculated confidence scores for interactions. Random forest is an ensemble 
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classifier that constructs multiple decision trees by stochastic discrimination (Kleinberg, 1996) 
and predicts a final class based on a weighted combination of the output class of each decision 
tree. It is considered to be a robust and accurate classifier for noisy datasets (Breiman, 2001). We 
evaluated the performance of our classifier by five-fold cross validation on our reference set 
(union of PRS and RRS) and obtained moderately good performance (AUC = 0.64). 
 
Determination of orthologs between S. pombe and S. cerevisiae 
We use the list of orthologs provided by PomBase (Wood et al., 2012). The genome of S. 
cerevisiae underwent a duplication event (Kellis et al., 2004). Thus, many S. pombe genes have 
two corresponding S. cerevisiae orthologous genes. Moreover, in a number of cases, the same S. 
cerevisiae gene has multiple S. pombe orthologs. Thus, the mapping considered for the study is 
“many-to-many”. 
 
Estimation of the conservation of interactions 
To estimate the conservation of protein-protein interactions between S. pombe and S. cerevisiae, 
we used a Bayesian framework that incorporates the precision and sensitivity of our Y2H assay: 
 
€ 
Pr(Det) = Pr(Det |Cons+) × Pr(Cons+) + Pr(Det |Cons−) × Pr(Cons−)   Eq. 10 
 
where Pr(Cons+) corresponds to the conservation of protein-protein interactions between S. 
cerevisiae and S. pombe. The best estimator for Pr(Det) (the probability of detecting a S. 
cerevisiae interaction among proteins pairs that are orthologous to an interacting protein pair in 
StressNet) is Fdet, the fraction of the 235 StressNet interactions in S. pombe with corresponding 
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Y2H-detected interactions in S. cerevisiae (35/235). Pr(Det|Cons+) and Pr(Det|Cons-) are 
estimated by FPRS and FRRS, the fractions of PRS and RRS interactions detected by our Y2H 
assay (20/54 and 0/43, respectively). By definition: 
 
 
€ 
Pr(Cons+) =1 − Pr(Cons−)        Eq. 11 
 
We can simplify the earlier equation to obtain an expression for Pr(Cons+): 
 
€ 
Pr(Cons+) = Pr(Det) − Pr(Det |Cons−)Pr(Det |Cons+) − Pr(Det |Cons−)      Eq. 12 
 
To estimate the error for the conservation percentage, we used the standard delta method as 
described earlier. The standard deviation of Cons+ is given by: 
 
σCons+=
(FPRS − FRRS )2σ Fdet2 + (Fdet − FRRS )2σ FPRS2 + (Fdet − FPRS )2σ FRRS2 )
(FPRS − FRRS )4
  Eq. 13 
  
Using the Y2H data, we calculated a conservation of 36.3 ± 2.9% interactions. 
 
Another approach for measuring the conservation is to calculate fraction of S. cerevisiae 
interactions conserved in S. pombe. We mapped all S. pombe proteins in our space to their 
corresponding S. cerevisiae orthologs. We calculated the number of interactions in this S. 
cerevisiae space detected by our Y2H assay. We then mapped all the observed S. cerevisiae 
interactions to their corresponding S. pombe ortholog pairs and calculate the number of pairs 
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detected as interacting in StressNet. We find that for 48/386 (12.4%) S. cerevisiae interactions, 
the corresponding S. pombe ortholog pairs also interact. Using the Bayesian framework 
described above, we calculate the conservation between S. pombe and S. cerevisiae interactions 
as 34.7 ± 2.0%, which is statistically the same (P = 0.708 using a cumulative binomial test) as 
the conservation calculated using the Y2H results (36.3 ± 2.9%).  
 
Interaction conservation and confidence scores 
After supplementing our Y2H experiments with high-quality interactions from the literature, we 
find that 90/235 (38.3%) interactions are conserved in StressNet. The statistical error associated 
with this measurement is related to the sample size and is calculated as the standard error 
[standard error = standard deviation / square root (N), where N is the number of samples]. The 
standard deviation is calculated based on the underlying probability distribution. The 
conservation percentage is obtained by a simple division (90/235 = 38.3%) and the underlying 
probability distribution is binomial (since each interaction can either be conserved or not, it 
corresponds to a Bernoulli event, the ensemble of which is modeled by a binomial distribution).  
The standard error is calculated using the appropriate formula for a binomial distribution: square 
root [p × (1-p) / N] = 3.2%, p = fraction of interactions that are conserved (90/235) and N = 
sample size (235)]. 
To test whether interactions with higher confidence scores were more likely to be conserved, we 
divided all StressNet interactions into two groups. The first group comprises interactions with 
confidence scores in the lower two quartiles and the second group comprises interactions with 
confidence scores in the upper two quartiles. We then compared the conservation for these two 
groups. We find that there is no significant difference (P = 0.37 using a two-sided Fisher exact 
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test) in conservation rate between the two groups. This validates that the observed conservation 
rate is robust and not correlated with the confidence score associated with each interaction.  
 
Evolutionary rates of genes and protein interactions  
The evolutionary rate of genes is commonly measured in terms of the ratio of asynchronous 
nucleotide substitutions per asynchronous site to synchronous substitutions per synchronous site 
or dN/dS. This quantifies the selective evolutionary pressure on certain protein-coding genes to 
diverge faster, as opposed to others that may almost remain unchanged across species. To 
calculate the dN/dS values for all S. pombe genes, used two sequenced species in the 
Schizosaccharomyces genus – S. cryophilus and S. octosporus. To determine orthology 
relationships, we used BLAST-x with default parameters on all S. pombe genes. The top BLAST 
hit for each S. pombe gene against the indexed database of proteins for each of the two species 
was designated to be an ortholog, provided the E-value of the hit was < 0.05. Although the E-
value cutoff is relatively high, it ensures that no potential pairs are missed. For pairs that have 
been incorrectly estimated to be orthologs, there is a correction step in downstream calculations 
that will return a dN/dS value of NaN (not a number), because of too high divergence. For all 
orthologous pairs, the Nei-Gojobori algorithm, which uses the Jukes-Cantor substitution model, 
was used to calculate dN/dS values.  
 
Conservation of interactions and sequence similarity 
Sequence similarity between S. pombe ORFs and their S. cerevisiae orthologs was measured by 
performing pairwise sequence alignment between all known ortholog pairs using the Needle 
program in the EMBOSS suite (Rice et al., 2000). It uses the Needleman-Wunsch alignment 
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algorithm (Needleman and Wunsch, 1970) to find the optimum alignment of two sequences 
along their entire length. The recommended default parameters – an affine gap penalty model 
(Vingron and Waterman, 1994) with an opening penalty of 10 and an extension penalty of 0.5 
and the BLOSUM62 scoring matrix (Henikoff and Henikoff, 1992) – were used for the 
alignment. Because the lengths of orthologs may be dissimilar, we calculated the overall 
similarity percentage (OPS) with reference to the length of the S. pombe ORFs:  
 
€ 
OPS = NstL _ Spt
        Eq. 14
 
 
where, Nst is the total number of similar residues and L_Spt is the total length of the S. pombe 
ORF.  
We then examined the relationship between the similarity percentage and the percentage 
of conserved interactions. Because the number of interactions varies considerably across 
different groups corresponding to different similarity percentages, we required each group to 
have at least 5 interactions. If any group had less than 5 interactions, it was merged with the next 
(higher) group. This ensured that our results were robust to outlier effects. We found that there 
was an increase in the degree of conservation with an increase in overall sequence similarity. To 
examine if the primary cause of this trend is the similarity of conserved domains, we identified 
domains on ortholog pairs that interact (Finn et al., 2005; Stein et al., 2011). We defined the 
percentage similarity of interacting domains (PSID) as: 
 
€ 
PSID = NsiL _ Spi
        Eq. 15 
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 where Nsi is the number of similar residues in interacting domains and L_Spi is the sum of the 
lengths of the interacting domains in S. pombe.  
 
Inferring interaction interfaces from 3did and iPfam  
In this study, we use interacting domains identified by 3did (Stein et al., 2011) and iPfam (Finn 
et al., 2005) to define interaction interface. To verify the reliability of inferring these domain-
domain interactions, we performed three-fold cross-validation for 1,456 interaction pairs that 
have co-crystal structures. Because there are few co-crystal structures for S. pombe, this 
approach allowed us to obtain a meaningful estimate of the quality of the domain-domain 
predictions in these two databases. We split the pairs into three subsets such that two subsets 
were used for training and the third one was the test set. For each interaction pair in the test 
dataset, we scored a successful structural prediction when the predicted domain-domain 
interaction(s) had at least one co-crystal structure in support of it. We repeated the procedure 
thrice with each of the three subsets as the test set. Among the 1,456 PPI pairs, over 90% were 
correctly predicted with corresponding interacting domains, indicating that the predicted 
interaction interfaces used for our calculations were accurate (Wang et al., 2012). 
 
Robustness of differences between sets of conserved and rewired interactions 
To assess the robustness of the differences between sets of conserved and rewired interactions, 
we constructed different sets of conserved and rewired interactions corresponding to different 
confidence levels. 
216
We constructed two sets of conserved interactions at different confidence levels – 
Conserved_HQ and Conserved_All. Conserved_HQ comprises only those interactions with 
corresponding S. cerevisiae ortholog pairs that tested positive in our Y2H experiments or were 
confirmed by two or more independent orthogonal assays in the literature. Conserved_All 
comprises all interactions in Conserved_HQ and those S. cerevisiae ortholog pairs that have been 
reported as interacting in the literature by only one assay. 
We constructed five sets of rewired interactions at different confidence levels – 
Rewired_ByDefn, Rewired_HQ, Rewired_LC, Rewired_All_DiffLocal, and Rewired_All. 
Rewired_ByDefn comprises only those StressNet interactions for which at least one of the 
interacting proteins does not have a S. cerevisiae ortholog and, therefore, no corresponding 
interaction can exist in S. cerevisiae. Thus, these interactions are rewired by definition. 
Rewired_HQ comprises all interactions in Rewired_ByDefn and those interactions for which the 
corresponding S. cerevisiae ortholog pairs have other high-quality interactions but have never 
been reported as interacting in the literature or tested positive in our Y2H experiments, and these 
ortholog pairs are known to have different cellular localizations. Thus, these correspond to S. 
pombe interactions with corresponding budding yeast ortholog pairs that are in principle non-
interacting, because they have different cellular localizations (Jansen et al., 2003; Yu et al., 
2008) and they participate in well-validated interactions with other proteins but have never been 
reported to interact in the literature. Rewired_LC comprises all interactions in Rewired_ByDefn 
and those interactions with corresponding ortholog pairs that have other high-quality interactions 
but have never been reported as interacting in the literature or tested positive in our Y2H 
experiments. Rewired_All_DiffLocal corresponds to all interactions in Rewired_ByDefn and 
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those interactions with corresponding ortholog pairs that have different cellular localizations. 
Rewired_All comprises all interactions that are not in Conserved_All.  
 
Construction of myc-sty1 and HA-snr1 expression clones 
S. pombe sty1 and snr1 genes were PCR amplified using the following primers – sty1-
pNCH1472-Forward, sty1-pNCH1472-Reverse, snr1-pSGP73-Forward, and snr1-pSGP73-
Reverse (Table 7.4). The sty1 PCR product was cloned into a pNCH1472-myc vector using the 
NotI and SalI restriction sites. The snr1 PCR product was cloned into a pSGP73-HA vector using 
the NotI and BglII restriction sites. pNCH1472-myc-sty1 and pSGP73-HA-snr1 were single or 
double transformed into S. pombe KGY553 (ATCC). Transformed yeast was selected on 
Edinburgh minimal medium (EMM)–Ura plates for pNCH1472-myc-sty1, EMM–Leu for 
pSGP73-HA-snr1, and EMM–Ura–Leu for double transformation. 
 
Coimmunoprecipitation and Western blotting 
Transformed yeast (KGY553) containing pNCH1472-myc-sty1 or pSGP73-HA-snr1 or both 
were cultured overnight in 10 mL EMM selection medium. Yeast pellets were washed in 5 mL 
of cold TE buffer before protein extraction. To lyse cells, 1 mL of lysis buffer (50mM Tris-HCl 
pH 7.5, 0.2% Tergitol, 150 mM NaCl, 5 mM EDTA, Complete Protease Inhibitor tablet) and 600 
µL glass beads were added to each tube and mixed in a beater for two rounds of 10 minutes each. 
Protein extracts were centrifuged for 10 minutes at 13,200 rpm at 4°C in an Eppendorf 5415R 
centrifuge.. Then, 500 µL of supernatant was immunoprecipitated overnight using 20 µL of 
EZview™ Red Anti-c-Myc Affinity Gel (Sigma-Aldrich E6654) or EZview™ Red Anti-HA 
Affinity Gel (Sigma-Aldrich E6779). The next morning, beads were washed three times using 
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cold lysis buffer before being subjected to SDS-PAGE and Western blotting analysis. Primary 
antibodies used in our analysis were anti-c-Myc (Santa Cruz sc-789), anti-HA (Roche 12CA5), 
and anti-γ-tubulin (Sigma-Aldrich T5192).  
 
Construction of yeast deletion strains 
The snr1∆ strain was obtained from the Bioneer Schizosaccharomyces pombe Genome-wide 
Deletion Library. The deletion strain was verified by PCR using primers SpEhd3_Up_Fwd and 
Sp_Dn_Rev spanning the 3’ end of snr1 and the region immediately downstream. Primers 
specific for KanMX4 (KanMX4-Fwd and KanMX4-Rev) were used to detect the deletion 
cassette. A PCR-based strategy was used to construct the sty1∆ strain. Briefly, in the first round 
of PCR, primers (PFA6a_Sty1_Fwd and PFA6a_Sty1_Rev) with 20 base pairs (bp) homology to 
the regions upstream and downstream of sty1, respectively, were synthesized for PCR of the 
pFA6a-KanMX6 cassette. Primers with 20 bp homology to the pFA6a-KanMX6 were 
synthesized to PCR 290 bp upstream (Sty1Del-Up_Fwd and Sty1Del-Up_Rev) and 290 bp 
downstream (Sty1Del-Dn_Fwd and Sty1Del-Dn_Rev) of sty1, not including the sty1 gene. The 
three PCR products were stitched together sequentially with a second round of PCR. Stitch PCR 
of the upstream region and pFA6a-KanMX6 and of the downstream region and pFA6a-KanMX6 
were carried out separately. In the third round of PCR, both upstream and downstream stitched 
PCR products were further stitched together to produce a final product of pFA6a-KanMX6 
flanked on the 5’ and 3’ ends by 290 bp that are homologous to the upstream and downstream 
regions of chromosomal sty1 (Sty1Del-Up_Fwd and Sty1Del-Dn_Rev). The final PCR product 
was transformed into S. pombe 972h- canonical wild-type (ATCC). Transformed yeast was 
selected on yeast extract-sucrose (YES) media plates containing 150 mg/L G418. Insertion of the 
219
pFA6a-KanMX6 cassette by homologous recombination at the sty1 locus was verified by PCR 
using primers to target the entire cassette (Sty1Del-Up_Fwd and Sty1Del-Dn_Rev) and to target 
a sty1 internal region of 401 bp (Sty1_Fwd and Sty1_Rev). In addition, sty1 and snr1 deletion 
were performed in S. pombe KGY553 (ATCC) wild-type (h- his3-D1 leu1-32 ura4-D18 ade6-
M216) background using a similar PCR strategy. Sequences of primers used for deletion and 
verification of strains in this study are listed in Table 7.4. 
 
Stress Sensitivity Assays  
S. cerevisiae was grown in YEPD and S. pombe was grown in YES medium. All yeast strains 
were initially grown as a starter culture overnight at 30°C. From the starter culture, yeast cells 
were diluted into fresh medium to an initial OD600nm = 0.2. The cultures were grown to mid-log 
phase (OD600nm = 0.7). The S. cerevisiae and S. pombe strains were serially diluted 4-fold in 
sterile water and spotted onto YEPD and YES plates, respectively, containing various stressors. 
Spotted plates were incubated at 30°C and yeast growth was assessed after 3 days. 
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7.6 FIGURE AND TABLE LEGENDS 
Figure  7.1. S. pombe stress-response binary interactome network, StressNet. (A) Functional 
classification of the proteins included in our high-quality high-coverage HT-Y2H screen. (B) 
Network view of the stress-response binary interactome network in S. pombe. (C) Fraction of 
protein pairs in PRS, RRS, and StressNet that tested positive using Y2H, PCA, and wNAPPA. 
Data are shown as measurements + statistical error (SE). (D) Degree distribution of StressNet.  
P(k) is the probability that a protein has a degree = k. 
Figure 7.2. Biological properties of StressNet interactions. (A) Pearson correlation coefficient 
(PCC) distribution of expression profiles of interacting and random protein pairs (dashed line 
corresponds to PCC cutoff above which pairs are considered to be significantly coexpressed; 
inset shows the fraction of significantly coexpressed pairs). (B) PCC distribution of genetic 
interaction profiles of interacting and random protein pairs (dashed line corresponds to PCC 
cutoff above which pairs are considered to be significantly similar; inset shows the fraction of 
pairs with significantly similar interaction profiles). (C) Enrichment of colocalized protein pairs. 
(D) Enrichment of protein pairs sharing similar functions. For each panel, the random set is 
constructed by considering all pairwise combinations of genes or proteins in the corresponding 
space. All P values represent comparisons between StressNet interactions and random pairs 
using a cumulative binomial test. Inset graphs and data in C and D are shown as measurements + 
SE. 
Figure 7.3. Evolutionary analysis of interactions. (A) Schematic of conserved and rewired 
interactions between the two yeast species. S.p., S. pombe; S.c., S. cerevisiae (B) Conservation 
rate (fraction of conserved interactions) in our interactome calculated in two different ways. 
Measured represents the value calculated using a Bayesian framework that incorporates the 
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precision and recall of our assay. Literature represents the value estimated using budding yeast 
interactions reported in the literature. (C) Fraction of conserved interactions involving essential 
and non-essential proteins. The differences in B and C are not significant based on a cumulative 
binomial test. (D) Distribution of the fraction of conserved interactions as a function of overall 
sequence similarity. (E) Distribution of the fraction of conserved interactions as a function of 
sequence similarity of interaction interfaces. For D and E, P values are used to test whether there 
is a significant difference (using a cumulative binomial test) in conservation percentage between 
the groups corresponding to the lowest and highest similarity percentages. R2 (coefficient of 
determination) represents the significance of the correlation between conservation and similarity 
percentages. (F) Distribution of dN/dS [ratio of the number of non-synonymous substitutions per 
non-synonymous site (dN) to the number of synonymous substitutions per synonymous site (dS)] 
as a function of number of rewired interactions. The differences are not significant based on a 
two-sided Kolmogorov-Smirnov test. Data are shown as the measurements + SE. 
Figure 7.4. Functional analysis of conserved and rewired interactions in S. pombe and S. 
cerevisiae. (A) Fraction of globally coexpressed pairs (as measured by PCC) among conserved 
and rewired interactions. (B) Fraction of locally coexpressed pairs (as measured by LES) among 
conserved and rewired interactions (C) Fraction of functionally similar pairs among conserved 
and rewired interactions. For each panel, the random set is constructed by considering all 
pairwise combinations of genes/proteins in the corresponding space. All P values represent 
comparisons between rewired interactions and random pairs using a cumulative binomial test. 
Data are shown as measurements + SE.  
Figure 7.5. Analysis of intact and co-evolved interactions. (A) Schematic of intact and co-
evolved interactions. (B) Fraction of intact and co-evolved interactions in our interactome. Data 
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are shown as measurements + SE. No significant difference detected using a cumulative 
binomial test. (C) The MAPK Sty1 stress response pathway. All undirected lines represent 
interactions detected in our interactome. The black arrow represents transcriptional regulation. 
(D) Sty1-Snr1 interaction validated in S. pombe using co-immunoprecipitation (N = 3 blots). (E) 
Y2H analysis of the ability of Hog1 and Ehd3 to interact and Sty1 and Snr1 to interact (N = 3 
experiments). (F) Sensitivity assays for different deletion strains of S. cerevisiae and S. pombe 
under various stress conditions (N = 3 experiments).  
Table 7.1. StressNet and interaction confidence scores. 
Table 7.2. Positive reference set. 
Table 7.3. Random reference set. 
Table 7.4 Primers used in the study.
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ORF_A ORF_B Gene_A Gene_B Confidence Score
SPAC1002.17C SPAC1002.17C URG2 URG2 0.9132
SPAC10F6.11C SPAC23H3.06 ATG17 APL6 0.8545
SPAC1142.06 SPAC14C4.05C GET3 HEH2 0.8958
SPAC1142.06 SPAC19A8.14 GET3 SPAC19A8.14 0.9139
SPAC1142.06 SPBC4C3.06 GET3 SYP1 0.9338
SPAC11E3.08C SPBC651.10 NSE6 NSE5 0.9501
SPAC12B10.02C SPAC14C4.05C SPAC12B10.02C HEH2 0.8522
SPAC13G7.02C SPBC3B9.01 SSA1 SPBC3B9.01 0.9322
SPAC14C4.05C SPAC17G6.09 HEH2 SEC62 0.8958
SPAC14C4.05C SPAC22F8.01 HEH2 SPAC22F8.01 0.8958
SPAC14C4.05C SPAC23A1.02C HEH2 SPAC23A1.02C 0.8804
SPAC14C4.05C SPAC26A3.16 HEH2 DPH1 0.8516
SPAC14C4.05C SPAC4G8.10 HEH2 GOS1 0.9176
SPAC14C4.05C SPAC644.13C HEH2 SPAC644.13C 0.8096
SPAC14C4.05C SPAC688.04C HEH2 GST3 0.8958
SPAC14C4.05C SPAC6F12.04 HEH2 SPAC6F12.04 0.8666
SPAC14C4.05C SPAC824.08 HEH2 GDA1 0.8814
SPAC14C4.05C SPBC119.09C HEH2 SPBC119.09C 0.9179
SPAC14C4.05C SPBC12D12.01 HEH2 SAD1 0.8524
SPAC14C4.05C SPBC146.04 HEH2 SPBC146.04 0.8547
SPAC14C4.05C SPBC365.12C HEH2 ISH1 0.8433
SPAC14C4.05C SPBC428.14 HEH2 SPBC428.14 0.8588
SPAC14C4.05C SPBC582.03 HEH2 CDC13 0.8270
SPAC14C4.05C SPBC646.05C HEH2 ERG9 0.9453
SPAC1565.04C SPBC1D7.05 STE4 BYR2 0.8529
SPAC15A10.03C SPAC644.14C RHP54 RHP51 0.9491
SPAC16A10.05C SPAC589.08C DAD1 DAM1 0.8522
SPAC17A5.10 SPAC17A5.10 SPAC17A5.10 SPAC17A5.10 0.8606
SPAC17A5.10 SPAC328.04 SPAC17A5.10 SPAC328.04 0.7981
SPAC17A5.10 SPAC821.07C SPAC17A5.10 MOC3 0.8522
SPAC17A5.10 SPBC1734.06 SPAC17A5.10 RHP18 0.8606
SPAC17D4.03C SPBC16E9.14C CIS4 ZRG17 0.9403
SPAC17G6.09 SPBC12D12.01 SEC62 SAD1 0.9286
SPAC17G6.14C SPAC17G6.14C UAP56 UAP56 0.9532
SPAC17G6.14C SPCC31H12.03C UAP56 SPCC31H12.03C 0.8791
SPAC17G8.10C SPAC24B11.06C DMA1 STY1 0.8132
SPAC17G8.10C SPAC4H3.11C DMA1 PPC89 0.7932
SPAC17G8.10C SPAC644.14C DMA1 RHP51 0.8958
SPAC17G8.10C SPAC6F12.04 DMA1 SPAC6F12.04 0.8554
SPAC17G8.10C SPBC12D12.01 DMA1 SAD1 0.8149
SPAC17G8.10C SPBC13E7.08C DMA1 SPBC13E7.08C 0.8155
SPAC17G8.10C SPBC29A3.16 DMA1 RRS1 0.8958
SPAC17G8.10C SPBC317.01 DMA1 MBX2 0.8522
SPAC17G8.10C SPBC56F2.07C DMA1 SPBC56F2.07C 0.7932
SPAC17H9.04C SPAC821.07C SPAC17H9.04C MOC3 0.9523
SPAC1805.16C SPAC1805.16C SPAC1805.16C SPAC1805.16C 0.8100
SPAC1834.11C SPAC1834.11C SEC18 SEC18 0.9306
SPAC1834.11C SPAC227.13C SEC18 ISU1 0.9524
SPAC1834.11C SPAC29B12.06C SEC18 RCD1 0.8792
SPAC19A8.07C SPCC757.09C SPAC19A8.07C RNC1 0.8316
SPAC19A8.10 SPBC1734.06 RFP1 RHP18 0.9562
SPAC19A8.10 SPBC3D6.11C RFP1 SLX8 0.9029
Table 7.1: StressNet and interaction confidence scores
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SPAC19D5.01 SPAC24B11.06C PYP2 STY1 0.9328
SPAC19G12.03 SPAC19G12.03 CDA1 CDA1 0.9212
SPAC19G12.04 SPAC19G12.04 SPAC19G12.04 SPAC19G12.04 0.9105
SPAC1D4.11C SPBC1685.01 LKH1 PMP1 0.8591
SPAC1D4.13 SPAC31G5.09C BYR1 SPK1 0.8097
SPAC1D4.13 SPAC821.07C BYR1 MOC3 0.8958
SPAC1D4.13 SPAC9E9.10C BYR1 CBH1 0.8958
SPAC1D4.13 SPBC14F5.12C BYR1 CBH2 0.8958
SPAC1D4.13 SPBC1D7.05 BYR1 BYR2 0.8958
SPAC1D4.13 SPBC56F2.07C BYR1 SPBC56F2.07C 0.8958
SPAC1F3.02C SPBC543.07 MKH1 PEK1 0.9627
SPAC1F8.07C SPAC1F8.07C SPAC1F8.07C SPAC1F8.07C 0.9464
SPAC20H4.07 SPAC30D11.10 RHP57 RAD22 0.9212
SPAC20H4.08 SPAC2F7.02C SPAC20H4.08 SPAC2F7.02C 0.8370
SPAC222.08C SPAC222.08C SPAC222.08C SPAC222.08C 0.9542
SPAC222.08C SPAC29B12.04 SPAC222.08C SNZ1 0.8376
SPAC222.11 SPAC26H5.09C HEM13 SPAC26H5.09C 0.8100
SPAC227.06 SPAC644.13C SPAC227.06 SPAC644.13C 0.8522
SPAC227.13C SPAC644.14C ISU1 RHP51 0.9501
SPAC227.13C SPBC2D10.11C ISU1 NAP2 0.9406
SPAC227.13C SPCC162.08C ISU1 NUP211 0.9464
SPAC227.18 SPBC725.07 LYS3 PEX5 0.9380
SPAC22F8.08 SPBC26H8.01 SEC24 THI2 0.8587
SPAC23A1.14C SPAC23A1.14C SPAC23A1.14C SPAC23A1.14C 0.8919
SPAC23A1.14C SPBC725.07 SPAC23A1.14C PEX5 0.8853
SPAC23A1.15C SPBC691.02C SEC20 SPBC691.02C 0.9370
SPAC23D3.06C SPBC31E1.05 NUP146 GLE1 0.9328
SPAC24B11.06C SPAC24B11.06C STY1 STY1 0.8027
SPAC24B11.06C SPBC29B5.01 STY1 ATF1 0.7991
SPAC24B11.06C SPBC2D10.09 STY1 SPBC2D10.09 0.7998
SPAC24B11.06C SPBC409.07C STY1 WIS1 0.7657
SPAC24B11.06C SPCC4F11.02 STY1 PTC1 0.8225
SPAC24C9.14 SPAC343.09 OTU1 UBX3 0.8082
SPAC24C9.14 SPBC119.05C OTU1 SPBC119.05C 0.8958
SPAC25G10.08 SPACUNK12.01 SPAC25G10.08 SPACUNK12.01 0.9393
SPAC26A3.16 SPAC26A3.16 DPH1 DPH1 0.9139
SPAC26A3.16 SPAC3C7.12 DPH1 TIP1 0.9475
SPAC26A3.16 SPBC27.01C DPH1 SPBC27.01C 0.8055
SPAC26H5.05 SPBC32F12.08C SPAC26H5.05 DUO1 0.8799
SPAC27D7.03C SPBC19C2.05 MEI2 RAN1 0.9491
SPAC27D7.04 SPAC27D7.04 OMT2 OMT2 0.9328
SPAC27D7.04 SPAC29B12.06C OMT2 RCD1 0.8351
SPAC27D7.04 SPCC962.03C OMT2 CUT15 0.8217
SPAC29B12.04 SPAC29B12.04 SNZ1 SNZ1 0.9088
SPAC29B12.04 SPBC119.04 SNZ1 MEI3 0.8958
SPAC2C4.15C SPAC2C4.15C UBX2 UBX2 0.8626
SPAC2C4.15C SPAC343.09 UBX2 UBX3 0.8290
SPAC30D11.10 SPAC30D11.10 RAD22 RAD22 0.8433
SPAC30D11.10 SPAC3C7.03C RAD22 RHP55 0.9571
SPAC30D11.10 SPAC644.14C RAD22 RHP51 0.8575
SPAC31A2.11C SPAC31A2.11C CUF1 CUF1 0.9380
SPAC328.04 SPAC328.04 SPAC328.04 SPAC328.04 0.9491
SPAC328.04 SPAC3C7.02C SPAC328.04 SPAC3C7.02C 0.9501
SPAC328.04 SPBC582.03 SPAC328.04 CDC13 0.8958
SPAC343.09 SPBC428.05C UBX3 ARG12 0.8958
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SPAC343.11C SPAC637.12C MSC1 MST1 0.9491
SPAC3A12.10 SPBC2D10.11C RPL2001 NAP2 0.8370
SPAC3A12.12 SPAC3C7.02C ATP11 SPAC3C7.02C 0.8958
SPAC3A12.12 SPAC644.14C ATP11 RHP51 0.8155
SPAC3A12.12 SPAC7D4.04 ATP11 TAF1 0.7961
SPAC3A12.12 SPACUNK12.01 ATP11 SPACUNK12.01 0.8606
SPAC3A12.12 SPBC2D10.11C ATP11 NAP2 0.8958
SPAC3C7.02C SPBC1347.10 SPAC3C7.02C CDC23 0.8958
SPAC3C7.02C SPBC32F12.08C SPAC3C7.02C DUO1 0.8958
SPAC3C7.12 SPBC1604.20C TIP1 TEA2 0.9229
SPAC3C7.12 SPCC1223.06 TIP1 TEA1 0.9447
SPAC3H5.05C SPCC830.11C RPS1401 SPCC830.11C 0.9212
SPAC3H5.10 SPBC2D10.11C RPL3202 NAP2 0.9369
SPAC4H3.11C SPBC582.03 PPC89 CDC13 0.8958
SPAC589.08C SPAC8C9.17C DAM1 SPC34 0.9491
SPAC589.08C SPBC32F12.08C DAM1 DUO1 0.9491
SPAC5H10.09C SPAC5H10.09C SPAC5H10.09C SPAC5H10.09C 0.8919
SPAC637.12C SPCC830.05C MST1 EPL1 0.9441
SPAC644.14C SPAC644.14C RHP51 RHP51 0.8861
SPAC644.14C SPBC119.04 RHP51 MEI3 0.8958
SPAC644.14C SPBC1347.10 RHP51 CDC23 0.8341
SPAC644.14C SPBC1921.03C RHP51 MEX67 0.9129
SPAC644.14C SPBC19C2.05 RHP51 RAN1 0.9292
SPAC644.14C SPBC28F2.07 RHP51 SFR1 0.8245
SPAC644.14C SPBC2D10.09 RHP51 SPBC2D10.09 0.8958
SPAC644.14C SPBC317.01 RHP51 MBX2 0.8958
SPAC644.14C SPBC32F12.08C RHP51 DUO1 0.8928
SPAC644.14C SPBC582.03 RHP51 CDC13 0.9501
SPAC688.11 SPAC688.11 END4 END4 0.9399
SPAC7D4.04 SPAC7D4.04 TAF1 TAF1 0.9486
SPAC7D4.04 SPBC1347.10 TAF1 CDC23 0.8556
SPAC7D4.04 SPBC16A3.11 TAF1 ESO1 0.8919
SPAC7D4.04 SPBC1718.07C TAF1 ZFS1 0.8683
SPAC7D4.04 SPBC32F12.08C TAF1 DUO1 0.9161
SPAC7D4.04 SPBC3B8.11 TAF1 RRN6 0.8523
SPAC7D4.04 SPBC839.07 TAF1 IBP1 0.9030
SPAC7D4.04 SPCC364.02C TAF1 BIS1 0.8958
SPAC7D4.04 SPCC4F11.02 TAF1 PTC1 0.9225
SPAC7D4.04 SPCC548.05C TAF1 SPCC548.05C 0.8064
SPAC806.06C SPAC806.06C SPAC806.06C SPAC806.06C 0.9212
SPAC806.07 SPAC806.07 NDK1 NDK1 0.9238
SPAC821.07C SPAC821.07C MOC3 MOC3 0.9362
SPAC821.07C SPAC9E9.10C MOC3 CBH1 0.8958
SPAC821.07C SPBC19C2.05 MOC3 RAN1 0.8341
SPAC821.07C SPBC21B10.05C MOC3 POP3 0.8708
SPAC821.07C SPBC582.03 MOC3 CDC13 0.9478
SPAC890.02C SPCC895.07 ALP7 ALP14 0.8347
SPAC8C9.03 SPAC8C9.03 CGS1 CGS1 0.8376
SPAC8C9.17C SPAC8C9.17C SPC34 SPC34 0.8958
SPAC8E11.11 SPCC16C4.13C SPAC8E11.11 RPL1201 0.8354
SPAC959.10 SPAC959.10 SEN15 SEN15 0.9226
SPAC9E9.10C SPAC9E9.10C CBH1 CBH1 0.8881
SPAC9E9.10C SPBC2D10.09 CBH1 SPBC2D10.09 0.9338
SPAC9G1.02 SPAC9G1.02 WIS4 WIS4 0.8958
SPAC9G1.02 SPBC725.02 WIS4 MPR1 0.9491
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SPAC9G1.02 SPBC887.10 WIS4 MCS4 0.9417
SPACUNK12.01 SPBC19G7.15 SPACUNK12.01 NUP44 0.8958
SPACUNK12.01 SPBC337.13C SPACUNK12.01 GTR1 0.9362
SPACUNK12.01 SPBC839.07 SPACUNK12.01 IBP1 0.8958
SPAP27G11.09C SPAP27G11.09C SPAP27G11.09C SPAP27G11.09C 0.8559
SPAP8A3.06 SPBC146.07 SPAP8A3.06 PRP2 0.8231
SPAPB1E7.12 SPBC2D10.11C RPS602 NAP2 0.9485
SPBC1105.04C SPBC1105.04C CBP1 CBP1 0.9491
SPBC119.04 SPBC19C2.05 MEI3 RAN1 0.9491
SPBC11B10.10C SPBC2D10.11C PHT1 NAP2 0.9476
SPBC11B10.10C SPCC830.11C PHT1 SPCC830.11C 0.8958
SPBC12C2.07C SPBC12C2.07C SPBC12C2.07C SPBC12C2.07C 0.9212
SPBC12D12.01 SPBC12D12.01 SAD1 SAD1 0.9416
SPBC12D12.01 SPBC582.03 SAD1 CDC13 0.8881
SPBC1347.10 SPBC211.04C CDC23 MCM6 0.9478
SPBC1347.10 SPCC162.08C CDC23 NUP211 0.9523
SPBC13G1.03C SPCC338.13 PEX14 COG4 0.9107
SPBC14F5.05C SPBC14F5.05C SAM1 SAM1 0.9088
SPBC14F5.09C SPBC14F5.09C ADE8 ADE8 0.9226
SPBC14F5.12C SPBC14F5.12C CBH2 CBH2 0.9559
SPBC14F5.12C SPBC354.03 CBH2 SWD3 0.8732
SPBC16E9.01C SPBC26H8.06 PHP4 GRX4 0.9491
SPBC1706.01 SPCC1223.06 TEA4 TEA1 0.8692
SPBC1734.06 SPBC1734.06 RHP18 RHP18 0.9340
SPBC1773.05C SPBC1773.05C TMS1 TMS1 0.9427
SPBC211.02C SPCC364.02C CWF3 BIS1 0.9429
SPBC215.14C SPBC651.05C VPS20 DOT2 0.8522
SPBC215.15 SPBC8D2.20C SEC13 SEC31 0.7981
SPBC21C3.10C SPBC21C3.10C SPBC21C3.10C SPBC21C3.10C 0.9229
SPBC23E6.10C SPBC23E6.10C SPBC23E6.10C SPBC23E6.10C 0.9572
SPBC25H2.09 SPCC4F11.02 SPBC25H2.09 PTC1 0.8958
SPBC26H8.01 SPBC26H8.01 THI2 THI2 0.9427
SPBC28F2.01C SPBC28F2.01C SPBC28F2.01C SPBC28F2.01C 0.8438
SPBC29A3.16 SPCC4F11.02 RRS1 PTC1 0.8958
SPBC2D10.09 SPBC725.04 SPBC2D10.09 SPBC725.04 0.8648
SPBC2D10.11C SPBC2D10.11C NAP2 NAP2 0.9017
SPBC2D10.11C SPBC32F12.08C NAP2 DUO1 0.8958
SPBC2D10.11C SPBC582.03 NAP2 CDC13 0.8867
SPBC2D10.11C SPCC1672.07 NAP2 SPCC1672.07 0.8649
SPBC2D10.11C SPCC663.04 NAP2 RPL39 0.9075
SPBC30D10.05C SPBC30D10.05C SPBC30D10.05C SPBC30D10.05C 0.9108
SPBC317.01 SPBC32F12.08C MBX2 DUO1 0.8958
SPBC317.01 SPBC354.03 MBX2 SWD3 0.9488
SPBC31F10.11C SPCC1739.11C CWF4 CDC11 0.9372
SPBC32F12.08C SPCC162.08C DUO1 NUP211 0.8370
SPBC32H8.12C SPBC32H8.12C ACT1 ACT1 0.9462
SPBC342.05 SPBC582.03 CRB2 CDC13 0.9464
SPBC342.05 SPCC4F11.02 CRB2 PTC1 0.9406
SPBC354.03 SPBC685.09 SWD3 ORC2 0.9399
SPBC3E7.02C SPBC3E7.02C HSP16 HSP16 0.9471
SPBC3E7.02C SPBC543.07 HSP16 PEK1 0.8958
SPBC3F6.03 SPBC3F6.03 TRR1 TRR1 0.9427
SPBC409.07C SPBC725.02 WIS1 MPR1 0.9427
SPBC428.05C SPBC428.05C ARG12 ARG12 0.9212
SPBC56F2.07C SPBC56F2.07C SPBC56F2.07C SPBC56F2.07C 0.8448
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SPBC582.03 SPBC685.09 CDC13 ORC2 0.8567
SPBC582.03 SPCC1739.11C CDC13 CDC11 0.9107
SPBC725.02 SPBC887.10 MPR1 MCS4 0.9491
SPBC725.02 SPCC74.06 MPR1 MAK3 0.9328
SPBC725.13C SPBP4H10.21C PSF2 SLD5 0.8426
SPBC800.03 SPBC800.03 CLR3 CLR3 0.9491
SPBC887.10 SPBC887.10 MCS4 MCS4 0.9429
SPCC1223.06 SPCC895.05 TEA1 FOR3 0.9501
SPCC1322.12C SPCC1322.12C BUB1 BUB1 0.9464
SPCC1322.12C SPCC895.02 BUB1 SPCC895.02 0.9429
SPCC162.08C SPCC364.02C NUP211 BIS1 0.9417
SPCC1739.11C SPCC1739.11C CDC11 CDC11 0.9493
SPCC18.07 SPCC330.13 RPC53 RPC37 0.9244
SPCC24B10.13 SPCC4F11.02 SKB5 PTC1 0.9212
SPCC330.05C SPCC330.05C URA4 URA4 0.9088
SPCC4B3.06C SPCC4B3.06C SPCC4B3.06C SPCC4B3.06C 0.9066
SPCC4G3.17 SPCC4G3.17 SPCC4G3.17 SPCC4G3.17 0.9439
SPCC757.09C SPCC757.09C RNC1 RNC1 0.9043
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ORF_A ORF_B Gene_A Gene_B
SPAC926.04C SPCC613.04C HSP90 RNG3
SPAC1D4.13 SPAC31G5.09C BYR1 SPK1
SPAC30D11.10 SPAC30D11.10 RAD22 RAD22
SPAC30D11.10 SPAC644.14C RAD22 RHP51
SPBC1604.20C SPBC1604.20C TEA2 TEA2
SPBC1347.10 SPBC211.04C CDC23 MCM6
SPAC27F1.09C SPBC146.07 PRP10 PRP2
SPBC3E7.02C SPBC3E7.02C HSP16 HSP16
SPAC3C7.12 SPBC1604.20C TIP1 TEA2
SPAC3C7.12 SPCC1223.06 TIP1 TEA1
SPBC244.01C SPCC1739.11C SID4 CDC11
SPBC244.01C SPBC244.01C SID4 SID4
SPBC146.03C SPBP4H10.06C CUT3 CUT14
SPAC9G1.02 SPBC409.07C WIS4 WIS1
SPAC16A10.07C SPBC1778.02 TAZ1 RAP1
SPAC16E8.09 SPAC22H10.07 SCD1 SCD2
SPAC890.02C SPCC895.07 ALP7 ALP14
SPAC644.06C SPCC18B5.03 CDR1 WEE1
SPAC27D7.03C SPAC8E11.02C MEI2 RAD24
SPAC27D7.03C SPBC19C2.05 MEI2 RAN1
SPAC23G3.01 SPBC31F10.09C RPB2 NUT2
SPBC14F5.08 SPBC31F10.09C MED7 NUT2
SPBC1105.06 SPBC31F10.09C PMC4 NUT2
SPBC146.07 SPBC530.14C PRP2 DSK1
SPAC8E11.03C SPAC8E11.03C DMC1 DMC1
SPAC17H9.09C SPBC1D7.05 RAS1 BYR2
SPAC15A10.03C SPAC644.14C RHP54 RHP51
SPAC19A8.12 SPBC3B9.21 DCP2 DCP1
SPAC2E1P5.04C SPAPB1A10.04C CWG2 CWP1
SPAC11E3.08C SPBC651.10 NSE6 NSE5
SPAC24H6.05 SPCC1322.08 CDC25 SRK1
SPBC31F10.09C SPCC1020.04C NUT2 RPB6
SPAC637.07 SPBC646.09C MOE1 INT6
SPAC24B11.06C SPBC29B5.01 STY1 ATF1
SPAC24B11.06C SPBC409.07C STY1 WIS1
SPAP8A3.06 SPBC146.07 SPAP8A3.06 PRP2
SPBC1706.01 SPCC1223.06 TEA4 TEA1
SPAC19D5.01 SPAC24B11.06C PYP2 STY1
SPAC3C7.03C SPAC644.14C RHP55 RHP51
SPAC1F7.04 SPBC12D12.04C RHO1 PCK2
SPAC19A8.10 SPBC3D6.11C RFP1 SLX8
SPAC19A8.10 SPBC1921.02 RFP1 RAD60
SPAC1565.04C SPBC1D7.05 STE4 BYR2
SPAC1142.03C SPAC664.01C SWI2 SWI6
SPAC644.14C SPAC644.14C RHP51 RHP51
SPBC1105.17 SPBC409.04C CNP1 MIS12
Table 7.2: Positive reference set
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SPBC725.02 SPBC887.10 MPR1 MCS4
SPAC20H4.07 SPAC3C7.03C RHP57 RHP55
SPBC1D7.05 SPBC1D7.05 BYR2 BYR2
SPBC216.06C SPBC30D10.04 SWI1 SWI3
SPAC23C11.16 SPCC4B3.15 PLO1 MID1
SPBC1604.14C SPBC1604.14C SHK1 SHK1
SPAC18G6.15 SPAC3C7.12 MAL3 TIP1
SPAC18G6.15 SPAC18G6.15 MAL3 MAL3
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ORF_A ORF_B Gene_A Gene_B
SPCC1020.11C SPCC24B10.13 SPCC1020.11C SKB5
SPAC13F5.05 SPBC4C3.06 SPAC13F5.05 SYP1
SPAC227.18 SPAC959.10 LYS3 SEN15
SPAC222.08C SPAC688.11 SPAC222.08C END4
SPAC20G8.02 SPAC23H3.05C SPAC20G8.02 SWD1
SPBC26H8.06 SPCC1223.06 GRX4 TEA1
SPAC3C7.03C SPBC691.03C RHP55 APL3
SPAC8C9.03 SPBC3B9.09 CGS1 VPS36
SPAC16E8.17C SPBC2D10.04 SPAC16E8.17C SPBC2D10.04
SPAC23C4.06C SPAC343.09 SPAC23C4.06C UBX3
SPAC22A12.10 SPAC22F3.13 SPAC22A12.10 TSC1
SPBC15D4.04 SPCC4G3.13C GPT2 SPCC4G3.13C
SPBC30D10.13C SPBP4H10.06C PDB1 CUT14
SPBC27.01C SPBC31F10.11C SPBC27.01C CWF4
SPAC20H4.08 SPBC29A3.06 SPAC20H4.08 SPBC29A3.06
SPCC18.11C SPCC4B3.06C SDC1 SPCC4B3.06C
SPAC3G9.08 SPBC21H7.07C PNG1 HIS5
SPAC1F7.04 SPBC3B9.01 RHO1 SPBC3B9.01
SPAPYUK71.02 SPBC119.16C SPAPYUK71.02 SPBC119.16C
SPAC23C11.13C SPAC2F7.02C HPT1 SPAC2F7.02C
SPBC146.03C SPBC428.03C CUT3 PHO4
SPCC4F11.02 SPCC63.05 PTC1 SPCC63.05
SPAC1006.02 SPBC409.20C ASA1 PSH3
SPAC17A5.17 SPCC74.06 SPAC17A5.17 MAK3
SPAC14C4.02C SPAC1805.06C SMC5 HEM2
SPAC23C4.06C SPBC119.04 SPAC23C4.06C MEI3
SPBC16A3.11 SPBC28F2.10C ESO1 NGG1
SPAC1486.03C SPBC18E5.05C SPAC1486.03C SPBC18E5.05C
SPAC23D3.11 SPAC821.10C AYR1 SOD1
SPAC16E8.03 SPCC1281.07C GNA1 SPCC1281.07C
SPAC977.15 SPBC543.09 SPAC977.15 SPBC543.09
SPAC31G5.09C SPCP31B10.06 SPK1 MUG190
SPAC30D11.10 SPCC1235.03 RAD22 SPCC1235.03
SPAC1002.17C SPCC1393.14 URG2 TEN1
SPAC17A2.09C SPBC16A3.11 CSX1 ESO1
SPBC13G1.09 SPCC613.10 SPBC13G1.09 QCR2
SPAC3H5.10 SPBC21C3.04C RPL3202 SPBC21C3.04C
SPAC1486.03C SPBC2D10.04 SPAC1486.03C SPBC2D10.04
SPAC6F12.01 SPBC31F10.11C SPAC6F12.01 CWF4
SPBC1711.08 SPBC1815.01 SPBC1711.08 ENO101
SPAC2F7.11 SPAC823.15 NRD1 PPA1
SPAC22E12.08 SPBC3H7.13 RRN10 SPBC3H7.13
SPAC24H6.12C SPAC637.14 UBA3 SPAC637.14
Table 7.3: Random reference set
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Table 7.4: Primers used. 
  
Primer Name Primer Sequences (5'-3') 
Sty1-pNCH1472-
Forward AAGGAAAAAAGCGGCCGCATGGCAGAATTTATTCGTAC 
Sty1-pNCH1472-
Reverse GGTGTCGACGGATTGCAGTTCATTATCCATG 
snr1-pSGP73-Forward AAGGAAAAAAGCGGCCGCATGGGATTGAAATTAAATATC 
snr1-pSGP73-Reverse GGAAGATCTCTATAAATAAGGATAAGTC 
SpEhd3_Up_Fwd CTTAAACAGCCTGATTTTGT 
SpEhd3_Dn_Rev AACTATCGTACGCACAGCTA 
KanMX4-Fwd TTAGCTTGCCTCGTCCCC 
KanMX4-Rev TTTCGACACTGGATGGCG 
Sty1Del-Up_Fwd TACAAGCAAACACCACAATC 
Sty1Del-Up_Rev TTAATTAACCCGGGGATCCGTTTATTCAAACTGGTTACAAAAAGGAC 
PFA6a_Sty1_Fwd TTGTAACCAGTTTGAATAAACGGATCCCCGGGTTAATTAA 
PFA6a_Sty1_Rev AGGCTTTATCTACAACTTGTGAATTCGAGCTCGTTTAAAC 
Sty1Del-Dn_Fwd GTTTAAACGAGCTCGAATTCACAAGTTGTAGATAAAGCCTTAAAAGTTGTTC 
Sty1Del-Dn_Rev ACACCACACTTGAAAATCGC 
Sty1_Fwd AATTGAGACGATTTGCAGTAAAAAC 
Sty1_Rev TAATACGCTTACGAGGATCAAAGAC 	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CHAPTER 8 
A proteome-wide fission yeast interactome reveals network evolution principles from yeasts 
to human 
 
In the following chapter, we expand our study of network evolution to the scale of the proteome. Using a 
proteome-wide fission yeast network, we identify several key mechanisms by which protein interactions 
have evolved from yeasts to human. I am a co-first author of the paper resulting from this chapter (Vo*, 
Das* et al Cell 2016, *=Equal contribution) and led all computational analyses. The first author of the 
paper, Tommy Vo, led the entire experimental effort. Michael Meyer, also a co-first author also made a 
significant contribution to several analyses in the paper.   
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8.1 ABSTRACT 
 
Here, we present FissionNet, a proteome-wide binary protein interactome for S. pombe, 
comprising 2,278 high-quality interactions, of which ~50% were previously not reported in any 
species. FissionNet unravels previously unreported interactions implicated in processes such as 
gene silencing and pre-mRNA splicing. We developed a rigorous network comparison 
framework that accounts for assay sensitivity and specificity, revealing extensive species-
specific network rewiring between fission yeast, budding yeast, and human. Surprisingly, 
although genes are better conserved between the yeasts, S. pombe interactions are significantly 
better conserved in human than in S. cerevisiae. Our framework also reveals that different modes 
of gene duplication influence the extent to which paralogous proteins are functionally 
repurposed. Finally, cross-species interactome mapping demonstrates that coevolution of 
interacting proteins is remarkably prevalent, a result with important implications for studying 
human disease in model organisms. Overall, FissionNet is a valuable resource for understanding 
protein functions and their evolution. 
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8.2 INTRODUCTION 
 
Proteins function primarily by physically interacting with other proteins. Gain or loss of these 
interactions within an organism can modulate protein functions and disease states (Sahni et al., 
2015; Wei et al., 2014). The importance of protein interactions to our understanding of 
fundamental biological processes has spurred the mapping of protein interactome networks for 
several organisms (Arabidopsis Interactome Mapping Consortium, 2011; Giot et al., 2003; 
Rolland et al., 2014; Stelzl et al., 2005; Yu et al., 2008). However, the budding yeast 
Saccharomyces cerevisiae remains the only eukaryotic organism for which a high-coverage 
binary protein interactome has been mapped by systematic interrogation of pairwise 
combinations of all proteins in triplicate (Yu et al., 2008). Here, we present FissionNet, a high-
coverage proteome-wide protein interactome network generated for the fission yeast 
Schizosaccharomyces pombe. 
We compared FissionNet with the only other proteome-scale eukaryotic interactomes 
available (>50% of all protein pairs screened), the interactome networks of S. cerevisiae and 
human. Surprisingly, we find that FissionNet is more similar to the human network than it is to 
that of S. cerevisiae. Furthermore, among interactions involving conserved proteins, there is 
significant species-specific rewiring that is not completely determined by overall sequence 
similarity of orthologs. Instead, we identify several other determinants of interaction 
conservation, including local network constraints and conservation of interacting protein 
domains. Also, by comparing FissionNet with the proteome-wide interactome of S. cerevisiae, 
we are able to ascertain how gene duplication events influence the process by which paralogs 
acquire novel functions. 
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S. pombe is an important model organism for studying fundamental biological processes such 
as RNA splicing, cell cycle regulation, RNA interference (RNAi), and centromeric maintenance, 
which are conserved in metazoans but divergent in budding yeast (Wood et al., 2002). We use 
FissionNet to unveil previously unreported protein associations between gene regulatory factors 
involved in pre-mRNA splicing and silencing of stress-response genes and at pericentromeric 
regions, illustrating the value of our network as a proteome-scale resource to understand 
biological processes. 
 
8.3 RESULTS 
 
A proteome-wide high-coverage binary protein interactome map of S. pombe 
To generate a proteome-wide interactome network for S. pombe, which we call FissionNet, we 
systematically tested all pairwise combinations of proteins encoded by 4,989 S. pombe genes 
(corresponding to >99% of all S. pombe coding genes) using our high-quality yeast two-hybrid 
(Y2H) assay, the same pipeline that we used to generate the budding yeast and human 
interactome networks (Yu et al., 2008; Yu et al., 2011). Extensive screenings in triplicate (a total 
of ~75 million protein pairs) yielded 2,278 interactions between 1,305 proteins, of which 2,130 
(93.5%) have not been previously reported in S. pombe (Figure 8.1A, downloadable from 
hint.yulab.org under S. pombe binary HQ corresponding to PMID: 26771498) (Das and Yu, 
2012). Furthermore, FissionNet contains 1,034 interactions that have not been reported between 
orthologs in any other species before. Of these, 142 interactions involve S. pombe proteins that 
both have human orthologs, but at least one does not have a S. cerevisiae ortholog and, hence, 
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cannot be studied in S. cerevisiae. Thus, FissionNet provides a valuable repertoire of biological 
insights. 
To assess the sensitivity and specificity of our Y2H assay (Yu et al., 2008), we constructed a 
positive reference set (PRS) consisting of 93 well-validated S. pombe interactions from the 
literature and a negative reference set (NRS) of 168 random S. pombe protein pairs that are not 
known to interact in the literature and whose orthologs in other species are also not known to 
interact (Table 8.1, see Materials and Methods). We performed Y2H and protein 
complementation assay (PCA) (Das et al., 2013; Yu et al., 2008) to test what fraction of the PRS, 
NRS, and a random sample of 220 FissionNet interactions can be detected using orthogonal 
methods (Figure 8.1B). We found that the detection rates of the PRS and FissionNet interactions 
are indistinguishable from each other and are significantly higher than that of the NRS (Figure 
8.1B; >15% difference in detection rates between the PRS and NRS for both assays, P<10-3, Z 
test). The robust validation rates of FissionNet interactions by an orthogonal assay confirm the 
high quality of the network. Furthermore, although it has been speculated that Y2H interactions 
involving proteins with many interaction partners (hubs) could be of low quality (Bader et al., 
2004), we found that the validation rate by PCA of hub interactions is the same as the overall 
PCA validation rate for FissionNet (Figure 8.1B; P=0.34, Z test), confirming that FissionNet 
interactions involving hubs are of high quality. 
Biological relationships between interacting proteins in FissionNet were assessed by 
measuring similarities in protein localization, functional annotations, and expression profiles (see 
Materials and Methods). We found that FissionNet interactions are significantly enriched for 
protein pairs that are co-localized, functionally similar, and encoded by coexpressed genes 
relative to random expectation (Figures 8.1C to 8.1E; P<0.05 in all three cases using a KS test 
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for coexpression and Z test for co-localization and functional similarity). Furthermore, the 
enrichment of these interactions for all three categories is similar to that of literature-curated 
binary interactions. These results confirm that FissionNet interactions are functionally relevant in 
vivo. We illustrate this by focusing on two previously unreported interactions: Tas3-Hhp1 and 
Atf1-Cid12, and their potential roles in gene silencing. 
 
FissionNet provides insights into functions of proteins and interactions 
The regulation of centromeric silencing is a well-conserved process in S. pombe and metazoans 
but is divergent from that in S. cerevisiae (Holoch and Moazed, 2015). FissionNet revealed a 
previously unidentified interaction between Tas3 and Hhp1 that we confirmed in vivo (Figures 
8.1F and 8.1G). Tas3 is a component of the RNA-induced transcriptional silencing (RITS) 
complex that mediates gene silencing at S. pombe centromeres (Verdel et al., 2004). Hhp1 is a 
conserved mitotic checkpoint kinase (Johnson et al., 2013) not known to be involved in 
centromeric silencing. In S. pombe cells where the ura4+ reporter gene was inserted at the 
centromere inner repeats of chromosome 1 (imr1R) (Verdel et al., 2004), we find that hhp1Δ 
confers loss of silencing at the centromere, similar to tas3Δ cells (Figure 8.1H). Furthermore, 
levels of endogenous centromeric transcripts are elevated in hhp1Δ cells. Moreover, loss of hhp1 
leads to a decrease in the dimethylation of histone 3 lysine 9 (H3K9me2) at the centromere. 
These results show that Hhp1 is involved in centromeric silencing. 
We also identified a previously unreported interaction between the transcription factor Atf1 
and the polyadenylation polymerase Cid12 (Figure 8.2A). Atf1 mediates transcriptional 
responses to stresses such as high temperatures (Shiozaki and Russell, 1996). At S. pombe 
centromeres, Cid12 is a core component of the RNA-directed RNA-polymerase complex 
252
 	  
(RDRC) (Motamedi et al., 2004). The RDRC is responsible for generating double-stranded 
RNAs, a key step for Dcr1-dependent centromeric silencing. Interestingly, it has been reported 
that Dcr1 transcriptionally represses the Atf1-target genes hsp16 and hsp104 under non-stressed 
conditions (Woolcock et al., 2012). 
Pull-down experiments confirm the interaction of Atf1 and Cid12 in S. pombe (Figure 8.2B), 
and cid12Δ cells grown under non-stressed conditions show elevated mRNA levels of hsp16 and 
hsp104 as compared to wild-type cells, similar to dcr1Δ cells (Figure 8.2C). Additionally, double 
mutant cid12Δ dcr1Δ cells do not exhibit more drastic transcript accumulation than the single 
deletion mutants, suggesting both genes function in the same pathway (Figure 8.2C). Together, 
these results suggest that Cid12 may be involved in repressing aberrant gene expression of Atf1-
target genes. 
Next, we identified two Cid12 mutations, lysine-213 to isoleucine (Cid12K213I) and aspartic 
acid-260 to valine (Cid12D260V), that disrupt the interaction of Cid12 with Atf1 while preserving 
interactions within the RDRC complex (Figure 8.2D; see Materials and Methods). Exogenous 
expression of wild-type Cid12 in cid12Δ cells enables the transcriptional repression of hsp16 and 
hsp104. In stark contrast, neither mutant can repress gene expression (Figure 8.2E). The mutant 
phenotype is not due to complete loss of protein caused by destabilization because these Cid12 
mutant proteins express in S. pombe cells. Furthermore, in cid12Δ cells where the ura4+ reporter 
gene was inserted at the centromeric imr1R, we find that exogenous expression of either Cid12 
wild-type or mutants equally permit the silencing of the ura4+ reporter (Figure 8.2F). Thus, we 
show that Cid12 has dual roles in regulating the expression of heat-shock genes and the 
centromere. Importantly, the roles can be selectively uncoupled via specific disruption of the 
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Atf1-Cid12 interaction. These examples illustrate the usefulness of FissionNet as a resource to 
uncover areas of biological inquiry. 
 
Comparative network analyses reveal species-specific conservation of interactions 
High-quality protein interactome networks have previously been reported in budding yeast (Yu 
et al., 2008) and human (Rolland et al., 2014). A fundamental question, which can be addressed 
with FissionNet and these networks, is how protein-protein interactions have evolved and 
whether this trend mirrors gene-level evolution. From sequence-based phylogenetic analyses, the 
two yeasts are less divergent from each other than either yeast is from human (Figure 8.3A) 
(Sipiczki, 2000). Additionally, the two yeasts share a greater fraction of protein-coding genes 
than either yeast does with human (Figures 8.4A and 8.4B). 
To calculate interaction conservation, we considered only those interactions that have the 
potential to be conserved, i.e., the two interacting proteins in the reference species have orthologs 
in the other species. However, directly calculating the overlap between sets of interactions 
obtained from the literature would be erroneous because currently available interactomes are 
incomplete and are derived from assays with varied and often unreported false positive and false 
negative rates (Yu et al., 2008). Therefore, to accurately estimate the underlying interaction 
conservation fractions, we required interactomes of all species to be derived from the same 
experimental assay. Since interactomes in budding yeast (Yu et al., 2008) and human (Rolland et 
al., 2014) have been generated using our version of Y2H (Figure 8.4C and 8.4D), we were able 
to compare FissionNet to these interactome networks to measure the observed extent of 
interaction conservation. We developed a rigorous Bayesian framework that incorporates both 
the false positive and false negative rates of our Y2H assay to estimate the underlying interaction 
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conservation fraction from the observed fraction for each pair of species (see Materials and 
Methods). Surprisingly, we find that interaction conservation follows a completely different 
trend from gene conservation (Figures 8.3B, 8.4E, and 8.4F). While only ~40% of S. pombe 
interactions are conserved in S. cerevisiae (of the 1,331 interactions where both proteins have S. 
cerevisiae orthologs and were pairwise retested using our Y2H assay), ~65% of S. pombe 
interactions are conserved in human (of the 652 interactions where both proteins have human 
orthologs and were pairwise retested using our Y2H assay) (Figure 8.3B; P=1.4×10-4, Z test). 
However, when using budding yeast as the reference species, the fraction of conserved 
interactions is as high in fission yeast as in human, comparable to the fraction conserved between 
fission yeast and human (Figure 8.3B). We were able to recapitulate these results using 
interaction datasets generated by other assays (Figures 8.4G to 8.4I; >1.5 fold difference between 
fission yeast interactions conserved in budding yeast and human; P<10-3 in all cases, Z test; see 
Materials and Methods). Thus, our results suggest that a large fraction of interactions are 
conserved between human and S. pombe, but have been lost specifically in the S. cerevisiae 
lineage. 
One possible explanation for these surprising results is that fission yeast proteins that are 
conserved in human could have higher overall sequence similarity than those that are conserved 
in budding yeast. However, we find that proteins in interactions that have the potential to be 
conserved based on orthology are actually slightly more similar in sequence between the two 
yeasts than between S. pombe and human (Figure 8.3C; P<10-5, U test; see Materials and 
Methods). 
Another possibility is that the observed difference primarily arises from interactions 
involving proteins that are conserved between fission yeast and human but lost in budding yeast. 
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To test this, we first focused on proteins that are conserved in all 3 species. We still find that 
~20% more interactions are conserved between S. pombe and human as compared to between the 
two yeasts (Figures 8.3D, 8.4J, and 8.4K; P<0.05, Z test). 
We next explored the conservation of interactions involved in various biological processes as 
defined by the Gene Ontology (GO) (Ashburner et al., 2000). We find wide variation in species-
specific interaction conservation among different processes (Figures 8.3E and 8.4L to 8.4N). We 
show that S. pombe interactions are more conserved in human than in S. cerevisiae for 10 out of 
13 GO Slim categories containing ≥50 interactions (Figure 8.3E; P<0.05, as marked, Z test). The 
same trend is observed with GO Slim categories containing ≥30 or ≥75 interactions (Figures 
8.4L and 8.4N). Some of these categories, such as “chromosomal organization”, “chromosome 
segregation”, and “cell cycle”, are far better conserved in human than in S. cerevisiae, and 
accordingly S. pombe has been used as a model organism for studying these processes (Wood et 
al., 2002). Furthermore, considering GO Slim categories that are well conserved in all three 
species (using cutoffs of ≥50, 100, and 200 genes annotated per species), we find that the 
conservation of S. pombe interactions in these core biological processes is also higher in human 
than in S. cerevisiae (Figures 8.3F and 8.4O; P<10-3, Z test). Overall, these results suggest that 
insights gained from FissionNet may be widely applicable to the study of human biology across 
many important cellular processes. 
We validated three cases of previously unreported functional conservation between fission 
yeast and human proteins. Uncharacterized S. pombe factors Srrm1, SPAC30D11.14C, and 
SPAC1952.06C interact with known splice factors Srp1, Usp104, and Cwf15, respectively 
(Figure 8.3G). Although these proteins have no orthologs in S. cerevisiae, they are orthologous 
to human SRRM1, KIAA0907, and CTNNBL1, respectively. Interestingly, all three human 
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orthologs have been implicated in pre-mRNA splicing or were found to associate with 
spliceosomal factors in human (Blencowe et al., 1998; Hegele et al., 2012; Rolland et al., 2014). 
We used DNA microarrays to measure changes in the splicing of every known intron in the S. 
pombe deletion mutants. The loss of srrm1, SPAC30D11.14C, or SPAC1952.06C results in 
widespread splicing defects, confirming the roles for these proteins in the splicing pathway 
(Figure 8.3H). Moreover, Srrm1 and Srp1 share many gene targets, suggesting that the 
interacting proteins are functionally related (Figure 8.4P). Notably, an analysis of the introns 
whose splicing is affected by srrm1 deletion shows a strong enrichment for introns with weak 
splice site signals (Figure 8.4Q). This is consistent with previous findings that human SRRM1 
affects splice site selection by binding to exonic splicing enhancers and facilitating interactions 
between spliceosomal proteins (Blencowe et al., 1998). These results highlight the utility of 
FissionNet to reveal proteins that are functionally conserved between S. pombe and human. 
 
Determinants of interaction conservation 
Previous studies have shown that increased protein sequence similarity facilitates conservation of 
protein interactions (Matthews et al., 2001). Indeed, we also found a positive correlation between 
sequence similarity of proteins and the fraction of their associated interactions conserved 
between S. pombe and human or S. cerevisiae, demonstrating a proteome-scale dependence of 
protein sequence and function (Figure 8.5A; R2S.p-H.s=0.948 and R2S.p-S.c=0.976). However, 
protein interaction conservation is not completely dependent on overall sequence similarity, as 
we find many instances of conserved interactions involving proteins with low overall sequence 
similarity (<40%) with their orthologs (Figure 8.5A; 40% and 13% of 116 interactions in human 
and 196 interactions in S. cerevisiae, respectively). To investigate whether certain highly 
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conserved domains in these proteins play an important role in interaction conservation, we 
inferred protein interaction domains from co-crystal structures of 124 human interactions 
conserved in S. pombe and 293 conserved in S. cerevisiae. We find that the sequence similarity 
within protein interaction domains tends to be higher than in other domains for interactions 
conserved between fission yeast and human (Figure 8.5B; 7.0% higher, P=0.012, U test). For 
instance, the human DR1-DRAP1 heterodimer is orthologous to the protein pair Ncb2 and Dpb3 
in S. pombe. While the overall sequence similarity of the orthologs is quite low (0.58 and 0.51, 
respectively), the interaction is conserved in fission yeast. Moreover, we also find that the 
proteins can interact with the orthologs of their native interaction partner (Figure 8.5C). Based on 
a crystal structure of the human DR1-DRAP1 complex, we were able to determine the 
interaction domains of these proteins (Figure 8.5D) (Kamada et al., 2001). The sequence 
similarity within these domains in DR1 and DRAP1 with their fission yeast orthologs is 0.78 and 
0.80, respectively, while the conservation outside of these interaction domains is only 0.45 and 
0.38. Thus, the basis for this high degree of functional conservation is likely dependent on the 
interaction domains. 
Strikingly, interaction conservation is nearly three times higher between S. pombe and human 
than between the two yeasts at low levels of overall sequence similarity (Figure 8.5A; at <40% 
similarity, P=0.030, Z test). As sequence similarity approaches 100%, interaction conservation 
converges. Therefore, for the vast majority of interactions corresponding to proteins with lower 
sequence similarity to their orthologs, our results strongly suggest that species-specific factors, 
independent of overall protein sequence similarity, influence conservation of protein-protein 
interactions. 
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We then sought to explore other factors that could explain the basis of interaction 
conservation. First, we used ClusterOne (Nepusz et al., 2012) to detect topological protein 
clusters in FissionNet (see Materials and Methods). We find that intra-cluster FissionNet 
interactions are >3 times more likely to be conserved in both budding yeast and human than 
inter-cluster interactions (Figures 8.5E; P<0.05 for both organisms, Z test). Next, we examined 
biological processes defined by GO (Ashburner et al., 2000) and observed the same trend 
(Figures 8.5F; P<10-3 for both organisms, Z test). Using genetic interactions, it has been earlier 
hypothesized that while individual functional modules are conserved, inter-modular connectivity 
could be rewired across evolution (Roguev et al., 2008). In this study, we provide direct 
molecular level evidence on a proteome scale that while interactions within modules tend to be 
conserved across evolution, the cross-talk among these modules changes significantly from one 
species to another. 
 
Gene duplication shapes the functional fate of paralogs 
Gene duplication has long been known as a major source of evolutionary novelty (Arabidopsis 
Interactome Mapping Consortium, 2011). Previous studies have found that a whole-genome 
duplication (WGD) event leads to more functional redundancy between paralogous proteins than 
small-scale duplications (SSDs) (Arabidopsis Interactome Mapping Consortium, 2011; Hakes et 
al., 2007). However, there has been much debate in the literature regarding the relative extents of 
sub-functionalization and neo-functionalization for diverged paralogs (Gibson and Goldberg, 
2009; He and Zhang, 2005). Previous studies on functional evolution of paralogs often used 
interaction datasets from the literature, which, as mentioned earlier, suffer from detection and 
completeness biases (Yu et al., 2008). Until now, it has not been possible to measure the extent 
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of sub-functionalization and neo-functionalization using an unbiased framework because there 
was only one proteome-wide high-coverage binary protein interactome available, that of S. 
cerevisiae. Here, we compare the unbiased proteome-wide networks of S. pombe (FissionNet) 
and S. cerevisiae (CCSB-YI1) (Yu et al., 2008) that we produced using the same Y2H assay to 
analyze these two types of functional divergence. 
We first examined the extent to which interactions in S. pombe and S. cerevisiae tend to be 
conserved across species but not shared between within-species paralogs (sub-functionalized) 
(Figure 8.6A; see Materials and Methods). We find that fission yeast paralog pairs tend to 
undergo more sub-functionalization than budding yeast paralog pairs (Figure 8.6B; difference in 
log odds ratio=2.8 using 1,762 fission yeast paralog pairs and 2,068 budding yeast paralog pairs, 
P<10-5, Z test). Since S. pombe paralogs arose via SSDs, while many S. cerevisiae paralogs arose 
via a WGD event (Kellis et al., 2004), this result suggests that duplication modes could impact 
paralog divergence differently. To test this, we compared paralog pairs generated via the WGD 
event with those generated via SSDs in S. cerevisiae. We find that SSD pairs are more sub-
functionalized than WGD pairs (Figures 8.6C and 8.7A to 8.7D; P<0.05, Z test; see Materials 
and Methods). 
Next, we compared the extent of neo-functionalization (rewiring) (Figure 8.6A) for the two 
species and found that fission yeast paralog pairs tend to undergo more neo-functionalization 
than budding yeast pairs (Figures 8.6D and 8.7E; difference in log odds ratio=0.5 using 1,158 
fission yeast paralog pairs and 1,175 budding yeast paralog pairs, P=0.015, Z test). Furthermore, 
within S. cerevisiae, SSD pairs are significantly more neo-functionalized than WGD pairs 
(Figures 8.6E and 8.7F to 8.7I; P<0.05, Z test). 
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In a WGD, the entire genome is duplicated almost at once. Soon afterward, a vast majority of 
the duplicates are purged while only a few are retained (Kellis et al., 2004). However, the 
duplicates that remain are under strong evolutionary pressure to maintain stoichiometric ratios 
with their interaction partners and, thus, evolve more slowly (Fares et al., 2013). On the other 
hand, SSDs arise sporadically and are under less pressure to maintain stoichiometric ratios (Fares 
et al., 2013), which explains why they can undergo greater functional divergence. This increased 
pressure on WGD genes to maintain stoichiometry is illustrated by their propensity to be 
enriched in protein complexes compared to SSD genes (Hakes et al., 2007). Using 408 high-
quality literature-curated complexes from CYC2008 (Pu et al., 2009), we observed the same 
enrichment. Moreover, we find that the enrichment increases with the size of the complex, 
further supporting the notion that stoichiometric constraint influences the fate of WGD genes 
(Figure 8.7J). 
Since WGD pairs are more functionally redundant than SSD pairs, these genes tend to be 
non-essential (Guan et al., 2007). It has also been shown that double deletions of these WGD 
pairs lead to a higher synthetic lethality rate than SSD pairs (Guan et al., 2007). Using a genome-
scale genetic interaction map (Costanzo et al., 2010), we confirmed that deletion of WGD pairs 
is more likely to lead to synthetic lethality (Figure 8.6F; >6 fold difference in the fraction of 
synthetically lethal pairs, P<10-10, Z test). Moreover, when we further stratify both groups of 
paralogs into pairs that are known to share interactors and pairs that have not been reported to 
share interactors, double deletions of the former are more likely to cause synthetic lethality than 
double deletions of the latter (Figure 8.6F; ~1.5 fold difference between the 2 sets for both SSD 
and WGD pairs, P<0.05 for both SSD and WGD pairs, Z test). This shows that paralog pairs that 
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share interactors are more likely to be functionally redundant, regardless of whether they arose 
via SSD or WGD. 
There have been conflicting reports in the literature regarding coexpression patterns of SSD 
and WGD pairs (Conant and Wolfe, 2006; Guan et al., 2007). Using a compendium of genome-
wide expression datasets for S. cerevisiae genes (Yu et al., 2008), we found no significant 
difference in coexpression patterns of these pairs (Figure 8.7K). However, we find that SSD and 
WGD paralog pairs that share interactors are significantly more likely to be coexpressed than 
pairs that are not known to share interactors (Figures 8.6G, 8.7L, and 8.7M; >10% more 
coexpressed for paralogs that are known to share interactors, P<0.02 in both cases, Z test; see 
Materials and Methods). The tendency to be coexpressed among SSD pairs and WGD pairs that 
share interactors is the same. Furthermore, among pairs that are not known to share interactors, 
WGD pairs tend to be more coexpressed than SSD pairs (Figures 8.6G, 8.7L, and 8.7M; >10% 
more coexpressed for WGD paralogs compared to SSD paralogs, P<0.02 in all cases, Z test). 
These results show that for both duplication modes, because paralog pairs that are known to 
share interactors tend to be functionally redundant, the regulation of their gene expression also 
tends to be retained. Only for paralog pairs that are not known to share interactors is there a 
significant difference in coexpression between SSD and WGD paralogs, suggesting that even 
these WGD pairs might still be more functionally redundant than SSD pairs. It should be noted 
that, due to the incompleteness of current interactomes, paralog pairs could share interactors that 
are currently unreported.  
The availability of proteome-wide interactomes helps dissect functional redundancy and 
divergence, and to some degree the regulation of expression, between paralogs. Overall, our 
results show that a WGD leads to greater functional redundancy while SSDs lead to greater 
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functional diversification by sub-functionalization and neo-functionalization. Moreover, while 
there has been debate in the literature regarding the ubiquity of neo-functionalization (Gibson 
and Goldberg, 2009; He and Zhang, 2005), our results provide accurate measurements of the 
extent of neo-functionalization in the two yeasts. 
 
Coevolution of conserved interactions revealed by cross-species interactome mapping 
To further dissect the nature of conserved interactions, we implemented a cross-species 
interactome mapping approach to determine the prevalence of coevolution. We consider an 
interaction to be coevolved when its proteins have evolved in a coordinated manner to maintain 
the interaction in different species, but have developed incompatible binding interfaces with 
orthologs of their partners. To determine whether conserved interactions are intact or coevolved, 
we test by Y2H whether a protein in one species can interact with the ortholog of its interacting 
partner in another species. If the cross-species interaction can occur, the interaction is intact 
(Figure 8.5C), otherwise it is coevolved between the two species (Figure 8.8A). For example, 
through our cross-species mapping, we discovered that interactions of farnesyltransferase subunit 
Cwp1 with other subunits Cpp1 and Cwg2 have coevolved between S. pombe and S. cerevisiae; 
Cwp1 cannot interact with either Ram1 or Cdc43, S. cerevisiae orthologs of Cpp1 and Cwg2, 
respectively (Figure 8.8B). A previous study showed that expression of Cwp1 cannot 
complement a non-functional mutant of its S. cerevisiae ortholog, Ram2 (Arellano et al., 1998). 
This suggests that Cwp1, although conserved between S. pombe and S. cerevisiae at the gene 
level, has evolved incompatible interaction interfaces with other farnesyltransferase subunits in 
S. cerevisiae and is thus unable to reconstitute an active enzyme complex. 
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It is known that evolution in protein folds is essentially the result of many random mutation 
events (Lockless and Ranganathan, 1999). However, since only a small fraction of changes that 
occur via random drift will satisfy the pairwise constraints necessary for interaction 
conservation, coevolution at the residue level only occurs at a few specific sites and is relatively 
rare (Talavera et al., 2015). Surprisingly we find that coevolution at the interaction level is not 
uncommon: ~33% and 50% of conserved interactions between S. pombe and S. cerevisiae or 
human are coevolved, respectively (Figure 8.8C). This shows that even among conserved 
interactions, only a few key alterations at important binding sites can make the cross-species 
interactions incompatible and the interactions coevolved. Thus, these sites are critical to protein 
binding and subsequent function, and changes at these sites alter protein interactions in a manner 
analogous to a single amino acid change disrupting protein interactions in human disease (Wang 
et al., 2012; Wei et al., 2014). 
Among interactions for which we were able to determine coevolution status, we found that 
the likelihood for an interaction to be intact between S. pombe-S. cerevisiae and S. pombe-human 
is significantly higher than random expectation, while the likelihood for an interaction to be 
intact for one species pair and coevolved for the other species pair is significantly lower (Figure 
8.8D; difference in log odds ratio=1.7, P=0.022, Z test; see Materials and Methods). Thus, these 
intact interactions are likely involved in functions that have remained unchanged among yeasts 
and human throughout evolution. 
We then investigated potential factors that could determine whether an interaction is intact or 
coevolved with respect to another species. We find that overall sequences of proteins involved in 
intact interactions tend to be better conserved across species than sequences of proteins in 
coevolved interactions (Figure 8.8E; 18.0% higher, P=2.1×10-4 for S. pombe-human, U test). 
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High sequence conservation may indicate higher levels of evolutionary constraint existing within 
the local network neighborhood of a given interaction. In fact, we find that proteins involved 
only in intact interactions have twice the number of interactors as compared to proteins involved 
in only coevolved interactions (Figure 8.8F; P=1.1×10-3, U test), suggesting that the added 
evolutionary constraint of maintaining many interacting partners may prevent the coevolution of 
two interacting proteins. Finally, we find that the most highly evolutionarily correlated inter-
protein residue pairs in coevolved interactions are significantly more correlated than top residue 
pairs in intact interactions, suggesting that the maintenance of coevolved interactions involves 
compensatory changes at the amino acid residue level. 
 
Implications of FissionNet for the study of human disease 
We explored the relevance of FissionNet to human disease by considering the context of known 
human disease mutations from HGMD (Stenson et al., 2014) within proteins of the human 
interactome conserved in S. pombe. We find that among human interactions conserved in either 
S. pombe, S. cerevisiae, or both, ~40% of inter-protein pairs of disease mutations cause the same 
disease (Figure 8.9A). This is significantly higher than in human interactions that are not 
reported to be conserved in either yeast or cannot be conserved in either due to lack of protein 
orthologs (Figure 8.9A; P<10-10 for all pairwise comparisons, Z test). Based on these results, 
mutations that break specific protein-protein interactions to cause diseases may be 
overrepresented among interactions conserved in model organisms. From a global network view, 
FissionNet may be highly relevant to the study of human disease based on the large portion of S. 
pombe interactions in which both proteins have human orthologs with known germline disease or 
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somatic cancer-associated mutations (Figure 8.9B; 902 interactions) (Forbes et al., 2015; Stenson 
et al., 2014). 
To demonstrate the plausibility of studying specific human disease mutations using 
FissionNet, we explored whether human disease mutations that disrupt human interactions intact 
in S. pombe also disrupt the corresponding interactions of the fission yeast orthologs. We focused 
on three examples: two Mendelian disease variants (Stenson et al., 2014) that disrupt the human 
NMNAT1-NMNAT1 and PCBD1-PCBD1 interactions and one population variant from the 
Exome Sequencing project (Fu et al., 2013) that disrupts the human SNW1-PPIL1 interaction. 
We find that introducing these human protein residue changes into their S. pombe orthologs also 
disrupts the fission yeast interactions (Figure 8.9C). These results indicate that cross-species 
interactome mapping enables investigation of whether interaction interfaces are altered at the 
molecular level between model organisms and human, a finding with potentially far-reaching 
implications for the study of protein function and human disease. 
Our results regarding gene duplication modes may also be relevant to the study of human 
disease. We find that human WGD paralog pairs have a significantly higher likelihood to be 
involved in the same disease compared to human SSD paralog pairs, in agreement with our 
observation that WGD paralog pairs tend to be functionally redundant (Figure 8.9D; 7 fold 
difference in the fraction of WGD and SSD pairs that cause the same disease, P<10-10, Z test; see 
Materials and Methods). Thus, our findings have direct implications for understanding the 
functional roles of paralogous genes, from yeasts to human. 
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8.4 DISCUSSION 
 
FissionNet provides a wealth of functional information. For example, we find that the Atf1-
Cid12 interaction mediates silencing at Atf1-target genes hsp16 and hsp104. It has been shown 
that the RNAi pathway is involved in silencing of these genes (Woolcock et al., 2012). Hence, it 
is possible that the Atf1-Cid12 interaction is part of an RNAi-dependent regulatory pathway.  
By comparing FissionNet to protein networks in budding yeast and human, we have shown 
that the molecular bases for interaction conservation among orthologous proteins are complex 
and different from those that underlie gene conservation. This is highly relevant to the use of the 
two yeasts as model organisms as there are functions that can be better studied using fission 
yeast. We find that divergence across species is not completely dictated by sequence level 
changes, suggesting that rewiring of interactomes plays an important role in species evolution. 
Additionally, our finding that proteins in a significant fraction of conserved interactions have 
undergone coevolution to maintain interactions has major implications for studies reliant on the 
expression of human proteins in model organisms to identify functional mechanisms (Tardiff et 
al., 2013). 
 
Gene duplications introduce evolutionary innovation and robustness 
Gene duplication is a key process shaping evolution (Figure 8.9E). Our results show that 
paralogs arising via WGD are under strong constraints to maintain stoichiometric ratios with 
their interaction partners and, hence, tend to maintain functional redundancy; on the other hand, 
duplicates arising via SSDs are not under such strong constraints and are more likely to gain 
novel functions (Figure 8.9F). For example, it has previously been reported that duplicate copies 
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of the SRGAP2 gene that arose via segmental duplications (SSD-like events) have gained new 
functions related to brain development specifically in the human lineage (Dennis et al., 2012).  
Gene duplications play an important role in the evolutionary mechanism governing 
speciation as well as the evolution of developmental and morphological complexity in 
vertebrates (Rensing, 2014; Ting et al., 2004). For example, two rounds of WGD have been 
predicted in the origin of jawed vertebrates (Figure 8.9E) (Kasahara, 2007). During speciation, 
while certain key functions need to be evolutionarily preserved, new functions are necessary for 
differential adaptation between species (Ting et al., 2004). Previous studies have identified how 
duplication events can lead to functional changes through gene dosage alterations (Papp et al., 
2003). Our results help establish on a proteomic scale that paralogs arising via WGD are more 
likely to preserve functions and provide robustness for important cellular functions, while 
paralogs arising via SSDs are more likely to contribute to novel functions gained by specific 
species. These findings further our understanding of human biology and disease.  
 
Future directions 
Our analyses focus on budding yeast, fission yeast, and human, as they are the only three 
eukaryotic organisms for which we have proteome-scale interactome networks using our version 
of the Y2H assay (>50% of all protein pairs screened). Once more interactome networks are 
systematically generated in other species, using assays with measured sensitivity and specificity, 
the comparative network analysis framework established in this study can be readily applied to 
further elucidate the extent and nature of the evolution of protein functions across many species. 
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8.5 MATERIALS AND METHODS 
 
Generation of the binary protein-protein interactome map of S. pombe 
FissionNet was generated by triplicate independent screening of ~4,900 S. pombe ORFs. The 
network was validated by testing a representative 220 interacting ORF pairs using PCA assays 
and by determining its functional properties with respect to random pairs and to a literature-
curated network.  
 
Conservation of interactions in S. pombe, S. cerevisiae, and human 
We focused only on interactions that can be conserved, i.e., both proteins involved in the 
interaction have orthologs in the other species We mapped interactions in the reference species to 
their corresponding ortholog pairs in the other species and tested these pairs using our Y2H assay 
in a pairwise fashion. Overall, results from these pairwise retests for all three species (a total of 
~20,000 individual Y2H experiments) are used to obtain the observed conservation fraction. To 
accurately estimate the true conservation fraction, we developed a rigorous Bayesian framework 
that takes into account both the false positive and false negative rates of our Y2H assay, and 
computes the true conservation fraction from the observed fraction. 
 
Positive and negative reference sets 
The PRS and NRS constitute sets of positive and negative controls, respectively. Our PRS 
comprises 93 S. pombe interactions that have been previously reported in 2 or more publications. 
To construct the NRS we choose 168 random protein pairs that have not been reported to interact 
in S. pombe and whose orthologs have not been reported to interact in any species. In a set of 
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random protein pairs, the expected fraction of interactions is ~10-3-10-4 (Riley et al., 2005; Yu et 
al., 2008), the expected number of interactions in a random set of 168 pairs is <10-3×168 (≈0.2). 
Since we exclude pairs that are known to interact, the expected number of interactions in our 
NRS is even lower. 
 
Identification of Cid12 mutants 
In order to select residues integral to the Cid12-Atf1 interaction (i.e., at the interface), but not to 
Cid12-Hrr1 or Cid12-Rdp1, we used Direct Coupling Analysis (Morcos et al., 2011) to 
determine evolutionarily correlated residues across interfaces of these interactions in 28 yeast 
species. Cid12 residues exhibiting the strongest evolutionary couplings with Atf1 residues were 
considered likely to facilitate the Cid12-Atf1 interaction. In order to increase the chances of 
selecting Cid12 residues that are not at the interaction interface of other Cid12 interactions, we 
did not consider any Cid12 residues with strong evolutionary couplings with Hrr1 or Rdp1. Once 
Cid12 residues were chosen, we introduced amino acid mutations designed to strongly alter the 
hydrophobicity of the wild-type amino acid. 
 
Detection rates of the positive (PRS) and negative (NRS) reference sets 
Of the 168 NRS pairs, 78 are between proteins with different sub-cellular localizations and 90 
have the same sub-cellular localization (Matsuyama et al., 2006). However, there is no 
significant difference in the fraction of random pairs detected by either Y2H (0/78 and 0/90 for 
the two sets respectively, P=0.92 using a Z test) or PCA (8/78 and 9/90 for the 2 sets 
respectively, P=0.96 using a Z test). To examine if there are any species-specific biases of our 
Y2H assay, we computed the fractions of PRS and PRS-nonY2H (subset of PRS interactions that 
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have been detected using an assay other than Y2H) interactions in the three different species that 
are recapitulated by our Y2H assay. We find that there is no significant difference between the 
detection rates across species (P>0.35 for all pairs, Z test). Furthermore, we find that there is no 
significant difference in interaction density (i.e., number of interactions detected divided by total 
number of protein pairs screened) for FissionNet and previously reported Y2H interactomes in S. 
cerevisiae (Yu et al., 2008) and human (Rolland et al., 2014) (all interaction densities differ by 
<2 fold). These results confirm that our Y2H assay has no species-specific detection biases. 
 
Calculating the coexpression of genes 
To measure the coexpression of transcripts corresponding to proteins involved in FissionNet 
interactions, we calculated the Pearson Correlation Coefficient (PCC) between their expression 
profiles: expression values measured at different time-points in the cell cycle (Rustici et al., 
2004). We also calculated the PCC between expression profiles of transcripts corresponding to 
proteins involved in high-quality S. pombe interactions from literature curation. Finally, we 
defined two different sets of random pairs: (1) all random pairs, (2) random pairs by permuting 
edges between proteins in the network. We first compared the different distributions using a KS 
test. Next, we calculated the fractions of significantly co-expressed interactions, as well as the 
fraction of significantly co-expressed random pairs. We defined significant coexpression as PCC 
≥ a threshold value. When comparing the fractions of interactions or pairs that are significantly 
co-expressed, P-values were calculated using a Z test. 
 
Other functional properties of FissionNet 
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For other calculations, since small-scale studies could focus on proteins with more complete 
annotations in GO, we restricted our analyses to a set of proteins found in both high-quality 
literature-curated S. pombe interactions (Das and Yu, 2012) and interactions in FissionNet. We 
then defined 3 sets of protein pairs such that both proteins are from the previously defined set: 
(1) high-quality S. pombe interactions from literature curation, (2) S. pombe interactions from 
FissionNet, and (3) all pairs of proteins for which the two proteins have never been reported to 
interact. We performed the following calculations on these 3 sets: 
 
Calculating functional similarity 
 We calculated functional similarity using a total ancestry method that computes all 
pairwise functional similarities in a set of proteins by determining for each given pair of proteins, 
the number of other protein pairs sharing the same set of parent GO terms (Yu et al., 2007). In 
this framework, a pair of proteins that are very dissimilar will share their GO ancestry with a 
large number of other protein pairs. Conversely, a pair of proteins that are very similar will share 
their GO ancestry with only a few or none of the other pairwise combinations of proteins in the 
same set. Each similarity score for a pair of proteins was computed as a percentile ranking of 
their total ancestry score among all such scores calculated for all pairwise combinations of 
proteins in the set. We considered the top 1% of protein pairs in this ranking to be functionally 
similar. P-values were calculated using a Z test. 
 
Calculating co-localization 
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 To calculate the co-localization of proteins involved in FissionNet interactions, we 
calculated the fraction of protein pairs that have the same sub-cellular localization (Matsuyama 
et al., 2006). P-values were calculated using a Z test. 
 
Conservation of genes 
To analyze the extent to which genes are conserved, we calculated the fraction of genes in the 
reference species i that also have orthologs in the other species j: 
 
where denotes the total number of genes in species i and  the number of genes in species i 
that have corresponding orthologs in species j. Using ortholog annotations from PomBase and 
the Saccharomyces Genome Database, we computed the extent of gene conservation between 
different species pairs for all coding genes (Cherry et al., 2012; McDowall et al., 2015). We also 
used orthologs from InParanoid to compute the extent of gene conservation between different 
species pairs for all coding genes (Sonnhammer and Ostlund, 2015). We observe the same gene 
conservation trends regardless of which database is used for determining orthology, confirming 
the robustness of our result. 
 
Estimating true interaction conservation fractions  
 To calculate the extent to which interactions are conserved, we focused only on those 
interactions that can be conserved, i.e., both proteins involved in the interaction have orthologs in 
the other species. For each pair of organisms, we used both organisms as the reference (six 
comparisons for 3 species). We mapped interactions in the reference species to their 
corresponding ortholog pairs in the other species and tested these pairs using our Y2H assay in a 
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pairwise fashion. We performed pairwise retests because we have shown earlier that not all 
interactions detected by Y2H in a pairwise fashion will be detected in a high-throughput screen 
where individual baits are tested against minipools of ~188 preys (Yu et al., 2008). Overall, 
results from these pairwise retests for all three species (a total of ~20,000 individual Y2H 
experiments) are used to obtain the observed conservation fraction. To accurately estimate the 
true conservation fraction, we used a rigorous Bayesian framework that takes into account both 
the false positive and false negative rates of our Y2H assay, and computes the true conservation 
fraction from the observed fraction. 
 
Using the law of total probability, we can write: 
  (1) 
Here,  denotes the event that an interaction occurs in the reference species, I the event that the 
interaction occurs in another species,  the event that the interaction does not occur in the other 
species and D the event that it is detected in the other species using our Y2H pipeline. The 
observed conservation rate is P(D| ). The true conservation rate is P(I| ). As an interaction in 
the reference species can only be either conserved or rewired in the other species: 
  (2) 
Finally, we can assume conditional independence between D and  given I. In other words, 
given that an interaction occurs in the other species, whether it is Y2H detectable in that species 
and whether its ortholog pair interacts in the reference species are independent of each other. 
Using this: 
  (3) 
Using similar arguments, 
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 (4) 
Substituting equations (2), (3) and (4) in equation (1), we obtain: 
  (5) 
P(D| ) is estimated using the fraction of interactions in the reference species that are detected by 
Y2H to interact in the other species (fd). P(D|I) is estimated using the fraction of a set of true 
interactions (PRS) that we can detect using our Y2H assay (fprs). Finally, P(D| ) is estimated 
using the fraction of a set of random pairs that are unlikely to interact (NRS) that we can detect 
using our Y2H assay (fnrs). So, for any species pairs: 
 (6) 
We can estimate the error using the delta method: 
  (7) 
 
Interaction conservation using assays other than Y2H 
We examined the observed conservation as detected by individual assays rather than using 
overall interactome networks from the literature as these are derived from assays with varied and 
unknown false positive and false negative rates. However, for a single assay with unknown false 
positive and false negative rates, while we will be unable to calculate the true underlying 
conservation fraction, we can still compute the observed conservation fraction. We first 
calculated the fraction of FissionNet interactions whose corresponding S. cerevisiae and human 
ortholog pairs have been shown to interact in co-crystal structures (Das and Yu, 2012). We find 
that that fission yeast interactions are better conserved in human than in budding yeast (>2 fold 
difference in observed conservation, P<10-3). Next, we calculated the fraction of FissionNet 
275
 	  
interactions whose corresponding S. cerevisiae and human ortholog pairs have been detected as 
interacting by proteome-scale affinity purification/mass spectrometry experiments (Gavin et al., 
2006; Huttlin et al., 2015; Krogan et al., 2006). Here, we also find that fission yeast interactions 
are better conserved in human than in budding yeast (>1.5 fold difference in observed 
conservation, P<10-3 in both cases).  
 
Identifying proteins conserved in eukaryotes 
To identify proteins that are conserved across eukaryotes, we used clusters of conserved 
eukaryotic orthologous groups of genes (KOGs) as defined by Koonin et al. (Koonin et al., 
2004). These conserved KOGs often comprise genes essential for survival and could be 
considered to approximate “a minimal set of essential eukaryotic genes” (Koonin et al., 2004). 
Each KOG consists of orthologous genes in up to 7 representative eukaryotic species studied by 
the authors. We defined proteins conserved in eukaryotes as those proteins from these KOGs that 
are conserved in ≥5 species. 
 
Interaction conservation in different biological processes 
We used the Gene Ontology (GO) (Ashburner et al., 2000) to categorize interactions based on 
the annotations of the proteins involved. We computed interaction conservation in GO Slim 
Biological Process (BP) categories, a set of 70 terms representative of diverse biological 
processes not specific to any one organism. For all analyses, we considered only genes annotated 
with experimental evidence codes (Ashburner et al., 2000). We considered an interaction to be 
within a category if either of its interacting proteins is annotated in that category or one of its 
children.  
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Sequence conservation of proteins and interactions  
To determine the sequence conservation between two proteins, alignments were produced using 
the pairwise2.align.global function of the BioPython Python module, an implementation of the 
Needleman-Wunsch global alignment algorithm (Needleman and Wunsch, 1970). We used the 
BLOSUM62 scoring matrix, a gap-open penalty of -10 and a gap-extend penalty of -0.5. Two 
amino acids are considered similar if the BLOSUM62 score associated with a substitution 
between the two residues is >0. Unless otherwise specified, sequence similarity is measured with 
sequences of S. pombe proteins serving as the reference. Sequence similarity between an S. 
pombe protein and an ortholog in another species is measured as the fraction of S. pombe 
residues similar to their aligned residues in either S. cerevisiae or human. To calculate the 
sequence similarity of pairs of proteins with orthologous pairs, the individual sequence 
similarities of each protein with their orthologs are averaged. P-values were calculated using a Z 
test. 
 
Interface domain conservation based on co-crystal structures  
We compiled a set of co-crystal structures from the PDB representing human protein-protein 
interactions. For each structure, we calculated interface residues using NACCESS to determine 
surface residues whose solvent accessible surface area was altered by ≥1Å2 between bound and 
unbound states (Hubbard, 1996). To determine interface residues of protein interactions, we took 
the union of interface residues determined from each representative PDB chain pair for which at 
least 5 interface residues were calculated in each chain. In the human interactions, we identified 
Pfam domains at the interaction interface as those domains containing at least 5 interface 
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residues. All domains not meeting this criterion are considered 'Other' as we don't know if they 
facilitate the interaction or not. We then aligned the full human protein sequences in each 
interaction to their orthologs in S. pombe and S. cerevisiae using the alignment method 
mentioned previously. Here, we used the human sequences as the reference and only calculated 
sequence similarity within the portions of the alignment in the human domain regions. P-values 
were calculated using a U test. 
 
ClusterOne 
 We performed clustering with ClusterONE (Nepusz et al., 2012). ClusterONE finds 
overlapping functional modules and is specifically tuned for clustering biological networks. We 
used ClusterONE with parameters s=3 (minimum cluster size) and d=0.5 (minimum cluster 
density) and found 193 clusters in our network. Since proteins can belong to multiple clusters, 
we defined an intra-cluster interaction as any interaction for which there is a cluster that contains 
both proteins and an inter-cluster interaction as any interaction for which both proteins belong to 
clusters, but there is no cluster that contains both proteins. Intra-cluster and inter-cluster 
conservations were calculated using the fraction of interactions within and across clusters that 
are detected as conserved using our Y2H assay, transformed via the Bayesian framework 
described above to obtain the true conservation fractions. P-values were calculated using a Z test. 
 
Distribution of intact and coevolved interactions across species 
We computed the log-odds ratios for 3 scenarios: an interaction is intact in both species pairs (S. 
pombe-S. cerevisiae and S. pombe-human), an interaction is coevolved in both species pairs, an 
interaction is intact in one species pair but coevolved in the other: 
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where, p1 is the observed fraction of interactions in each category and p2 the expected fraction of 
interactions in each category. The expected fraction is calculated assuming independence 
between the events of being intact/coevolved in each species pair. Standard error was calculated 
using the delta method: 
 
P-values were calculated using a Z test. 
 
Sub-functionalization and neo-functionalization 
We obtained a set of 3,853 fission yeast paralog pairs and 6,846 budding yeast paralog pairs 
from Ensembl Biomart (Kinsella et al., 2011). For budding yeast, WGD paralogs were defined 
based on annotations from Kellis et al. (Kellis et al., 2004), and the rest were considered to be 
SSD paralogs.  
 To measure the extent of sub-functionalization, we calculated the fraction of interactions 
that are conserved but not shared among paralog pairs. We normalized this by the fraction of 
conserved but not shared interactions among all pairs of proteins that do not have a paralog. The 
fraction of conserved and not shared interactions is equal to 1 – the fraction of conserved and 
shared interactions. To calculate the fraction of conserved and shared interactions, we first 
constructed a set of high-quality interactions from the literature that are conserved. If we use the 
literature to ascertain how many of these interactions are shared, the fraction will be inaccurate 
as literature-curated interactomes are incomplete and suffer from detection rate biases. To 
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circumvent this, we first calculated the fraction of conserved interactions that were detected as 
shared using our Y2H assay. We then used our previously developed framework to calculate the 
actual number of shared interactions: 
 
where fobs is the detected fraction of shared pairs using our Y2H assay and fshared is the actual 
fraction of shared pairs (Yu et al., 2008). Precision, completeness, assay-sensitivity, and 
sampling-sensitivity for FissionNet are calculated as previously described (Yu et al., 2008). For 
the CCSB-YI1 network, they have been previously reported (Yu et al., 2008). With the 
calculated fractions of conserved and not shared interactions, we computed the following log 
odds ratio for S. pombe and S. cerevisiae: 
 
where p1 is the fraction of interactions that are conserved with its ortholog but not shared among 
paralog pairs and p2 by the fraction of conserved but not shared interactions among all pairs of 
proteins that do not have a paralog. Standard error was calculated using the delta method as 
described earlier. P-values were calculated using a Z test. 
 To measure the extent of neo-functionalization, we calculated the log odds ratio of the 
fractions of rewired interactions involving proteins that have and do not have paralogs. We 
computed the same log odds ratio for S. pombe and S. cerevisiae: 
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where, p3 is the fraction of rewired interactions involving proteins where at least one has a 
paralog and p4 the fraction of rewired interactions between proteins that do not have paralogs. 
The fraction of rewired interactions is defined as 1 – the fraction of conserved interactions. Since 
we are able to calculate the true fraction of conserved interactions using a Bayesian framework 
that accounts for assay false positive and negative rates (please refer to ‘Conservation of 
interactions in S. pombe, S. cerevisiae, and human’), the fraction of rewired interactions used 
for this calculation is also accurate and has taken into account for assay detection rates. Standard 
error was calculated using the delta method as described earlier. P-values were calculated using a 
Z test. 
 Our definition of rewiring is based on the interactions in the orthologous species. 
However, in cases where a paralog pair in the reference species shares an interaction that is 
rewired in the orthologous species, it is possible that the common ancestor may have this 
interaction. It could be argued that if the common ancestor does have the interaction, it is not 
truly neo-functionalized. To account for this (and since the interactome for the common ancestor 
is unknown), we constructed a set of interactions involving at least one protein that has a paralog, 
and the interactor of the paralog has only degree one (only one interaction), i.e., by definition 
that interactor cannot be shared between paralogs in the reference species. Even for this set, we 
find that S. pombe paralog pairs are significantly more neo-functionalized than S. cerevisiae 
paralog pairs, confirming the robustness of our results.  
 
Correcting for divergence times, sequence evolution rates and sequence identities 
 We obtained JTT-corrected divergence times for paralog pairs from Fares et al. (Fares et 
al., 2013). To ensure that the observed differences between SSD and WGD paralog pairs are not 
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due to differences in divergence times, we selected only those SSD and WGD pairs whose 
divergence times are between the 10th and the 90th percentile of the WGD divergence time 
distribution. The rationale here is to use the WGD distribution as a reference (we remove the top 
and the bottom 10 percentiles to eliminate outliers) and sample SSD paralog pairs that are only 
from this divergence time window. 
 We used Ka to calculate sequence evolution rates. Ka (not Ks or Ka / Ks) is an appropriate 
choice to correct for sequence evolution rate because synonymous substitutions between WGD 
pairs are essentially saturated (Byrne and Wolfe, 2007). As mentioned earlier, to ensure that the 
observed differences between SSD and WGD paralog pairs are not due to differences in 
sequence evolution rates, we selected only those SSD and WGD pairs whose sequence evolution 
rate are between the 10th and the 90th percentile of the WGD Ka distribution.  
 We obtained paralog sequence identities from Ensembl BioMart. Here too, as earlier, to 
ensure that the observed differences between SSD and WGD paralog pairs are not due to 
differences in sequence identity, we selected only those SSD and WGD pairs whose identities 
are between the 10th and the 90th percentile of the WGD sequence identity distribution. Since 
sequence identity depends both on divergence time and sequence evolution rates, correcting for 
sequence identity simultaneously corrects for both covariates. 
 
Functional properties of S. cerevisiae SSD and WGD pairs 
 To calculate the fraction of SSD and WGD pairs in complexes, we used high-quality 
literature curated complexes from CYC2008 (Pu et al., 2009). We computed the fractions of 
proteins from SGD and WGD pairs that are in all CYC2008 complexes, complexes with ≥10 
proteins, and complexes with ≥20 proteins. P-values were calculated using a Z test. 
282
 	  
 To calculate the fraction of SSD and WGD pairs that involve non-essential genes but lead 
to synthetic lethality when both genes are deleted, we used genome-scale double knockout 
phenotype data (Costanzo et al., 2010). We considered a double deletion to lead to synthetic 
lethality if the genetic interaction score (ε) is strongly negative, i.e., passes a stringent cutoff as 
defined by the authors at http://drygin.ccbr.utoronto.ca/~costanzo2009/ where ε<-0.12 and 
P<0.05. We considered a paralog pair to “share interactors” if both proteins had at least 2 
interactors and they shared >50% of their interactors. “Other” paralog pairs are defined as those 
pairs that are not known to have any shared interactors based on the literature. P-values were 
calculated using a Z test. 
 To calculate the fraction of SSD and WGD pairs that are coexpressed, we used a 
normalized expression dataset constructed as described in Yu et al. (Yu et al., 2008). Paralog 
pairs that “share interactors” and “other” paralog pairs are defined as described above. We 
defined significant coexpression as PCC ≥a threshold value. To ensure that our conclusions are 
robust to the choice of this threshold, we used three different thresholds: 0.3, 0.4 and 0.5. When 
comparing the fractions of significantly co-expressed pairs, P-values were calculated using a Z 
test. 
 
Calculation involving human SSD and WGD pairs 
A set of human WGD (ohnolog) pairs was obtained from Makino and McLysaght (Makino and 
McLysaght, 2010). A set of human SSD pairs was identified as described in Singh et al. (Singh 
et al., 2014). This study also used the previous set of human WGD pairs (Makino and 
McLysaght, 2010) for their analyses. We calculated the fractions of SSD and WGD pairs 
containing genes that are known to cause the same disease based on HGMD (Stenson et al., 
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2014). Two genes are said to cause the same disease if at least one HGMD mutation on each of 
the two genes is associated with the same disease. 
 
8.6 FIGURE LEGENDS 
 
Figure 8.1. 
A Proteome-wide Binary Protein Interactome Map of S. pombe 
(A) Network representation of FissionNet. Proteins are color-grouped based on PomBase GO 
slim categories. The number of FissionNet interactions per group is indicated. (B) Y2H and PCA 
detection rates of the PRS, NRS, FissionNet, and FissionNet hub interactions. (C) Pearson 
correlation coefficient (PCC) distribution of gene expression profiles of interacting and all 
random protein pairs. (D) Enrichment of co-localized protein pairs. (E) Enrichment of protein 
pairs sharing similar functions. (F) Subnetwork of Tas3 and Hhp1 in FissionNet. (G) 
Coimmunoprecipitation of Tas3-myc and Hhp1-HA in vivo. (H) Centromeric silencing assay of 
tas3Δ and hhp1Δ cells. A schematic of the imr1R region with the ura4+ reporter gene is shown. 
WT denotes wild-type. Data are shown as measurements + standard error (SE). * denotes 
significant (P<0.05); n.s. denotes not significant. 
 
Figure 8.2. 
Atf1-Cid12 Interaction Mediates Silencing at Heat-shock Genes 
(A) Subnetwork of Atf1 and Cid12 in FissionNet. (B) Coimmunoprecipitation of Atf1-myc and 
Cid12-HA in vivo. (C) Semi-quantitative real-time PCR (semi qRT-PCR) shows hsp16 and 
hsp104 transcript levels in deletion strains. (D) Y2H confirms Cid12 mutants cannot interact 
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with Atf1, but maintain interactions with Hrr1 and Rdp1. (E) Semi qRT-PCR shows that the 
Cid12 mutants in cid12Δ cells do not restore the repression of hsp16 or hsp104. (F) Centromeric 
silencing assay shows that Cid12 mutants retain centromeric silencing function. -RT, no reverse 
transcriptase. +RT, with reverse transcriptase. Act1+ serves as loading control. WT denotes wild-
type.  
 
Figure 8.3. 
S. pombe Protein Interactions are More Conserved in Human than in S. cerevisiae 
(A) Sequence-based phylogeny dendrogram of S. pombe (S.p.), S. cerevisiae (S.c.), and human 
(H.s.). (B) Interaction conservation between reference-query species. (C) Sequence conservation 
for ortholog pairs that could be conserved between S.p.-S.c. and S.p.-H.s. (D) Interaction 
conservation between reference-query species for proteins that are conserved in all three species. 
(E) Interaction conservation in GO Slim categories with at least 50 interactions. (F) Interaction 
conservation among GO Slim categories that are conserved in all three species. (G) FissionNet 
subnetworks of Srrm1, SPAC30D11.14C, and SPAC1952.06C. (H) Global splicing profiles of 
deletion strains relative to wild-type. Columns represent total mRNA (T), pre-mRNA (P), and 
mature mRNA (M). Data are shown as measurements + SE. * denotes significant (P<0.05); n.s. 
denotes not significant.  
 
Figure 8.4.  
S. pombe Protein Interactions Are More Conserved in Human than S. cerevisiae 
(A and B) Pairwise comparisons of the conservation of all coding genes between reference-query 
species pairs. (A) Orthologs are defined by PomBase (McDowall et al., 2015) and 
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Saccharomyces Genome Database (SGD) (Cherry et al., 2012). (B) Orthologs are defined by 
InParanoid (Sonnhammer and Ostlund, 2015). (C) Y2H detection rates of PRS and 
PRS_nonY2H (subset of PRS interactions that have been detected using an assay other than 
Y2H) interactions in fission yeast, budding yeast, and human. (D) Interaction density, i.e., 
interactions detected out of the total number of proteins pairs screened (log scale) in different 
organisms. (E) Observed interaction conservation between reference-query species pairs. (F) 
Observed interaction conservation between reference-query species pairs for proteins that have 
1:1 orthologs between reference and query species. (G) Observed interaction conservation 
between reference-query species pairs using co-crystal structures for S. cerevisiae and human. 
(H and I) Observed interaction conservation between reference-query species pairs using large-
scale AP/MS datasets for S. cerevisiae and human. For both panels, the human AP/MS dataset 
used is from (Huttlin et al., 2015). (H) The S. cerevisiae AP/MS dataset is from Gavin et al. 
(2006). (I) The S. cerevisiae AP/MS dataset is from Krogan et al. (2006). (J) Observed 
interaction conservation between reference-query species pairs for proteins that have 1:1:1 
orthologs between fission yeast, budding yeast, and human. (K) Observed interaction 
conservation between reference-query species pairs for proteins that are conserved in all 
eukaryotes. (L–N) Observed conservation fractions of S. pombe interactions in S. cerevisiae and 
human in different GO Slim biological process categories with at least (L) 30, (M) 50, and (N) 
75 interactions. (O) Observed interaction conservation among GO Slim categories that are 
conserved in all three species. (P) Overlap of genes whose intron splicing is affected by deletion 
of either Srrm1 or its interaction partner Srp1. Indicated within the diagrams are the number of 
genes affected. (Q) Distribution of log odds scores of affected (intron accumulation of log2 0.5 
or greater in srrm1D versus wild type cells) versus unaffected (intron accumulation of less than 
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log2 0.5 in srrm1D versus wild-type cells). The log odds score for each annotated 50 splice site 
measures the sequence similarity of that site relative to the consensus 50 splice site of each 
intron. Data are shown as measurements + SE. * denotes significant (p < 0.05); n.s. denotes not 
significant. 
 
Figure 8.5. 
Determinants of Interaction Conservation 
(A) Interaction conservation as a function of overall protein sequence similarity. (B) Sequence 
similarity within protein interaction domains and other domains for interactions conserved 
between yeasts and human. (C) Y2H confirms the interactions of human (H.s.) DRAP1-DR1, the 
orthologous S. pombe (S.p.) Dpb3-Ncb2, and the cross-species interactions. (D) Crystal structure 
of human DR1-DRAP1. Boxed region highlights interaction domains. Gray shaded regions 
denote aligned interaction domain sequences. (E) Interaction conservation within and across 
topological clusters. (F) Interaction conservation within and across GO categories. Data are 
shown as measurements + SE. * denotes significant (P<0.05); n.s. denotes not significant. 
Abbreviations are S. pombe (S.p.), S. cerevisiae (S.c.), and human (H.s.).  
 
Figure 8.6. 
Functional Divergence of Interactions Involving Paralogous Proteins 
(A) Schematic representation of sub-functionalization and neo-functionalization. (B-C) Log odds 
ratios of sub-functionalization (B) for S. pombe and S. cerevisiae paralog pairs and (C) for S. 
cerevisiae SSD and WGD paralog pairs after correcting for divergence times. (D-E) Log odds 
ratios of neo-functionalization (D) for S. pombe and S. cerevisiae paralog pairs and (E) for S. 
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cerevisiae SSD and WGD paralog pairs after correcting for divergence times. (F) Fraction of 
synthetic lethal pairs among SSD and WGD paralogs known or not known to share interactors. 
(G) Fraction of coexpressed pairs (PCC>0.4) among SSD and WGD paralogs known or not 
known to share interactors. Data are shown as measurements + SE. * denotes significant 
(P<0.05); n.s. denotes not significant.  
 
Figure 8.7.  
Functional Divergence of Interactions Involving Paralogous Proteins 
 (A–D) Log odds ratio of sub-functionalization for S. cerevisiae SSD and WGD paralog pairs: 
(A) correcting for sequence evolution rates, (B) correcting for sequence identities, (C) without 
correcting for any covariates, and (D) where SSD and WGD pairs are defined using an 
independent dataset (Fares et al., 2013). (E) Log odds ratio of neo-functionalization for S. pombe 
and S. cerevisiae paralog pairs that do not share interactions. (F–I) Log odds ratio of neo-
functionalization for S. cerevisiae SSD and WGD paralog pairs: (F) correcting for sequence 
evolution rates, (G) correcting for sequence identities, (H) without correcting for any covariates, 
and (I) where SSD and WGD pairs are defined using an independent dataset (Fares et al., 2013). 
(J) Enrichment of proteins from WGD paralog pairs compared to proteins from SSD paralog 
pairs in protein complexes of different sizes. (K) Fraction of SSD and WGD paralog pairs whose 
proteins are coexpressed (PCC > 0.4), without separating pairs that are known to share and not 
known to share interactions. (L and M) Fraction of coexpressed pairs at other PCC cutoffs of (L) 
> 0.3 or (M) > 0.5 among SSD and WGD paralogs that are known to share and not known to 
share interactions. Data are shown as measurements + SE. * denotes significant (p < 0.05); n.s. 
denotes not significant. 
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Figure 8.8. 
Intact and Coevolved Interactions 
(A) Schematic representation of conserved protein interactions that are either intact or 
coevolved. (B) Within- and cross-species Y2H detects coevolved interactions. (C) Fraction of 
S.p. interactions that are coevolved with respect to S.c. or human (H.s.). (D) Log odds ratio of co-
occurrence of intact and coevolved interactions between S.p.-S.c. and S.p.-H.s. (E) Overall 
protein sequence similarity of S.p. proteins involved in intact or coevolved interactions. (F) 
Number of interactors for proteins involved in intact or coevolved interactions. Data are shown 
as measurements + SE. * denotes significant (P<0.05); n.s. denotes not significant. 
Figure 8.9. 
FissionNet as a Resource for Studying Human Disease 
(A) Fraction of inter-protein HGMD mutation pairs that cause the same disease in human 
interactions with regard to their conservation status in S. pombe and S. cerevisiae. (B) Largest 
connected subcomponent of FissionNet wherein all proteins have human orthologs with known 
germline disease or somatic cancer-associated mutations. (C) Impact of human disease mutations 
and a population variant on intact interactions between human and fission yeast. (D) Fraction of 
human SSD and WGD paralogs that cause the same disease. (E) The 2R hypothesis predicts two 
recent WGD events leading to the vertebrate lineage. (F) WGD can lead to more functional 
redundancy through targeted gene loss that maintains stoichiometric ratios of protein products. 
SSD leads to more neo-functionalization and sub-functionalization through alterations to initially 
redundant paralogs. Data are shown as measurements + SE. * denotes significant (P<0.05); n.s. 
denotes not significant. 
Table 8.1 Positive and negative reference sets 
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Table 8.1. List of the positive reference set (PRS).
ORF_A ORF_B Y2H_status PCA_status
SPAC1002.06C SPBC1778.02 Nega1ve Nega1ve
SPAC110.03 SPAC22H10.07 Nega1ve Nega1ve
SPAC110.03 SPAC24H6.09 Nega1ve Nega1ve
SPAC110.03 SPBC1289.04C Nega1ve Nega1ve
SPAC110.03 SPBC1604.14C Nega1ve Nega1ve
SPAC13C5.07 SPAC13C5.07 Posi1ve Nega1ve
SPAC13C5.07 SPBC6B1.09C Nega1ve Nega1ve
SPAC1565.06C SPAC222.10C Posi1ve Nega1ve
SPAC1565.06C SPBC21.06C Posi1ve Nega1ve
SPAC16.02C SPBC530.14C Posi1ve Posi1ve
SPAC16A10.06C SPCC5E4.06 Nega1ve Posi1ve
SPAC16A10.07C SPAC16A10.07C Nega1ve Posi1ve
SPAC16A10.07C SPBC1778.02 Nega1ve Nega1ve
SPAC16E8.09 SPAC22H10.07 Posi1ve Nega1ve
SPAC17H9.09C SPBC1D7.05 Nega1ve Posi1ve
SPAC1834.04 SPBC428.08C Nega1ve Posi1ve
SPAC18G6.02C SPBC83.03C Posi1ve Posi1ve
SPAC19A8.12 SPBC3B9.21 Posi1ve Nega1ve
SPAC19D5.01 SPAC24B11.06C Nega1ve Nega1ve
SPAC222.10C SPAC6F6.08C Posi1ve Nega1ve
SPAC22E12.07 SPAC22E12.07 Nega1ve Nega1ve
SPAC22F3.09C SPBC2F12.11C Posi1ve Nega1ve
SPAC22F3.09C SPBC336.12C Posi1ve Nega1ve
SPAC22H10.07 SPBC1604.14C Nega1ve Nega1ve
SPAC23A1.06C SPAC24B11.06C Nega1ve Nega1ve
SPAC23C11.16 SPCC4B3.15 Nega1ve Nega1ve
SPAC23C4.15 SPBC28F2.12 Nega1ve Nega1ve
SPAC23C4.15 SPCC1442.10C Nega1ve Nega1ve
SPAC23C4.18C SPAC6B12.11 Nega1ve Nega1ve
SPAC23G3.01 SPCC1442.10C Nega1ve Nega1ve
SPAC23H3.13C SPBC19C7.03 Nega1ve Nega1ve
SPAC24B11.06C SPBC29B5.01 Nega1ve Posi1ve
SPAC24B11.06C SPBC409.07C Posi1ve Posi1ve
SPAC24B11.11C SPBC428.13C Nega1ve Nega1ve
SPAC24B11.11C SPCC1739.11C Nega1ve Nega1ve
SPAC24H6.05 SPCC1259.13 Nega1ve Nega1ve
SPAC24H6.05 SPCC18B5.11C Nega1ve Nega1ve
SPAC26H5.06 SPAC26H5.06 Nega1ve Nega1ve
SPAC27E2.05 SPBC1734.02C Nega1ve Nega1ve
SPAC27F1.09C SPBC146.07 Nega1ve Nega1ve
SPAC30.03C SPCC736.09C Nega1ve Nega1ve
SPAC30D11.10 SPAC30D11.10 Nega1ve Nega1ve
SPAC30D11.10 SPAC644.14C Posi1ve Nega1ve
SPAC3A12.07 SPCC1442.10C Nega1ve Nega1ve
SPAC3F10.01 SPBC25D12.03C Nega1ve Nega1ve
SPAC637.07 SPBC646.09C Nega1ve Posi1ve
SPAC644.06C SPCC18B5.03 Nega1ve Posi1ve
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SPAC644.14C SPAC644.14C Posi1ve Posi1ve
SPAC664.01C SPAC664.01C Nega1ve Posi1ve
SPAC694.06C SPCC18B5.11C Nega1ve Nega1ve
SPAC6F12.09 SPBC83.03C Nega1ve Posi1ve
SPAC6G9.13C SPBC1778.02 Nega1ve Nega1ve
SPAC8E11.02C SPCC1259.13 Nega1ve Nega1ve
SPAC8E11.03C SPAC8E11.03C Posi1ve Posi1ve
SPAC9E9.08 SPBC216.05 Nega1ve Nega1ve
SPAP8A3.06 SPBC146.07 Posi1ve Nega1ve
SPBC11B10.09 SPBC14C8.07C Nega1ve Nega1ve
SPBC11B10.09 SPBC32F12.09 Nega1ve Posi1ve
SPBC11B10.09 SPCC18B5.03 Nega1ve Posi1ve
SPBC11C11.08 SPBC530.14C Nega1ve Posi1ve
SPBC1289.02C SPBC146.07 Nega1ve Nega1ve
SPBC146.03C SPBP4H10.06C Nega1ve Nega1ve
SPBC146.07 SPBC530.14C Nega1ve Posi1ve
SPBC14C8.12 SPCC1442.10C Nega1ve Nega1ve
SPBC14F5.08 SPBC31F10.04C Nega1ve Posi1ve
SPBC1604.14C SPBC1604.14C Nega1ve Nega1ve
SPBC16D10.09 SPBC1734.02C Nega1ve Nega1ve
SPBC16H5.11C SPBC16H5.11C Nega1ve Nega1ve
SPBC1703.06 SPBC409.05 Nega1ve Nega1ve
SPBC1778.06C SPBC32H8.12C Nega1ve Nega1ve
SPBC1921.02 SPCC18B5.11C Nega1ve Nega1ve
SPBC211.04C SPBC25D12.03C Nega1ve Nega1ve
SPBC216.05 SPCC1259.13 Nega1ve Nega1ve
SPBC216.05 SPCC18B5.11C Nega1ve Nega1ve
SPBC216.06C SPBC30D10.04 Posi1ve Nega1ve
SPBC244.01C SPBC244.01C Posi1ve Nega1ve
SPBC25D12.03C SPBC4.04C Nega1ve Nega1ve
SPBC28F2.07 SPBC409.03 Nega1ve Nega1ve
SPBC28F2.12 SPCC1020.04C Nega1ve Posi1ve
SPBC28F2.12 SPCC1442.10C Posi1ve Nega1ve
SPBC4.04C SPBC776.12C Nega1ve Posi1ve
SPBC409.03 SPBC409.03 Nega1ve Nega1ve
SPBC409.05 SPCC18.04 Nega1ve Posi1ve
SPBC646.14C SPBC685.09 Nega1ve Posi1ve
SPBC6B1.09C SPCC338.08 Nega1ve Nega1ve
SPBC725.02 SPBC887.10 Nega1ve Nega1ve
SPBC776.12C SPCC550.13 Nega1ve Nega1ve
SPCC11E10.08 SPCC613.12C Posi1ve Nega1ve
SPCC1223.06 SPCC1223.06 Nega1ve Nega1ve
SPCC1739.03 SPCC663.12 Nega1ve Nega1ve
SPCC18B5.03 SPCC18B5.11C Nega1ve Nega1ve
SPAC15A10.03C SPAC644.14C Posi1ve Posi1ve
SPBC1706.01 SPCC1223.06 Posi1ve Nega1ve
Table 8.1. List of the negative reference set (NRS).
ORF_A ORF_B Y2H_status PCA_status
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SPAC1002.17C SPAC2F3.09 Nega1ve Nega1ve
SPAC1006.03C SPCC1494.07 Nega1ve Nega1ve
SPAC1142.07C SPAC186.06 Nega1ve Nega1ve
SPAC11D3.01C SPBC11G11.06C Nega1ve Posi1ve
SPAC12B10.06C SPBC800.03 Nega1ve Posi1ve
SPAC13G7.10 SPBC17D1.02 Nega1ve Posi1ve
SPAC1486.08 SPAC1805.06C Nega1ve Nega1ve
SPAC1705.03C SPBC776.08C Nega1ve Nega1ve
SPAC17A2.08C SPCC14G10.01 Nega1ve Nega1ve
SPAC17C9.15C SPBC31F10.02 Nega1ve Nega1ve
SPAC1834.04 SPAC922.05C Nega1ve Nega1ve
SPAC186.07C SPCC70.10 Nega1ve Nega1ve
SPAC18B11.08C SPAPB17E12.07C Nega1ve Nega1ve
SPAC18G6.02C SPAC644.06C Nega1ve Nega1ve
SPAC18G6.13 SPAC1952.01 Nega1ve Nega1ve
SPAC1952.02 SPAC23G3.04 Nega1ve Nega1ve
SPAC1B1.01 SPBC16D10.01C Nega1ve Nega1ve
SPAC1B3.18C SPAC890.05 Nega1ve Nega1ve
SPAC1F7.11C SPCC1840.10 Nega1ve Nega1ve
SPAC1F8.02C SPBC800.02 Nega1ve Nega1ve
SPAC20G8.06 SPCC613.10 Nega1ve Nega1ve
SPAC20G8.07C SPBC19G7.13 Nega1ve Nega1ve
SPAC20H4.01 SPAPB1E7.04C Nega1ve Nega1ve
SPAC227.16C SPBC713.08 Nega1ve Nega1ve
SPAC22A12.08C SPCC1902.02 Nega1ve Nega1ve
SPAC23A1.12C SPAC458.06 Nega1ve Nega1ve
SPAC23C4.07 SPBC660.08 Nega1ve Nega1ve
SPAC23H4.01C SPBC25H2.14 Nega1ve Nega1ve
SPAC26A3.15C SPBC211.09 Nega1ve Posi1ve
SPAC31G5.09C SPCC4G3.06C Nega1ve Nega1ve
SPAC323.02C SPBC685.03 Nega1ve Nega1ve
SPAC3G6.03C SPAC4F10.05C Nega1ve Nega1ve
SPAC3H1.04C SPCC663.14C Nega1ve Nega1ve
SPAC4A8.07C SPAC890.08 Nega1ve Nega1ve
SPAC4D7.13 SPCC965.07C Nega1ve Nega1ve
SPAC56F8.04C SPAC869.10C Nega1ve Nega1ve
SPAC57A10.06 SPBC2D10.04 Nega1ve Nega1ve
SPAC589.11 SPBC409.16C Nega1ve Nega1ve
SPAC5H10.10 SPCP25A2.02C Nega1ve Nega1ve
SPAC688.11 SPCC830.09C Nega1ve Posi1ve
SPAC688.15 SPBP22H7.03 Nega1ve Nega1ve
SPAC806.07 SPCC132.03 Nega1ve Nega1ve
SPAC821.10C SPBC26H8.11C Nega1ve Nega1ve
SPAC821.11 SPBC2D10.04 Nega1ve Nega1ve
SPAC869.03C SPBC1683.03C Nega1ve Nega1ve
SPAC890.06 SPBC609.02 Nega1ve Nega1ve
SPAC8C9.02 SPBPB2B2.01 Nega1ve Nega1ve
SPAC8C9.10C SPBC21H7.02 Nega1ve Nega1ve
SPAC922.04 SPBC25B2.02C Nega1ve Nega1ve
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SPAC9G1.05 SPBC1198.10C Nega1ve Nega1ve
SPAP14E8.04 SPBC25H2.07 Nega1ve Nega1ve
SPAP27G11.03 SPBP35G2.13C Nega1ve Nega1ve
SPAP7G5.02C SPBC1348.01 Nega1ve Nega1ve
SPAP7G5.06 SPBC649.04 Nega1ve Nega1ve
SPBC1105.03C SPBC36B7.04 Nega1ve Nega1ve
SPBC1105.16C SPCC965.10 Nega1ve Nega1ve
SPBC1215.01 SPBC336.04 Nega1ve Nega1ve
SPBC1604.10 SPBC17A3.08 Nega1ve Nega1ve
SPBC1685.01 SPCC74.04 Nega1ve Nega1ve
SPBC16G5.17 SPCC1620.08 Nega1ve Nega1ve
SPBC1709.04C SPCC1223.02 Nega1ve Nega1ve
SPBC17A3.08 SPBC3B8.07C Nega1ve Nega1ve
SPBC25H2.07 SPBC354.04 Nega1ve Posi1ve
SPBC25H2.08C SPBC4C3.02C Nega1ve Nega1ve
SPBC27B12.14 SPBC800.13 Nega1ve Nega1ve
SPBC28E12.03 SPCC550.02C Nega1ve Nega1ve
SPBC2G2.05 SPBC3D6.04C Nega1ve Posi1ve
SPBC32H8.13C SPCC1620.07C Nega1ve Nega1ve
SPBC336.05C SPCC70.10 Nega1ve Nega1ve
SPBC3B8.04C SPBP8B7.20C Nega1ve Nega1ve
SPBC3B8.08 SPCC584.15C Nega1ve Posi1ve
SPBC4C3.06 SPCC297.05 Nega1ve Nega1ve
SPBC947.10 SPCC16C4.12 Nega1ve Nega1ve
SPBP8B7.24C SPCC594.02C Nega1ve Nega1ve
SPBP8B7.25 SPCC2H8.05C Nega1ve Nega1ve
SPCC320.06 SPCPB16A4.06C Nega1ve Nega1ve
SPCC417.05C SPCC4F11.01 Nega1ve Nega1ve
SPCC622.21 SPCP1E11.06 Nega1ve Nega1ve
SPAC1002.03C SPBC409.20C Nega1ve Nega1ve
SPAC1039.08 SPCC417.12 Nega1ve Nega1ve
SPAC1071.02 SPAC24B11.05 Nega1ve Nega1ve
SPAC1071.04C SPAC3A12.06C Nega1ve Nega1ve
SPAC1071.05 SPCC63.06 Nega1ve Nega1ve
SPAC11D3.18C SPAC212.08C Nega1ve Nega1ve
SPAC11G7.06C SPCC11E10.04 Nega1ve Nega1ve
SPAC12G12.05C SPAC23C4.15 Nega1ve Nega1ve
SPAC13C5.01C SPCP1E11.10 Nega1ve Nega1ve
SPAC13C5.05C SPAC17H9.09C Nega1ve Posi1ve
SPAC144.03 SPBC577.05C Nega1ve Nega1ve
SPAC16.01 SPAC4H3.08 Nega1ve Nega1ve
SPAC1783.07C SPAC328.03 Nega1ve Nega1ve
SPAC17D4.01 SPAC1F12.08 Nega1ve Posi1ve
SPAC186.07C SPBC25H2.07 Nega1ve Nega1ve
SPAC18B11.08C SPBC83.12 Nega1ve Nega1ve
SPAC19A8.10 SPBC15D4.10C Nega1ve Nega1ve
SPAC19B12.06C SPAC9G1.07 Nega1ve Nega1ve
SPAC19G12.04 SPBC577.05C Nega1ve Nega1ve
SPAC19G12.05 SPBC19G7.18C Nega1ve Nega1ve
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SPAC1B2.02C SPBC660.08 Nega1ve Nega1ve
SPAC1F7.08 SPBC1734.12C Nega1ve Nega1ve
SPAC1F8.02C SPAPB8E5.03 Nega1ve Nega1ve
SPAC222.07C SPBC8D2.18C Nega1ve Nega1ve
SPAC227.17C SPAC3G6.09C Nega1ve Nega1ve
SPAC22E12.11C SPCC1682.13 Nega1ve Nega1ve
SPAC22G7.10 SPAC8E11.11 Nega1ve Nega1ve
SPAC23C4.11 SPCC645.02 Nega1ve Nega1ve
SPAC23H4.07C SPCC1020.11C Nega1ve Nega1ve
SPAC24B11.04C SPBC1709.04C Nega1ve Posi1ve
SPAC2F3.13C SPBC1677.03C Nega1ve Nega1ve
SPAC2H10.02C SPBC1604.10 Nega1ve Nega1ve
SPAC30.02C SPCC663.09C Nega1ve Nega1ve
SPAC30.03C SPBC691.02C Nega1ve Nega1ve
SPAC31A2.02 SPAPB1E7.10 Nega1ve Nega1ve
SPAC31A2.03 SPAC4G9.17C Nega1ve Nega1ve
SPAC323.06C SPBC685.07C Nega1ve Posi1ve
SPAC323.06C SPCC613.04C Nega1ve Nega1ve
SPAC328.10C SPCC895.09C Nega1ve Nega1ve
SPAC3G6.09C SPBC3B9.03 Nega1ve Nega1ve
SPAC458.04C SPAC694.05C Nega1ve Nega1ve
SPAC4A8.14 SPBC725.03 Nega1ve Nega1ve
SPAC4D7.09 SPBC17G9.08C Nega1ve Nega1ve
SPAC4G8.08 SPBC1604.07 Nega1ve Nega1ve
SPAC521.03 SPAC869.01 Nega1ve Nega1ve
SPAC56E4.03 SPBC17D1.08 Nega1ve Nega1ve
SPAC57A7.05 SPBC16G5.18 Nega1ve Nega1ve
SPAC5D6.06C SPCC285.11 Nega1ve Nega1ve
SPAC607.08C SPBC12D12.03 Nega1ve Posi1ve
SPAC6C3.04 SPBC4.06 Nega1ve Nega1ve
SPAC6C3.09 SPBP23A10.09 Nega1ve Nega1ve
SPAC6F12.13C SPBC1734.15 Nega1ve Posi1ve
SPAC6F6.05 SPBC557.02C Nega1ve Nega1ve
SPAC6G10.08 SPBC29A3.15C Nega1ve Nega1ve
SPAC823.01C SPBC119.15 Nega1ve Nega1ve
SPAC823.12 SPBC8D2.10C Nega1ve Nega1ve
SPAC9.10 SPBC15D4.04 Nega1ve Nega1ve
SPAP27G11.04C SPCC364.05 Nega1ve Nega1ve
SPAP27G11.06C SPBC1734.10C Nega1ve Nega1ve
SPAPB1E7.09 SPBC119.09C Nega1ve Nega1ve
SPBC106.11C SPCC4B3.06C Nega1ve Nega1ve
SPBC1198.07C SPBC25H2.14 Nega1ve Posi1ve
SPBC13A2.03 SPBC2A9.06C Nega1ve Nega1ve
SPBC13G1.01C SPBC17A3.01C Nega1ve Nega1ve
SPBC13G1.01C SPBC725.14 Nega1ve Nega1ve
SPBC15C4.03 SPBC21B10.08C Nega1ve Nega1ve
SPBC15D4.15 SPCC14G10.05 Nega1ve Nega1ve
SPBC1683.07 SPCC1450.12 Nega1ve Nega1ve
SPBC16A3.06 SPCC4F11.02 Nega1ve Nega1ve
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SPBC16G5.06 SPBC342.03 Nega1ve Nega1ve
SPBC16H5.03C SPCC622.19 Nega1ve Nega1ve
SPBC1709.10C SPBC1921.07C Nega1ve Nega1ve
SPBC1709.15C SPCC126.14 Nega1ve Nega1ve
SPBC17A3.03C SPBC4B4.12C Nega1ve Nega1ve
SPBC18H10.20C SPBC19C7.08C Nega1ve Nega1ve
SPBC19C2.02 SPBC29A3.19 Nega1ve Nega1ve
SPBC1A4.02C SPBC3D6.15 Nega1ve Posi1ve
SPBC20F10.06 SPCC970.02 Nega1ve Nega1ve
SPBC21C3.16C SPBC28F2.09 Nega1ve Nega1ve
SPBC23E6.06C SPBC577.08C Nega1ve Nega1ve
SPBC2G5.01 SPBC4F6.16C Nega1ve Nega1ve
SPBC30D10.18C SPBC31F10.04C Nega1ve Nega1ve
SPBC342.03 SPCC24B10.13 Nega1ve Nega1ve
SPBC3H7.05C SPCC1259.10 Nega1ve Nega1ve
SPBC4.02C SPCC1795.08C Nega1ve Nega1ve
SPBC405.07 SPCC132.01C Nega1ve Posi1ve
SPBP19A11.05C SPCP1E11.02 Nega1ve Nega1ve
SPBP8B7.32C SPCC285.04 Nega1ve Nega1ve
SPBPJ758.01 SPCC297.04C Nega1ve Nega1ve
SPCC1682.01 SPCC550.06C Nega1ve Nega1ve
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